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Abstract 
Prostate cancer (PCa) is a leading cause of cancer-related death in men 
worldwide, with an estimated 33,000 deaths projected in the U.S. in 2020.  
Although primary (localized) tumors can be cured by surgery or radiation, 
approximately 40% of patients eventually develop recurrent disease.  While initially 
responsive to androgen-deprivation therapy (ADT), many patients with recurrent 
PCa eventually progress to a more advanced disease state known as metastatic 
castration-resistant PCa for which treatment options are less effective. Despite the 
clinical successes of treating various types of cancers with immune checkpoint 
blockade (ICB), responses in PCa patients remain limited.  This is perhaps 
unsurprising given the low expression of co-inhibitory molecules, low mutational 
burden, and the immunosuppressive tumor microenvironment (TME) found in this 
disease.  As described in the first chapter of this dissertation, tumor-associated 
antigens expressed by prostate tumor cells induce an immune response in patients 
with PCa, a notion that has been exploited previously by the FDA-approved 
Sipuleucel-T vaccine. In chapter 2 of this dissertation, we describe the robust 
tolerance to a model antigen that is established by the TME.  We found that 
continuous expression of a model antigen leads to increased infiltration of 
regulatory T cells (Tregs) and polymorphonuclear myeloid-derived suppressor cells 
(PMN-MDSCs) to the TME of ADT-treated PCa tumors.  In chapter 3, we 
investigated the tumor intrinsic mechanisms that lead to the recruitment and 
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accumulation of PMN-MDSCs. Our results suggest that loss of androgen-receptor 
mediated suppression of interleukine-8 (IL-8) expression and its subsequent 
upregulation as a potential mechanism that mediates the infiltration of PMN-
MDSCs in ADT-treated PCa tumors.  In chapter 4, we evaluated the pre-clinical 
significance of targeting PMN-MDSCs migration in an animal model. These studies 
show that mitigating the recruitment of PMN-MDSCs in combination with ICB and 
ADT increased polyfunctional CD8 T cells in tumor draining lymph nodes and 
spleens, and significantly delayed the onset of castration-resistance.  This 
dissertation contributes to the understanding of PCa immunogenicity, the 
establishment of tolerance to CD8 antigen-specific T cell responses in the context 
of an immunosuppressive TME, and how PCa cells themselves orchestrate the 
recruitment of PMN-MDSCs to the TME.   
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Prostate cancer (PCa) is the second most common cause of cancer mortality in 
men in the United States, accounting for 1 in 5 new diagnoses of cancer and 
ranking second in mortality among all cancers in men.1  The standard primary 
treatment for patients with localized PCa includes surgery and/or radiation therapy, 
followed by androgen-deprivation therapy (ADT: chemical or surgical castration) if 
disease returns.  Alternatively, patients may be monitored closely if the cancer is 
thought to be of sufficiently low risk2 and treated only upon signs of  progression.  
In general, the earliest sign of recurrence after primary therapy comes in the form 
of ‘biochemical recurrence’ (BCR), an asymptomatic rise in prostate specific 
antigen (PSA) without any radiographic evidence of metastases.3 Serial 
quantification of PSA provides a window of opportunity to treat patients 2–3 years 
before their metastatic disease becomes evident by imaging methods.4  
“(In the U.S.) More will die from cancer 
over the next two years than died in 
combat in all the wars the United States 
has ever fought, combined.” 
Dr. Siddhartha Mukherjee (2010) – 
Assistant professor and oncologist at 
Columbia University, and the author 
of The Emperor of All Maladies: A 
Biography of Cancer.  
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PCa that presents in the metastatic state is generally treated with ADT, but 
most patients eventually become refractory to this treatment, developing 
castration-resistant disease, i.e. metastatic castration-resistant PCa (mCRPC).  
While there are a number FDA approved therapeutic agents for mCRPC 
(docetaxel, cabazitaxel, abiraterone, enzalutamide, radium-223, and sipuleucel-T) 
that have shown an impact on overall survival (OS), currently there is no treatment 
that can cure mCRPC.5  Immunotherapy based on the blockade of immune 
checkpoints plays a role in the treatment of most advanced cancers,6 but PCa is 
currently a notable exception.7  In this introduction, we describe the adaptive 
immune response to tumor cells in PCa, and what is known about the mechanisms 
of tolerance and immune escape for these tumors.  Next, we discuss the 
immunosuppressive tumor microenvironment (TME) in PCa, as well as new 
evidence for tumor-cell mediated myeloid infiltration through the PI3K / PTEN / 
AKT signaling pathway and, an alternative mechanism for immune evasion that 
may be regulated by an ER stress response.  Finally, we discuss several 
interventions to break immunological tolerance induced by the mechanisms above. 
The Adaptive Immune Response in Prostate Cancer 
It is generally understood that the turnover of necrotic tumor cells within the tumor 
microenvironment leads to the activation of an adaptive immune response.8 In this 
‘immunogenic cell death’ cellular contents are released into the extracellular space 
after necrosis, where they can be internalized, processed and presented on major 
histocompatibility complexes (MHC) I and II by antigen presenting cells (APCs).  
Upon stimulation by a pathogen associated molecular pattern (PAMPs) or damage 
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associated molecular pattern (DAMPs), APCs migrate to the lymph node to 
activate T lymphocytes of the adaptive immune system.  Both arms of adaptive 
immune system (T and B cell mediated) are important in controlling tumor growth. 
CD4 helper T (TH) cells can be defined into several functionally different subsets 
on the basis of the combinations of cytokines they secrete.9 Of these, interferon 
gamma (IFNγ) producing TH1 cells contribute to the anti-tumor response by 
inducing high affinity IgG-driven B cell responses and by enhancing CD8 T cell 
activation.  CD8 cytotoxic T lymphocytes (CTLs) are essential components of the 
adaptive anti-tumor immune response due to their ability to selectively and 
specifically induce apoptosis in tumor cells upon the interaction between their T 
cell receptor (TCR) and its ligand – an immunogenic tumor-associated antigen 
(TAA).  When an activated CD8 CTL engages with its cognate ligand, presented 
on an MHCI molecule, it can drive non-immunogenic cell death, apoptosis, by 
secreting granzyme B and pore-forming proteins known as perforins.10   
During the course of tumor progression, tumor cells undergo a process 
termed immunoediting that consists of three phases: elimination (i.e., cancer 
immunosurveillance), equilibrium, and escape.11 Mutated proteins specific to 
tumor cells, also known as neoantigens, are the likely drivers of an effective anti-
tumor immune response for the elimination of malignant cells and prevention of 
tumor outgrowth; however, this phase is followed by a latency period (equilibrium) 
in which, although many of the original malignant cells are destroyed, the 
emergence of new genetic variants is thought to help maintain growth until the 
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conditions in the TME allow for these cells to eventually escape 
immunosurveillance and establish as tumors.       
Not surprisingly, the presence of a significant population of tumor specific T 
cells has been found important for the generation of anti-tumor immunity.12  
However, the density of tumor specific CD8 T cells found in patients with PCa is 
relatively low; while in other cancer types, such as head & neck squamous cell 
carcinoma, the infiltration of CD8 T cells is more robust (Fig. I.1). Currently, it is 
unknown why PCa has a low intra-tumoral CD8 T cell infiltration, although it is likely 
that the low tumor mutational burden in PCa plays a role.    
 
Figure I.1 | Sparse CD8 T Cell Infiltration in Prostate Cancer. 
Immunohistochemical staining of tumor infiltrating CD8+ T cells in Prostatic 
Adenocarcinoma (left) and Head & Neck Squamous Cell Carcinoma (right) 




On the other side of T-cell activation, is T-cell ‘tolerance’, a broad term which 
encompasses several mechanisms.14  These two processes counteract each other 
to regulate the effective elimination of foreign antigens (i.e. pathogens) while 
maintaining immune tolerance to self-antigens (i.e., healthy tissues).  T cell 
activation or lack thereof determines T cell fate in both the thymus and the 
periphery. Mechanisms of ‘central tolerance’ in the thymus allow for selection of 
successful T cell clones based on their ability to interact with MHC class I or II on 
the surface of thymic epithelial cells (TECs) in the thymic cortex.15  This process 
of positive selection leads to maturation and upregulation of CCR7 for migration to 
the thymic medulla.16  There, T cells encounter tissue-specific antigens presented 
by medullary TECs via expression of AIRE.17  If binding is too strong, T cells are 
deleted in an effort to prevent autoimmunity (negative selection).18  T cells with 
intermediate binding become tolerized to potential self-antigens (natural regulatory 
T cells); while T cells with low binding can either recognize non-self (i.e., foreign or 
mutated) antigens or be further tolerized in the periphery.  Although many 
autoreactive T cells are eliminated in the thymus, the majority of self-reactive T 
cells survive negative selection and are exported into the periphery.19 
In the periphery, naïve T cells require three different signals for proper 
activation of their immune function: (i) TCR/antigen-MHC interaction, (ii) co-
stimulation (e.g., CD28) and (iii) cytokines. TCR stimulation of T cells in the 
absence of appropriate co-stimulatory signals leads to anergy.20-22 This low-level 
signaling pattern causes T cells to be functionally inert when encountering antigen 
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even in the presence of co-stimulation.23  Immunological ignorance refers to an 
important mechanism of peripheral tolerance in which T cells are physically 
inhibited from coming into contact with their cognate antigens.19,24 Tissues that are 
immunologically ‘ignored’ include the testes, ovaries, retina and possibly the non-
inflamed prostate gland.  In the context of cancer, the tumor microenvironment can 
also restrict the ability of T cells to interact with tumor cells.25  In addition, T cells 
can also enter a state of exhaustion upon continuous TCR-specific stimulation.26  
This phenotype is characterized by the expression of multiple co-inhibitory 
molecules or immune checkpoints, reduced proliferation capacity, and loss of 
cytokine production and effector function.27,28  Lastly, when the appropriate 
conditions are met (i.e., TGFβ, retinoic acid, and IL-2), conventional naïve CD4 T 
cells can be induced to express the transcription factor FOXP3 and become 
regulatory T cells (Tregs) in the periphery29 to complement the existing natural Tregs 
already in tissues. 
Immune Escape 
In order for a tumor to establish successfully, tumor cells must escape immune 
recognition. Indeed, tumor cells from the prostate, breast, and lung tissues have 
been reported to downregulate the antigen processing machinery as mechanism 
of immune evasion.30-34 In addition, molecules secreted by either tumor cells 
themselves or the tumor microenvironment have been shown to impair the proper 
recruitment, maturation and function of immune cells and ultimately hamper anti-
tumor immunity.35-37  The discovery of co-inhibitory molecules or immune 
checkpoints (i.e., CTLA-4 and PD-1 / PD-L1),38-40 however, stands above other 
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mechanisms in terms of clinical relevance.41-43 The integration of activating and 
inhibitory signals from the co-stimulatory and co-inhibitory molecules expressed 
on the surface of T cells at the time of TCR engagement determine whether T cells 
are activated or are rendered tolerant.44 This process helps to modulate immune 
responses and prevent autoimmunity, but it also contributes to tumor progression. 
Indeed, ample evidence suggest that antigen-specific T cells remain in tolerized 
states during tumor immune escape, and that CTLA-4 / B7-1/2 and PD-1 / PD-L1 
are two of the major interactions driving immune evasion in cancers.45  Although 
many co-inhibitory molecules have been discovered (e.g., LAG-3, BTLA, VISTA, 
and CD160), here we will focus on the co-inhibitory molecules that are FDA-
approved targets for cancer treatment. 
Cytotoxic Lymphocyte Antigen-4 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was the first co-inhibitory 
molecule to be discovered.38  CTLA-4 is closely related to the co-stimulatory 
molecule CD28,46 and inhibits T cell activation by competing with the co-
stimulatory molecule CD28 for binding to B7.1 and B7.2 ligands on APCs.47-49  
CTLA-4 has been shown to enable suppression of effector T cells by Tregs,50 and 
to play an important role in the prevention of autoimmune diseases.51,52  CTLA-4 
blockade facilitates de novo T cell priming events53 and thus enhances antigen-
specific T cell responses.54  Indeed, in the context of tumors, inhibiting CTLA-4 / 
CD28 interactions has led to an increase in T cell infiltration to the TME in animal 
models55 and patients.56  Furthermore, CTLA-4 blockade with a depleting 
monoclonal antibody has been shown to delay tumor progression in several pre-
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clinical tumor models, including PCa.55,57,58  While CTLA-4 blockade has failed to 
meet the studies’ primary end-point for the treatment of mCRPC in two randomized 
phase III studies,54,59 recently reported long-term data from one of those studies 
did show a statistically significant increase in OS in PCa patients receiving anti-
CTLA-4.60  
Programmed Death-1 
Programmed Death-1 receptor (PD-1) was the second co-inhibitory molecule to be 
discovered.39  PD-1 inhibits T cell function upon engaging with its ligands PD-L1 
and PD-L2 on tumor cells or APCs.61-64 Upon engagement, the immunoreceptor 
tyrosine switch motif (ITSM) on the intracytoplasmic tail of PD-1 binds to the Src 
homology region 2 domain of the phosphatase SHP-2 (step 1),65 and only then 
immunoreceptor tyrosine-based inhibitory motif (ITIM) binds the second SHP-2 
(step 2) leading to a conformational switch that in turn displays the catalytic domain 
of SHP2 and inhibits TCR signaling.66  Germline loss of PD-1 may lead to high 
levels of serum immunoglobulins,67 mild lupus-like autoimmunity,68 or 
cardiomyopathy.69  In the context of tumors, PD-L1 on tumor infiltrating myeloid 
cells,70 or possibly on tumor cells,71 mediates adaptive immune resistance by 
binding to PD-1 on the attacking T cells.72,73  Indeed, PD-L1 is expressed by tumor 
cells in various tumor types, including PCa,71 and is upregulated by several of the 
cytokines secreted as a consequence of T cell activation – such as interferon 
gamma (IFNγ).74,75  Thus, PD-1 or PD-L1 blockade can lead to exhausted T cells 
re-acquiring their effector function.76 
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In PCa, PD-L1 expression is associated with a more aggressive 
phenotype77 and it is observed in 8% of cases in primary tumors and approximately 
30% of mCRPC lesions (Fig. I.2).71 The reasonable prevalence of PD-L1 
expression in mCRPC suggests that targeting the PD-1 / PD-L1 pathway may have 
therapeutic implications in PCa treatment. While several clinical trials with anti-PD-
1 monotherapy have some activity in mCRPC,78 that activity is less significant than 
that observed in other tumor types.79,80  
 
Figure I.2 | PD-L1 Expression in Prostate Cancer. Immunohistochemical 
staining of PD-L1 in primary prostate tumors (left) and a mCRPC lesion (right).  
Courtesy of Dr. Michael Haffner. 
Immunosuppressive Tumor Microenvironment in Prostate Cancer 
In general, the prognosis of cancer patients depends on tumor intrinsic 
histopathological characteristics (tumor grade) and on the extent of disease (stage) 
as defined by spread to draining lymph nodes (N), and/or evidence of distant 
metastases (M).  Most recently, however, the importance of the composition of the 
immune compartment at the tumor site has become evident,81 with some tumor 
types being characterized by a lack of T cell infiltration and presence of 
suppressive myeloid populations (‘cold’ tumors), while others are characterized for 
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their high T cell density (‘hot’ tumors).82  These two immune phenotypes may be a 
reflection of possible disturbances in the cancer-immunity cycle (Fig. I.3). Through 
this cycle, anti-tumor immunity is generated in series of stepwise events.  First, 
tumor neoantigens are captured (step 1), processed (step 2) and presented by 
APCs in the presence of co-stimulation and cytokines (step 3).  Then, activated 
CD8 CTLs traffic to (step 4) and infiltrate the TME (step 5), where they recognize 
tumor neoantigens loaded on MHCI (step 6), and induce tumor cell death (step 
7).83  If neoantigens are presented by APCs in a tolerogenic context, T cell priming 
may then lead to the induction and expansion of Tregs.  Additional factors in the 




Figure I.3 | The Cancer-Immunity Cycle. The seven steps of the cancer immune 
cycle are described above. Abbreviations are as follows: APCs, antigen presenting 
cells; CTLs, cytotoxic T lymphocytes.83   
Myeloid-derived Cells in the Tumor Microenvironment 
Myeloid cells may orchestrate various aspects of cancer progression including: 1) 
establishing an immunosuppressive TME; 2) promoting tumor cell growth; 3) 
promoting angiogenesis; 4) establishing a metastatic niche and 5) facilitating 
metastasis.  We will focus on the myeloid-derived cells that have been described 
to play a role in PCa progression. 
Dendritic Cells 
Bone marrow derived dendritic cells (BMDCs) are a heterogeneous group of APCs 
that can be classified into two basic subtypes: plasmacytoid DCs (pDCs), which 
accumulate in blood and lymphoid tissue, and classical DCs (cDCs), which 
infiltrate lymphoid and non-lymphoid tissues.84  In humans, BMDCs are defined as 
cells that are negative for the lineage markers: CD3, CD19, CD20, CD56 and 
CD14, express class II MHC (HLA-DR+), and are low or intermediate for CD11c 
(ITGAX).85  While pDCs can be characterized by their production of interferon 
alpha (IFNα), cDCs express either CD1c (BDCA1) or CD141 (BDCA3).85  cDCs 
expressing CD141 are a noteworthy subset of cDCs superior at cross-presenting 
soluble antigen.86  In rodents, this subset of cross-presenting cDCs can be further 
sub-classified into two populations depending on their expression of surface 
markers and their localization: CD8α in lymphoid tissue and CD103 in non-
lymphoid tissue.87  Both types of cDCs differentiate from CD11c+ precursors.85   
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Regardless of their subtype, cDCs in non-lymphoid tissues process 
captured antigen and, after activation and up-regulation of CCR7 and L-selectin, 
migrate to T cell zones in lymph nodes where they present antigen to induce either 
T cell response or tolerance.  Cross-presenting cDCs are the most efficient antigen 
presenting cells and have the potential to activate  both CD4 Th cells and CD8 
CTLs.88  In the presence of cancer, a subset of immature dendritic cells migrates 
to the tumor draining lymph node where they may stimulate the expansion of 
naturally occurring Tregs by secreting transforming growth factor beta (TGF-β).89 
Interleukin 10 (IL-10) and other factors in the TME that hinder dendritic cell 
maturation90,91 and consequently facilitate antigen presentation in a suppressive 
context. Moreover, disrupting the ability of cDCs to present antigen to T cells may 
facilitate tumor immune evasion, as will be discussed later. In addition, CTLA-4 on 
Tregs may interact with the normally co-stimulatory molecules B7.1 and B7.2 on a 
subset of BMDCs (called suppressive DCs), inducing them to express indoleamine 
2,3-dioxygenase (IDO), which further contributes to the immunosuppressive 
microenvironment (Fig. I.4).92  This occurs when IDO catabolizes tryptophan, an 
essential amino acid for T cell function, in the TME.93  As will be discussed below, 
a number of IDO inhibitors were developed for cancer immunotherapy. 
Myeloid-Derived Suppressor Cells (MDSCs) 
During an inflammatory response, bone marrow derived monocytes migrate into 
the tissues and replenish the resident pool of macrophages (Mϕ) and dendritic 
cells.94  In cancer, this steady supply of mature leucocytes may be perturbed by 
factors promoting myelopoiesis - leading to an accumulation of immature myeloid 
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cells.  Additional factors prevent these cells from differentiating into mature cells of 
the myeloid lineage (Mϕ, dendritic cells, and mature neutrophils) and promote their 
pathologic function.95  Accordingly, monocytes from peripheral blood of PCa 
patients do not develop into mature dendritic cells as efficiently as those derived 
from healthy donor blood samples,96 although a number of studies have shown 
that prolonged ex-vivo culture of monocytes from cancer patients can result in fully 
functional cDCs for cancer vaccines.88 
Two main types of MDSCs have been identified: polymorphonuclear (PMN-
MDSCs) and monocytic (M-MDSCs).  PMN-MDSCs are phenotypically similar to 
neutrophils whilst M-MDSCs are similar to monocytes.  In humans, PMN-MDSCs 
are defined as CD11b+ (ITGAM+) CD14− CD15+ or CD11b+ CD14− CD66b+ (in 
some studies, CD33dim is used instead of CD11b+).97 In mice these cells are 
CD11b+ Ly6G+ Ly6Clow.97  M-MDSCs are defined as CD11b+ CD14+ HLA-DR−/low 
CD15− in humans and CD11b+ Ly6G− Ly6Chi in mice.97  These two types of MDSCs 
utilize different mechanisms of immunosuppression.98  Briefly, M-MDSCs produce 
high amounts of nitric oxide (NO; mediated by the Nos2 gene), decrease T cell 
nutrient availability (L-arginine, L-cysteine, and tryptophan) in the 
microenvironment, and induce Treg differentiation through the production of IL-10 
and TGF-β.99  PMN-MDSCs produce reactive oxygen and nitrogen species (ROS 
& RNS) that facilitate CXCR4–mediated tumor dissemination,100 lead to the down-
regulation of antigen presentation in cDCs,101 impede CD8 T cell infiltration,102 and 
induce antigen-specific CD8 T cell tolerance.103 In addition, both types of MDSCs 
decrease CD4 and CD8 T cell homing to lymph nodes through the cleavage of L-
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selectin from the plasma membranes of T cells.104  Supporting a potential role for 
PMN-MDSC in PCa, protein nitration (i.e. 3-nitro-tyrosine formation) was found to 
be associated with PCa but not benign prostatic hyperplasia.105  
Macrophages 
Inflammatory monocytes that enter into tissues from the bloodstream have been 
suggested as the major source of macrophages (Mϕ) in the TME, i.e. tumor-
associated Mϕ (TAMs).106  However, the contribution of in situ expansion of tissue-
resident Mϕ to TAMs in PCa remains an open question.  Inflammatory monocytes 
are defined as CD14hi CD16- CX3CR1low CCR2hi in humans and Ly6Chi CX3CR1low 
CCR2hi in mice.  The phenotype of these cells changes upon tumor infiltration; they 
mature into CD14low CD16+ CX3CR1+ CCR2low cells in humans and Ly6Clow 
CX3CR1+ CCR2low Mϕ in mice.107,108  Mature Mϕ are subsequently polarized into 
distinct phenotypes depending on the cytokines present in the TME.  In vitro, Mϕ 
can readily be polarized towards two distinct phenotypes (M1 and M2); but in vivo, 
these cells show a wide spectrum of polarization between those canonical 
states.109  Mature Mϕ can be identified by the markers CD68 in humans and F4/80 
(ADGRE1) in mice.110  In mice, MHC-IIhi Mϕ have been shown to express M1 
associated genes (IL1b, IL12b, and Ptgs2) and to produce NO more efficiently 
when stimulated with interferon gamma (INFγ) or LPS than MHC-IIlow Mϕ –which 
are characterized by the expression of M2 associated genes (IL10, Arg1, IL4Ra, 
and Mrc1).111  In general, M1 or classically activated Mϕ are considered anti-
tumorigenic, while M2 or alternatively activated Mϕ are considered pro-
tumorigenic.  TAMs may promote tumor growth by increasing tumor angiogenesis, 
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through the expression of angiogenic growth factors and matrix 
metalloproteinases,108 and by inducing Treg differentiation via IL-10 production in 
the TME.109  Interestingly, the phenotype of TAMs may flux between the M1 and 
M2 phenotype according to the cytokines present in the TME during tumor 
progression108 (Fig. I.4). 
Myeloid-derived Cells in Prostate Cancer Initiation and Progression  
Myeloid-derived Cells in Cancer Initiation / Establishment of the TME 
Chronic inflammation may play a role in PCa initiation.112  Although the precise 
initiators of inflammation are unknown, potential etiologies include infectious 
agents, chronic noninfectious inflammatory diseases and/or other environmental 
factors.113  Indeed, inflammation on biopsy cores of benign prostate tissue is 
associated with the presence of PCa.114  Supporting a potential role for an 
inflammatory insult in tumorigenic inflammation, a human prostatic isolate of 
Escherichia coli accelerated PCa initiation in Nkx3.1 mutant mice115 and 
progression in a spontaneous murine model of PCa (Hi-Myc).116   
Upon insult, inflammatory Mϕ (Ly6Chi CX3CR1low CCR2hi) accumulate in 
damaged tissue where paracrine signaling directs their maturation.108  Once in the 
TME, TAMs themselves become a major source of inflammatory mediators such 
as cytokines, chemokines and growth factors.108  Among these mediators, 
interleukin-6 (IL-6) is of particular interest in PCa.117  IL-6 binds to either its 
membrane receptor (IL6R) or its soluble receptor (sIL6R) to induce the formation 
of a functional complex that induces the homodimerization of interleukin 6 signal 
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transducer (IL6ST), also known as gp130, leading to the activation of the janus 
kinase (JAK) pathway.118  JAK–mediated phosphorylation then leads to the 
activation of multiple signaling pathways, in particular: signal transducer and 
transcription activator 3 (STAT3), mitogen activated protein kinase (MAPK), and 
phosphoinositol-3 kinase / a serine/threonine kinase (PI3K / AKT)119 (Fig. I.5).  
The downstream effects of IL-6 signaling are cell type dependent. While IL-
6 signaling has been suggested to promote cancer progression by regulating cell 
growth, differentiation and survival in prostate tumor cells,118 IL-6 can also exert its 
pro-tumorigenic effects by modulating the TME.  In this regard, IL-6 promotes 
monocyte differentiation toward M2-like Mϕ in culture,120 and induces naïve T cells 
to differentiate into a subtype known as TH17 that secretes high amounts of 
interleukin-17 (IL-17).121,122  The accumulation of IL-17 in the TME leads to further 
up-regulation of IL-6, potentially generating an amplification loop.123  In addition, 
paracrine IL-17 signaling may prime prostate tumor cells to produce factors that 
favor an M2-like phenotype within TAMs (Fig. I.4).  Indeed, when media from 
murine prostate tumor cells cultured in the presence of IL-17 is used to culture Mϕ, 
IL-10 expression is increased.124  Li and colleagues also reported that in vitro 
stimulation of a murine PCa cell line with IL-17 induces up-regulation of 
prostaglandin-endoperoxide synthase 2 (PTGS2), also known as COX-2.124  This 
PTGS2 activity then leads to the conversion of arachidonic acid into Prostaglandin 
E2 (PGE2),125 which in turn promotes the differentiation of monocytes into 
suppressive TAMs and prevents DC differentiation.126  These data suggest that IL-
6–mediated promotion of IL-17 secretion might play a pivotal role in the switch 
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between the M1 and M2 macrophage phenotypes during PCa initiation and 
progression.  
 
Figure I.4 | Contribution of Myeloid-derived Cells to Prostate Cancer 
Progression. M1-like Mϕ may contribute to tumor initiation after an inflammatory 
insult to the prostate gland,112 likely by inducing accumulation of IL-17 and tumor-
derived factors in the TME. Other myeloid-derived cells—M2-like Mϕ, MDSCs, and 
suppressive dendritic cells—likely infiltrate the TME early during tumor progression 
and suppress an antitumor response by inducing Tregs and preventing CD8 T cell 
infiltration and function. Bone resident Mϕ (osteoclasts) and PMN-MDSCs further 
contribute to tumor dissemination to bone by increasing osteoclastic bone 
resorption and regulating tumor cell homing (via CXCR4 expression), respectively. 
RNS, reactive nitrogen species; ROS, reactive oxygen species. 
Myeloid-derived Cells in Cancer Progression 
As shown in Figure I.4 above, there is a large body of evidence from clinical studies 
that suggests that myeloid cells (neutrophils, MDSCs and TAMs) contribute to 
cancer progression.127  In PCa, the immunosuppressive TME has been shown to 
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hinder monocyte differentiation and DC maturation.96  Accordingly, the percentage 
of M-MDSCs is significantly increased in the blood of PCa patients as compared 
to sex and age-matched controls.128,129  Mechanistically, the ability of these cells 
to suppress T cell proliferation and to express high levels of IL-10 has been 
confirmed in vitro.130  Although M-MDSCs levels return to normal after removal of 
the prostate gland,129 elevated levels of M-MDSCs have been associated with a 
shorter median OS in mCRPC.131 
Similarly, accumulation of PMN-MDSCs in the peripheral blood of PCa 
patients has been correlated with decreased OS, increased levels of CXCL8 and 
IL-6,132 and PCa progression from localized to metastatic disease.133  Accordingly, 
a retrospective analysis of patients with mCRPC that received personalized 
peptide vaccination showed that a PMN-MDSCs gene signature in peripheral 
blood mononuclear cells (PBMCs) post-vaccination correlated with poor 
prognosis.134  Other studies showed that an elevated neutrophil to lymphocyte ratio 
(NLR) in the periphery correlates with a positive needle biopsy for PCa135 and that 
NLR is a strong correlate of poorer OS in patients with mCRPC.136  In addition, 
mCRPC patients with a low NLR at baseline showed a significantly longer OS after 
first and second-line chemotherapy.128,137  At this point, it is difficult to discern 
whether the prognostic value of the NLR is due to the contribution of PMN-MDSCs 
in peripheral blood of PCa patients, or whether it reflects CXCL8 mediated 
neutrophil expansion.  In this regard, a recently identified marker (OLR1) that 
distinguishes human neutrophils from PMN-MDSCs138 may inform future studies 
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aimed at differentiating the contribution of neutrophil and PMN-MDSCs to PCa 
progression.  
TAMs in the PCa TME are also associated with poor prognosis and 
outcome.  An elevated density of CD68+ TAMs infiltrating the prostate at the time 
of radical prostatectomy correlates with extracapsular extension (a marker of poor 
prognosis).139   Similarly, CD68+ TAMs infiltration in prostate needle biopsy 
specimens correlates with PCa progression as determined by PSA recurrence or 
PSA failure in patients treated with hormonal therapy as the first line of 
treatment.140  In addition, an elevated density of CD68+ TAMs in tissue from 
patients that underwent ADT prior to radical prostatectomy was found to be 
associated with an increased risk of biochemical recurrence.141  In line with these 
observations, cell culture experiments have shown that IL-1β (a cytokine highly 
produced by Mϕ) in the TME may mediate androgen independence by inducing 
the degradation of the AR signaling complex.142,143  In animal models, the reduction 
in tumor growth following depletion of Mϕ using clodronate-encapsulated 
liposomes or pharmacologic inhibitors of CSF1R signaling (GW2580 and 
PLX3397) support a role for TAMs in progression144,145 and in biochemical 
recurrence in PCa.143  
cDCs, which, in general, promote an adaptive CTL response, are 
associated with an improved prognosis in PCa patients.146  In addition, elevated 
numbers of BMDCs in the peripheral blood of patients are associated with a less 
aggressive phenotype.147  Accordingly, PCa patients who received a cDC-based 
vaccine and successfully mounted a specific T cell response against the vaccine 
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antigen showed a significantly increased OS as compared to those who received 
the vaccine but did not mount a specific T cell response.148  These data highlight 
the potential importance of cDC maturation for an effective anti-tumor response 
and suggest that this process might be impeded in a subset of patients.  
Mechanistically, IL-10 inhibits BMDC differentiation from monocytes in culture90,91 
and may thus also inhibit the maturation of cDCs in the TME.  It should be noted, 
however, that ex-vivo generation of BMDC is feasible in most PCa patients.   
Myeloid-derived Cells and Cancer Cell Metastasis 
Over time, prostate tumor cells accumulate genetic alterations that allow them to 
emigrate from the primary tumor and seed metastases at different anatomic 
sites.149  These alterations may also allow them to recruit myeloid cells to the 
TME150 and reprogram these cells in ways that may facilitate escape from the 
prostate gland, survival in the circulation, and the establishment of a pre-metastatic 
niche in distant sites.151  Early evidence for the importance of TAMs in the 
metastatic process came from a breast cancer model where primary tumors 
developed similarly in macrophage-deficient mice but were unable to form 
pulmonary metastases.152  Although there is currently no pre-clinical model that 
accurately recapitulates the metastatic processes involved in human PCa, M2-like 
Mϕ have been reported to infiltrate metastatic PCa lesions in rapid autopsy 
samples in higher concentrations than adjacent normal tissues.120  In addition, 
clinical data support the accumulation of PMN-MDSCs and neutrophils in the 
peripheral blood of patients with mCRPC.132,136  
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Bone is the major metastatic site for human PCa153 and is a rich reservoir 
of MDSCs in animal models.99  Accordingly, prostate tumor cells may travel to this 
pre-metastatic niche following a chemokine gradient involving CXCR4151 (Fig. I.4). 
This mechanism resembles a normal physiological process, in which immature 
myeloid cells in the bone marrow are maintained by CXCR4 / CXCL12-dependent 
chemokine signaling.154  Indeed, increased CXCR4 expression on prostate tumor 
cells is associated with the presence of bone metastasis in PCa patients155 and its 
role in bone homing was highlighted by pre-clinical models showing that CXCR4 
blockade significantly reduced the total metastatic load in tumor-involved bone.156  
Interestingly, CXCR4 has been reported to be up-regulated by ROS–mediated 
phosphatase and tensin homolog (PTEN) loss100 suggesting that the pre-
metastatic niche might be driven to some degree by PMN-MDSC-derived ROS.  
Another subset of myeloid-derived cells fundamental for the successful 
establishment of cancer metastasis in the bone are bone-resident Mϕ or 
osteoclasts.  Osteoclasts are responsible for breaking down bone through a 
process of bone resorption that has the untoward effect of enabling tumor cell 
seeding151 (Fig. I.4).  This process is highly dependent on the receptor activator of 
NF-B (RANK), recently renamed as TNFRSF11A, and its ligand RANKL or 
TNFSF11.157  The RANK / RANKL pathway is a target of interest for the treatment 
of metastatic PCa; in addition to its role in osteoclast activity, the RANK / RANKL 
pathway can also be activated in tumor cells.  Using a transgenic mouse model 
that express the SV40 large T antigen in prostate epithelium (TRAMP), Luo and 
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colleagues showed that metastasis to lymph node, liver, and lung was dependent 
on NF-B signaling.158 
A Potential Role for PI3K / PTEN / AKT Pathway Activation and ER Stress in 
the Suppressive TME 
Recent pre-clinical data indicate that dysregulation of intrinsic pathways in tumor 
cells results in the production of inflammatory mediators and ultimately in immune 
infiltration.159-161  In addition, pre-clinical models in other cancer types support the 
notion that these tumor-cell intrinsic pathways may promote resistance to ICB.162  
This may help to explain why only a small fraction of PCa patients responds to 
checkpoint blockade163-166 and guide the search for new therapeutic agents to be 
used in combination with current immunotherapies.  
PI3K / PTEN / AKT Pathway Activation and Recruitment of Myeloid Cells 
The mutational landscape of mCRPC reveals that the most frequently altered 
genes include AR (62.7%), TMPRSS2-ERG and other ETS fusions (56.7%), TP53 
(53.3%), and PTEN (40.7%).167  Beyond these more common mutations, somatic 
alterations in genes involved in cell survival pathways (PI3K, Rb, RAF, and CDK), 
genome maintenance (BRCA2, BRCA1, ATM), and cell fate (WNT) are also 
common in advanced disease.167  Recent studies showed that T cell and dendritic 
cell infiltration may be mediated by PTEN loss and WNT / B-catenin activation in 
other tumor types.161  These findings raise the possibility that the mutational 
signatures present in mCRPC could potentially underlay the suppressive 
microenvironment associated with disease.     
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As above, in PCa, PTEN loss, and subsequent PI3K / PTEN / AKT 
activation,168,169 has been described by multiple groups.  Activation of this pathway 
correlates with a more aggressive phenotype170 and a decreased recurrence-free 
survival in patients with low-risk PCa (Gleason score 3+3 and 3+4).171  In addition 
to PTEN loss due to genetic or epigenetic factors, PTEN activity can also be lost 
as a consequence of a highly oxidative TME without overt loss of the gene itself.100  
These data suggest that abundant ROS-producing cells, such as PMN-MDSCs, 
could play an indirect role in sustained PTEN down regulation (Fig. I.5).  
 Additional pre-clinical evidence supports the notion that myeloid-derived 
cells can be recruited through PI3K / PTEN / AKT signaling in prostate tumor cells 
(Fig. I.5).  Using a conditional PTEN knockout mouse model, Garcia and 
colleagues showed that myeloid infiltration into the prostate gland is increased 
early during tumor development by epithelial PTEN loss.172  In addition, in vitro 
experiments showed that myeloid recruitment may be mediated by CXCL8 / 
CXCR2 signaling in human PCa cell lines in which PTEN is lost.173-175 It will be 
interesting to determine whether similar events occur in men with PCa, i.e. whether 
PTEN loss / PI3K activation correlates with the extent or function of an 
immunosuppressive microenvironment. 
Additional Mechanisms for PI3K / PTEN / AKT Pathway Activation 
One cytokine that may play a key role in linking PI3K / PTEN / AKT in tumor cells 
with myeloid recruitment is IL-6 (Fig. I.5).  Paracrine IL-6 signaling has been shown 
to induce intraperitoneal accumulation of monocytes in IL-6 knockout mice treated 
intra-peritoneally with a fusion protein containing IL-6 fused to sIL6R.176  This 
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signaling has been shown to activate the PI3K / PTEN / AKT signaling pathway in 
prostate tumor cells.119  Together, these data suggest that paracrine IL-6 signaling 
could indirectly lead to PI3K / PTEN / AKT–mediated myeloid recruitment (Fig. I.5). 
However, other cytokines in the TME are also likely to contribute to the 
accumulation of myeloid-derived cells in prostate tumors.159 
One process that may lay upstream of PI3K / PTEN / AKT activation and 
subsequent recruitment of MDSCs is prolonged ER stress – which ultimately leads 
to the unfolded protein response (UPR).  This adaptive response increases tumor 
cell viability in the TME, and is characterized by increased levels of the 
endoplasmic reticulum chaperone protein: heat shock protein family A (Hsp70) 
member 5 (HSPA5), also known as GRP78.177,178  The ER sensors: protein kinase 
RNA-like ER kinase (PERK), also known as EIF2AK3; inositol-requiring protein 
1alpha (IRE-1), also known as ERN1; and activating transcription factor 6 (ATF6) 
restore cell homeostasis in cancer cells in conditions of ER stress.179,180  Activation 
of both PERK and IRE-1 involves their dimerization, oligomerization, and trans-
autophosphorylation. Activated PERK leads to the inhibition of protein synthesis; 
while activated IRE-1 exposes its RNase domain which splices the mRNA of X-
box binding protein 1 (XBP1) to generate a transcription factor (XBP1s) that 
upregulates a subset of chaperone proteins. ATF6 translocates from the ER to the 
Golgi apparatus during stress conditions and is processed into ATF6f –a 
transcription factor that controls the expression of selected UPR target genes. The 
UPR response is complex, and is well-discussed in a recent review.181  Under 
resting conditions, HSPA5 binds to these ER sensors (PERK, IRE-1, and ATF6) 
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and maintains them in an inactive state182 thereby preventing an UPR response.  
A recent study in which persistent ER stress was modeled via multiple 
administrations of the toxin thapsigargin showed that ER stress induces the 
accumulation of MDSCs in the spleens of mice bearing subcutaneous colon 
tumors.183  Although this study did not directly address a role for AKT activity in 
tumor cells, experiments by Fu and colleagues showed that in vitro stimulation of 
human prostate tumor cells with thapsigargin resulted in ER stress and AKT 
activation.184  Furthermore, PI3K / PTEN / AKT activation was found to be 
abrogated by HSPA5 deletion in a PTEN conditional knockout mouse model.184  
Taken together, these data raise the intriguing possibility that, in PCa, myeloid 
recruitment following ER stress could possibly be regulated by PI3K / PTEN / AKT 
activation (Fig. I.5).  These observations must be tempered, however, by the 
experimental models employed as it is not clear how well prolonged thapsigargin 
treatment models physiological stressors in the human prostate TME. 
 Although multiple mechanisms may be responsible for an ER stress 
response, one physiological mediator of increased ER stress in PCa could be 
saturated fatty acids (FA).  Accumulation of saturated FA in the ER membrane 
activates the ER sensors IRE-1 and PERK by enhancing their dimerization via 
their transmembrane domains.185 Although not directly tested in PCa specimens, 
PTEN inactivation in a human PCa cell line led to increased expression of FA 
synthase (FASN), a lipogenic enzyme that catalyzes the terminal steps in the 
synthesis of long chain saturated fatty acids.186 In addition, de novo lipogenesis 
has been shown to promote membrane lipid saturation in prostate tumor cells187 
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and was found to be associated with an increased risk of PCa in a nested case-
control study.188 Together, these data suggest that saturated FA might induce ER 
stress and subsequent PI3K / PTEN / AKT pathway activation as a possible step 
in the recruitment of myeloid cells in PCa (Fig. I.5). 
 
Figure I.5 | Effects of PI3K / PTEN / AKT Pathway Dysregulation in Prostate 
Tumor Cells. The noncanonical activation of AKT via IL-6 signaling, ROS 
accumulation, and ER stress response in PCa tumor cells is illustrated. Increased 
PI3K / PTEN / AKT pathway activation leads to prostate tumor cell survival (i.e., 
increased angiogenesis/lipid biosynthesis and decreased apoptosis) and the 
recruitment of myeloid cells. Binding of IL-6 to its receptor activates JAK, which 
leads to the phosphorylation of PI3K and, ultimately, to AKT signaling. 
Accumulation of ROS can also indirectly mediate AKT phosphorylation by down-
regulating PTEN, which leads to unregulated PI3K activity. Finally, the ER stress 
response may also increase AKT signaling via the dissociation of HSPA5 from the 
ER sensors (PERK, IRE-1α, and ATF6), although the precise mechanism(s) by 
which this occurs is(are) currently unclear. In addition, XBP1s, generated by IRE-
1α RNase activity, increases lipid biosynthesis (saturated FA), which may also 
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activate ER stress and maintain AKT signaling. HSPA5, heat shock protein family 
A member 5; IL-6R, IL-6 receptor; IL6ST, IL-6 signal transducer. 
ER Stress in Myeloid Differentiation and Antigen Presentation 
Recent studies showed that ER stress can be ‘transmitted’ from tumor cells to 
myeloid cells; in these experiments Mϕ cultured in conditioned medium from ER-
stressed tumor cells evidenced an ER stress response themselves, with up-
regulation of  Hspa5 and Xbp1s.189 The exact mechanism by which this 
transmission is achieved is still a subject of investigation. It is possible, however, 
that TLR4 receptors on myeloid cells are activated as a consequence of 
immunogenic cancer cell death via the release of high mobility group protein B1 
(HMGB1)190 or lipids.191  The notion that ER stress can be ‘transmitted’ from tumor 
cells to myeloid cells suggests that ER stress may not only be involved in myeloid 
cell recruitment, but also in hindering myeloid differentiation and contributing to 
immune evasion in the TME.  Indeed, Gabrilovich and colleagues demonstrated 
that ER stress was increased in MDSCs isolated from both tumor-bearing mice 
and cancer patients with non–small cell lung cancer (NSCLC) and head and neck 
cancer (HNC).192  Specifically, they showed clear up-regulation of XBP1s.192 
XBP1s has been reported to regulate cell proliferation in PCa cell lines,193 but its 
role in MDSCs requires further investigation.  Additionally, recent data from pre-
clinical models involving induced ER stress in cancer cells stress suggest that 
XBP1s might regulate the immunosuppressive function of MDSCs by up-regulating 
Arg1 and Nos2.183  Since ER stress plays a pivotal role in human PCa, it is tempting 
to speculate that similar mechanisms might regulate the immunosuppressive 
phenotype of MDSCs in PCa.180 
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 The immunologically suppressive role of ER stress extends to other cell 
types. For example, in intra-tumoral cDCs ER stress leads to down-regulation of 
their antigen cross-presentation capacity and subsequently to decreased priming 
of CTLs.  This was demonstrated in animal models, where XBP1s up-regulation 
led to the accumulation of intracellular lipids in cDCs, as well as in vitro in BMDCs 
cultured with the ER stressor tunicamycin.101  Lipid accumulation in cDCs may be 
mediated by the macrophage scavenger receptor 1 (Msr1) on the plasma 
membrane of dendritic cells194 or by tumor-derived factors195 that could induce ER 
stress in a HSPA5 dependent manner.196  Cubillos-Ruiz and colleagues showed 
that cDCs accumulate lipids in a process that is mediated by triglyceride 
biosynthesis, rather than by lipid intake, and that is dependent on XBP1s.101  Using 
a mouse model with XPB1 specifically knocked out in CD11c+ cells, preventing ER 
stress in cDCs increased their function and enhanced their ability to prevent tumor 
progression as demonstrated by studies in which XPB1-/- cDCs were adoptively 
transferred to wild type mice challenged with ovarian tumors.101  Thus, it is 
intriguing to further speculate that the dysregulated lipid environment in PCa may 
also mediate immunosuppression by altering the function of APCs such as cDC.197 
Immunotherapy – Breaking Immunological Tolerance to Cancer 
Immunotherapy with PD-1 / PD-L1 blockade plays a role in the treatment of many 
tumor types; as above PCa remains one of several exceptions.  In PCa, the main 
challenge has been to overcome the so-called ‘cold’ tumor microenvironment given 
that the mechanisms underlying this phenotype remain unknown.  As a general 
principle, more heavily mutated tumors show increased T cell infiltration.198  
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Although the mutational burden in mCRPC is generally low (median, 2.9 
mutations/megabyte),199 and only 3% to 8.3% of advanced PCa tumors have high 
tumor mutational burden (TMB),199,200 tumors with microsatellite instability (MSI) 
have a greater number of tumor-associated antigens (TAAs) and thus be more 
likely to respond to immunotherapy approaches.167,200-203  An alternative 
mechanism driving the establishment of ‘cold’ TMEs is the infiltration of 
suppressive cell populations, including Tregs and MDSCs, discussed above. A 
number of approaches have been taken to attempt to convert ‘cold’ tumors into 
‘hot’ tumors and circumvent the development of tolerance in the setting of PCa 
immunotherapy, inhibition of negative regulators of immune activation (immune 
checkpoint blockade), induction of de novo anti-tumor immune response 
(vaccination and other neoantigen-driven approaches), and modulation of the 
myeloid compartment.  Below, we describe these therapeutic avenues. 
Immune Checkpoint Blockade (ICB)  
The ability of the immune system to fight tumor cells has revolutionized cancer 
treatment in the last decade.  Indeed, ICB, which targets co-inhibitory molecules 
on immune cells to promote anti-tumor immunity, has become the fourth pillar of 
cancer treatment along with standard therapies focused on targeting tumor cells 
themselves such as surgery, radiation, and chemotherapy.204  As discussed 
above, co-inhibitory molecules play an important role in maintaining tolerance to 
self-antigens as well as controlling the magnitude of the immune response.  While 
CTLA-4 is highly expressed on tumor infiltrating Tregs,205 the activity of PD-1 / PD-
L1 blockade is likely more restricted to CD8 CTLs, as described above.  Indeed, 
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anti-CTLA-4 has shown anti-tumor activity in two phase III clinical trials for 
mCRPC.54,59 However, the observed effects were modest and suggest that CTLA-
4 blockade alone is unlikely to be sufficient for robust clinical activity in PCa.76  A 
reanalysis of data from one of those phase  III clinical studies suggested that 
CTLA-4 blockade in combination with radiotherapy may be promising for the 
treatment of mCRPC with normal alkaline phosphatase, normal hemoglobin, and 
no visceral metastases.164  Similarly, targeting CD8 CTLs in the tumor 
microenvironment mCRPC seems to be restricted to a subset of tumors expressing 
PD-L1196 and/or presenting microsatellite instability.206,207  
The mainstay treatment for mCRPC, androgen-deprivation therapy (ADT), 
induces a pro-inflammatory infiltrate55,208 and temporarily abrogates immune 
tolerance to the prostate gland.209  We and others showed that the combination of 
immune checkpoint blockade with ADT could provide an additive or perhaps even 
synergistic effect on the treatment of PCa.76  Indeed, PD-1 blockade showed 
measurable radiographic response in 25% of PCa patients progressing on the 
second generation anti-androgen enzalutamide.210 In line with these results, a 
recent phase II study suggests activity for the combination of PD-1 blockade and 
CTLA-4 blockade in patients with AR-V7-positive prostate cancer with DNA-repair 
deficiency (DRD).211  This study enrolled 15 metastatic prostate cancer patients 
with AR-V7-expressing circulating tumor cells. Six of these patients had a positive 
DRD status as determined by targeted next-generation sequencing (three in 
BRCA2, two in ATM, one in ERCC4; none had microsatellite instability). 
Interestingly, PSA responses were observed in 33% of patients with a DRD+ 
31 
 
status, while none were observed on patients with a DRD- status.  Although these 
findings were not statistically significant. These encouraging results for CTLA-4 
and PD-1 blockade are supported by an additional phase II study in men who had 
previously received ADT.212 In this study, 25% of the 32 evaluated mCRPC 
patients receiving the combination therapy pre-chemotherapy had an objective 
response. Furthermore, an extended survival (51.2 months) was observed in 10% 
of mCRPC patients who received the combination therapy in the post-
chemotherapy setting.   
Cancer Vaccines and Other Neoantigen-driven Approaches  
As discussed above, the immune system has the capacity to recognize and 
destroy tumor cells. Thus, cancer vaccination represents a viable strategy to 
generate a de novo anti-tumor immune response, or to boost an existing one. 
However, in established tumors, the immune system has been rendered 
immunologically tolerant – which means therapeutic cancer vaccines not only need 
to overcome the immunosuppressive microenvironment, but also need to be 
directed towards an immunogenic tumor-associated antigen (TAA).  Thus, 
selecting an optimal TAA is a key aspect in developing a vaccine. Putative TAAs 
can either be selected as a consequence of tumor progression (mutation 
associated neoantigens or MANAs)213,214 or be shared between tumor and healthy 
cells (non-mutated neoantigens). Non-mutated neoantigens are generally 
temporally expressed during development (e.g., MAGE, PAGE, NY-ESO-1), 
overexpressed by tumor cells (e.g., WT1), or expressed in a tissue-specific manner 
(e.g., PAP, PSMA, PSA).215 Non-mutated TAAs have the advantage of being 
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readily recognized by T cell precursors due to incomplete thymic deletion or 
peripheral tolerance towards these self-antigens216.  TAAs used in vaccines are 
commonly expressed by genetically modified cells, either from the patient or from 
a cell line, to protein pulsed and matured dendritic cells (cell based vaccine; e.g., 
Sipuleucel-T and GVAX) or a viral / bacterial vector (e.g., Prostvac-VF and 
ADXS031-142).   
As discussed above, prostate tumors are characterized by a low mutational 
burden.  However, non-mutated prostate-specific TAAs such as prostatic acid 
phosphatase (PAP) has proven to be useful targets for immunotherapy. Indeed, 
the only FDA approved therapeutic vaccine for the treatment of mCRPC, 
Sipuleucel-T, directs an immune response against the PAP target.  In this 
approach, a patient’s peripheral blood leukocytes are collected to generate 
monocyte-derived dendritic cells (moDCs) that recognize the PAP antigen on 
tumor cells once reinfused into the patient.198,217  Similar approaches have shown 
to drive ex-vivo immune responses in patients with androgen independent disease 
when autologous moDCs are directed to target PSMA.218  Additional non-mutated 
TAA targets such as prostate-specific antigen (PSA) have also been tested using 
different vaccine formulations in clinical trials with less promising results, including 
a recent negative phase III study.76,219  In addition to single antigen targeting 
approaches, a whole cell vaccine combining LNCaP and PC3 PCa cell lines 
modified to secrete GM-CSF (GVAX) has also been investigated (Fig. I6).  The 
potential advantage of this approached is the diversity of TAA targets provided by 
the vaccine; however, phase III clinical studies were terminated early.198  Since 
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one of the mechanisms mediating the intrinsic resistance to vaccine therapies in 
PCa is immune tolerance, vaccines may need to be enhanced with combination 
approaches directed to modify the tumor microenvironment to be successful.  
Indeed, a phase I clinical trial evaluating GVAX in combination with anti-CTLA-4 
showed encouraging anti-tumor activity in mCRPC.220  Similarly, a PSA-targeting 
vaccine induced stable disease in about a third of patients when treated in 
combination with anti-PD-1 blockade.221  Currently, a trial is ongoing that tests a 
PSMA targeted peptide vaccine administrated in combination with a TLR-3 agonist 
in PCa patients with progressive disease (NCT00694551). 
Most recently, alternative approaches to activate cytotoxic T-cell responses 
independently of TCR signaling have been developed; namely, bispecific T-cell 
engagers (BiTEs) and chimeric antigen receptors (CARs). The first is a fusion of 
two monoclonal antibodies (single-chain fragment variable, scFvs) that 
simultaneously engage a TAA expressed in the surface of cancer cells and CD3ε 
T-cell receptor-associated molecule on the T-cell surface (Fig. I6).222  The second, 
involves T cell transduction with a virus containing a chimeric antigen receptor 
composed of three components: 1) an extracellular domain also composed an 
scFV that recognizes the target TAA; 2) a transmembrane domain composed of 
membrane domain regions of various immune receptors such as CD3, CD8, CD28, 
or FcεRI; and  3) a cytoplasmic domain which is composed of one or more of 
intracellular regions involved in T-cell activation or co-stimulation such as  CD8, 
CD28, CD137 or CD3ζ.223  This type of therapy has shown significant clinical 
activity in liquid tumors such as leukemia where the targeted TAA (CD19) is 
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present in every cancer cell.224-228  In solid tumors, an ideal target TAA would 
enable CAR-T cells to mount a cancer-specific immune response, thus sparing 
healthy tissue.229    
Notably, a fully human (AMG 160) BiTE targeting PSMA in PCa cells and 
CD3 in T cells, demonstrated anti-tumor activity in xenograft models.230  A phase I 
clinical study has shown the safety of this treatment approach;231 however, the 
clinical activity in mCRPC remains to be reported (NCT03792841).232 Similar 
BiTEs targeting PSCA have also shown some promise in  pre-clinical work.233 
Preliminary results with CAR T cell directed to PSCA alone234 or in combination 
with PSMA targeting CAR T cells,235 suggest the potential of this new therapeutic 
strategy for PCa. Multiple clinical trials evaluating this class of agent are ongoing, 
as are studies with CAR T cells targeting other TAAs, such as epithelial cell 
adhesion molecules (NCT03873805, NCT03089203, NCT04053062, 




Figure I.6 | Immunotherapy Approaches in Prostate Cancer. A, Sipuleucel-T 
involves leukapheresis of immune cells followed by incubation with specific fusion 
protein (PA2024) which consists of prostatic acid phosphatase (PAP) coupled with 
granulocyte-macrophage colony stimulating factor (GM-CSF). Cells are then re-
infused allowing for APC maturation and activation of CD4+ and CD8+ T cells to 
recognize and kill PAP presenting tumor cells. B, Checkpoint inhibitors are 
monoclonal antibodies which target immune checkpoints including programmed 
cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) and prevent 
binding to PD-L1 and CD80 or CD86 respectively, which are expressed on tumor 
and other immune cells. This leads to an enhanced antitumor T-cell response.  C, 
Bispecific antibodies are engineered antibodies that contain two binding sites, one 
for CD3 receptor found on T-cells and another for an antigen found on tumor cells. 
Several different constructs including Bi-specific T-cell engagers (BiTEs) are in 
clinical development.  D, J591 is a humanized monoclonal antibody specific for 
prostate-specific membrane antigen (PSMA). The antibody can be labeled with 
lutetium-177, an isotope ideal for radiation therapy. The radioactive antibody 
targets PSMA presenting tumor cells and kills them with radiation.  E, Chimeric 
antigen T-cell receptors (CAR-T) are receptors engineered to target antigens via 
an antibody derived single chain variable fragment, allowing the T-cell to function 
independent of the major histocompatibility complex. Pictured is a second-
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generation CAR which contains a co-stimulatory domain and CD3ζ signaling 
domain.198  
The combination of immunotherapy with treatments that lead to 
immunogenic cell death such as radiation therapy,236 chemotherapy drugs such as 
taxanes,237 or to high levels of T-cell infiltration such as androgen-deprivation 
therapy (ADT)141,238-240 is likely to increase objective responses in PCa patients. 
Indeed, a phase II trial showed PAP-specific T cell responses were two fold higher 
in patients that received Sipuleucel-T before ADT in comparison to those that 
received it after ADT.241  These data could have implications on the effect of ADT 
in modulating the tumor microenvironment, as well as in the sequence of 
immunotherapy administration for optimal clinical activity. Additional combination 
therapies targeting co-stimulatory molecules such as OX40, 4-1BB, CD30, CD40L, 
or ICOS may also increase the clinical responses achieved by these therapeutic 
interventions. 
Therapeutic Modulation of the Myeloid Components in the Prostate Cancer Tumor 
Microenvironment 
Although ICB has clear activity in multiple tumor types,242 studies in PCa with such 
agents have generally been disappointing.163-165  One possible explanation for this 
lack of activity could be related to the underlying myeloid components of the PCa 
microenvironment.  Multiple interventions targeting myeloid cells and their effects 
on the TME have been recently reviewed,243-245 and here we focus on novel targets 
relevant to the treatment of PCa. 
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One interesting agent in this regard is tasquinimod (Active Biotech AB, 
Sweden), a second-generation quinoline-3-carboxamide derivative.246  Although 
its mechanism of action is still under investigation, tasquinimod was shown to 
target S100A9 – leading to the reduction of MDSCs in the TME in a breast cancer 
model.247 In addition, tasquinimod was also reported to inhibit M2-like polarization 
and increase CTL infiltration when used in combination with a vaccine in a PCa 
model.248  Recently, tasquinimod was found to not improve OS in men with 
mCRPC in a phase III study.249,250  Still, the pre-clinical data suggest that 
tasquinimod could potentially be re-purposed in combination with 
immunotherapeutic approaches to PCa. 
 A novel approach to modulating the myeloid compartment in PCa is via 
targeting of the Hippo / YAP (Yes Associated Protein) pathway.  In this tumor 
suppressor pathway, Hippo restricts organ size in mammals by antagonizing the 
oncoprotein YAP.251 Consistent with a critical role for Hippo-YAP signaling in 
normal tissue homeostasis, the YAP oncoprotein is activated in a wide spectrum 
of human cancers.252  In PCa, recent studies showed that the common TMPRSS2-
ERG genomic fusion may lead to YAP activation.253  In addition, YAP has recently 
been shown to bind the promoter of CXCL5 (a homologue of CXCL8) and up-
regulate its expression in tumor cells to recruit MDSCs into the TME.254 These data 
suggest that the YAP antagonist verteporfin (Novartis Pharmaceuticals, 
Switzerland)252 and other related compounds could be of clinical use for the 
treatment of PCa.  Indeed, a phase I clinical trial of verteporfin in patients with 
established bone metastases has been initiated (NCT02464761).    
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 Another agent that targets the myeloid compartment is DS-8273a (Daiichi 
Sankyo Inc., Japan), a second-generation monoclonal antibody that targets death 
receptor 5 (DR5), also known as TNFRSF10B.  Pre-clinical data from a lymphoma 
model and from DR5 knockout mice showed that DR5 promotes the accumulation 
of MDSCs, such that DR5 inhibition facilitates the expansion and function of 
CTLs.192  These data suggest DR5 as a potential target for attenuating MDSCs 
infiltration into the TME.  An earlier monoclonal antibody against DR5, CS-1008 
(Daiichi Sankyo Inc., Japan), was demonstrated to be well-tolerated in a phase I 
trial and to induce stable disease in 8 out of 19 patients with metastatic colorectal 
cancer.255  Taken together, these data support the clinical potential of targeting 
DR5.  The safety and tolerability of DS-8273a is currently being evaluated in an 
open label clinical trial for patients with advanced solid tumors or lymphomas 
(NCT02076451) and, like the YAP inhibitor discussed above, DR5 inhibitors may 
eventually have utility in PCa. 
 Alternatively, the immunosuppressive microenvironment in PCa may be 
modulated by decreasing TAM recruitment to the tumor site.  Since this recruitment 
is at least partially mediated by colony stimulation factor 1 receptor (CSF1R) 
signaling on inflammatory Mϕ, its inhibition has been proposed as a potential 
treatment for several tumor types, including PCa.  In animal models of PCa, 
CSF1R blockade with small molecules was shown to delay tumor growth.143,145  
Accordingly, two tyrosine kinase inhibitors, PLX3397 (Plexxikon, Berkeley CA) and 
axitinib (Pfizer Inc, New York City NY), are now being tested in patients with 
advanced CRPC (NCT01499043) and in PCa patients undergoing androgen 
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ablation therapy (NCT01409200), respectively.  In addition to small molecules, 
monoclonal antibodies can be used to target CSF1R – resulting in the subsequent 
inhibition of the recruitment of inflammatory Mϕ to the TME.  Demonstrating clear 
enthusiasm for this approach, a total of four monoclonal antibodies against CSF1R 
are currently in clinical trials for the treatment of various tumor types: FPA008 
(FivePrime, San Francisco CA –NCT02526017), IMC-CS4 (Eli Lilly, Indianapolis 
IN –NCT01346358 & NCT02265536), AMG 820 (Amgen, Thousand Oaks CA –
NCT01444404 & NCT02713529), and RG7155 (Hoffmann-La Roche, Switzerland 
–NCT01494688, NCT02760797 & NCT02323191).  Interestingly, RG7155 was 
shown to induce objective clinical responses in 74% of patients with extra-articular 
pigmented villonodular tenosynovitis (PVNTS)256 and is now in clinical trials for 
several solid tumors in combination with chemotherapy (NCT01494688) and PD-
L1 blockade, atezolizumab (Hoffmann-La Roche, Switzerland –NCT02323191).  
Although the majority of these clinical studies are not specifically recruiting PCa 
patients, the activity of IMC-CS4 is being evaluated in a phase I study for advanced 
breast cancer and CRPC (NCT02265536).  
The phenotype of TAM could potentially be modulated by the neutralization 
of IL-6 / IL6R signaling. Current inhibitors of this pathway include monoclonal 
antibodies against IL-6, siltuximab (Janssen Pharmaceutica, Belgium), and IL6R, 
tocilizumab (Hoffmann-La Roche, Switzerland). Pre-clinical studies demonstrated 
a therapeutic effect of siltuximab in PCa;257 this observation was supported in a 
multicenter phase II study that tested siltuximab in patients with CRPC that were 
pretreated with one prior chemotherapy.258 Although none of the patients showed 
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a clinically defined response to the treatment, 23% achieved stable disease.258 
Less encouraging results were observed when siltuximab was given in 
combination with chemotherapy agents to patients with mCRPC,259 suggesting 
that IL-6 / IL6R blockade may be more effective earlier during disease progression 
when the contribution of TAM to the development of CRPC is likely to take place. 
Tocilizumab is currently FDA-approved for the treatment of rheumatoid arthritis, 
and was found to induce and maintain complete remission of patients with giant 
cell arteritis260– a disease for which Mϕ are the major drivers.261 The maximal 
tolerated dose of tocilizumab in hepatocellular carcinoma patients will be evaluated 
in a phase IB study that will be followed by the phase II design where the primary 
end point will be median progression free survival (NCT02997956). Although there 
are currently no trials underway, it is possible that tocilizumab could eventually be 
evaluated in PCa patients. 
An effective CTL response against PCa may also hinge upon addressing 
the suppressive phenotype of not only MDSCs but also a subset of BMDCs in the 
TME.  In this regard, IDO inhibition has been shown to decrease host-mediated 
immunosuppression and enhance antitumor immunity in multiple pre-clinical 
models.262  As discussed above, IDO is the rate-limiting step in the catabolism of 
tryptophan93 and is produced by MDSCs and suppressive DCs in the TME.  
Accordingly, IDO inhibition with 1-d-MT (a tryptophan racemic isoform: 1-methyl-l- 
tryptophan) was shown to improve response to CTLA-4 blockade in a pre-clinical 
model of melanoma263 suggesting that IDO inhibition can reverse the 
immunosuppressive microenvironment in cancer.  Three IDO inhibitors are 
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currently in clinical trials for the treatment of various solid tumors: indoximod 
(NewLink Genetics Corporation, Ames IA –NCT01560923 & NCT02077881), 
GDC-0919 (Genentech Inc, San Francisco CA –NCT02048709), and epacadostat 
(Incyte Corporation, Wilmington DE –NCT02752074 & NCT02327078).  Recently, 
data from an ongoing phase I/II study presented at the Society for Immunotherapy 
of Cancer annual meeting suggest interesting anti-tumor activity in several tumor 
types when epacadostat is used in combination with PD-1 blockade, 
pembrolizumab (Merck, Kenilworth NJ –meeting abstract #142); this combination 
is currently being tested in a phase III trial for advanced melanoma 
(NCT02752074).  Furthermore, epacadostat is being tested in combination with a 
second PD-1 blocking antibody, nivolumab (Bristol-Myers Squibb, New York City 
NY), in a phase I/II study for lymphomas and several solid tumors (NCT02327078).  
Although PCa patients are not being included in these studies, presumably due to 
the lack of activity of PD-1 and PD-L1 blockade as a single agent, it is possible 
that IDO inhibitors may reverse the immunosuppressive TME and prime T cells for 
checkpoint blockade in PCa.  The ongoing phase II combining indoximod with 
Sipuleucel-T (Valeant Pharmaceuticals, Canada) for the treatment of mCRPC is 
likely to shed some light on the effect of modulating the immunosuppressive 
microenvironment in PCa (NCT01560923). 
Elevated osteoclast activity is an important aspect of the pathophysiology 
of treatment-related complications in PCa.  The inhibition of bone-resident Mϕ 
(osteoclasts) with the RANKL directed monoclonal antibody, denosumab (Amgen, 
Thousand Oaks CA), or with zoledronic acid (Novartis Pharmaceuticals, 
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Switzerland) effectively reduces the loss of bone mineral density associated with 
androgen deprivation therapy264 and prolongs bone metastasis-free survival in 
CRPC patients.153  In phase III trials, denosumab was found to be superior at 
preventing skeletal complications than treatment with zoledronic acid.265  However, 
treatment with zoledronic acid was also shown to decrease the number of MDSCs 
in the spleens of tumor bearing mice and to increase the induction of an antigen-
specific CTL response when combined with vaccination.266  These data suggest 
zoledronic acid as a possible agent to reduce the accumulation of MDSCs in PCa 
and support its combination with a cancer vaccine for the treatment of PCa.  
Whether denosumab also decreases the number of MDSCs in PCa patients has 
yet to be examined. 
 In keeping with the data discussed above showing that CXCR4 / CXCL12 
chemokine signaling may be involved in metastatic dissemination (Fig. I.4), 
inhibition of CXCR4 / CXCL12 signaling was shown to inhibit tumor growth and 
reduce metastasis in pre-clinical models of PCa.267,268  Both the synthetic peptide 
CTCE-9908 (British Canadian BioScience Corporation, Canada), and AMD3100 
(Sanofi-Aventis, France), bind to CXCR4 on tumor cells and prevent CXCL12 
mediated recruitment to bone marrow.  As previously discussed, CXCR4 is also 
expressed on monocytes and MDSCs in the bone marrow; but the contribution of 
these cells to an anti-CXCR4 treatment response has yet to be investigated.  
Clinical data show that CXCR4 blockade results in myeloid-derived cells leaving 
the bone marrow.  Indeed, AMD3100 is FDA approved to increase hematopoietic 
stem cell recruitment to peripheral blood in the treatment of multiple myeloma.269  
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In addition, AMD3100 was shown to decrease the production of matrix 
metalloproteinases in the TME of a breast cancer tumor model,270 and CTCE-9908 
was shown to reduce angiogenesis (by inhibiting VEGF production) and 
recruitment of MDSCs into the TME of a PCa model.267  CTCE-9908 was well-
tolerated by patients with solid tumors in a phase I/II clinical trial.271  Recently, 
another small molecule, X4P-001 (X4 Pharmaceuticals, Cambridge, MA) has been 
reported to block CXCR4 in peripheral blood of patients infected with HIV272 and 
has now moved into a phase I/II study for the treatment of renal cell carcinoma in 
combination with the standard of care tyrosine kinase inhibitor, axitinib (Pfizer Inc, 
NY, NY –NCT02667886), and in combination with PD-1 blockade, nivolumab 
(Bristol-Myers Squibb, Princeton, NJ –NCT02923531).  In addition, AMD3100 is 
now being evaluated in a phase I study for the treatment of mCRPC 
(NCT02478125) and preliminary reports from clinical studies using MDX-1338, an 
IgG4 antibody that binds CXCR4, showed encouraging clinical activity in the 
treatment of in hematological malignancies273 and may be considered for the 
treatment of solid tumors like PCa in the future. 
Rationale for and Summary of Experimental Findings 
Is now fairly well accepted that cancers that are detected clinically must have 
evaded an antitumor immune response.274  Whereas CD8 T cells are effective in 
mediating tumor cell lysis, their infiltration into prostate tumors is modest in relation 
to the infiltration of these tumors with myeloid-derived cells in human and mouse 
specimens.141,159,172  Although TAAs expressed by prostate tumor cells are able to 
induce an immune response in patients with PCa, it seems likely that the 
44 
 
immunosuppressive microenvironment established by myeloid-derived cells 
(TAMs, PMN-MDSC/neutrophils, M-MDSC, and suppressive DCs) hinders the 
anti-tumor response in PCa.  The involvement of myeloid-derived cells in PCa 
treatment failure is supported by clinical evidence.141,275  Understanding the 
genetic alterations that lead to the dysregulation of intrinsic signaling pathways in 
prostate tumor cells and the mechanisms by which they regulate the infiltration of 
myeloid-derived cells may have a significant impact on PCa treatment.  These 
genetic alterations may not only serve as biomarkers to aid in treatment selection, 
but also as targets to modulate the infiltration of myeloid-derived cells and the 
immunosuppressive microenvironment.  Recent pre-clinical data suggest a link 
between PTEN loss, myeloid recruitment, and an immunosuppressive 
microenvironment in PCa. Disrupting the immunosuppressive microenvironment 
of PCa by inhibiting myeloid-derived cells, or their products, requires further 
exploration in the treatment of this malignancy.  It is possible, however, that the 
efficacy of these treatments may be limited as a single agent and that combination 
regimens may be required.  Interestingly, PCa is one of the few solid tumor types 
for which a therapeutic vaccine is currently FDA-approved.276  Conversely, immune 
checkpoint blockade with anti-CTLA-4 has shown relatively limited 
success;54,164,165 this may be partially explained by the pre-existence of an 
immunosuppressive TME.275   
In the data that follow, we present studies that advance our understanding 
of mechanisms of the immunosuppression in PCa.  Chapter 1 details the 
identification of a set of androgen-regulated genes expressed by the subpopulation 
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of epithelial cells surrounding the ductal lumen that survive chemical castration 
known as castration-resistant luminal epithelial cells (CRLECs).  We successfully 
identified transglutaminase 4 (Tgm4) as a potential prostate-specific antigen in 
mouse and human databases.  We showed that monocyte-derived dendritic cells 
(moDCs), pulsed with TGM4 whole protein induce pro-inflammatory CD4 and CD8 
T cells, responded in autologous co-culture experiments with PBMCs of healthy 
donors.  Furthermore, we found that breaking peripheral immune tolerance with a 
whole-cell vaccine, GVAX, results in the detection of TGM4 antibodies.  
Collectively, our findings suggest TGM4 as a prostate specific antigen that is 
conserved during the tumorigenic process and that could serve as a potential 
target for the development of a vaccine.  Chapter 2, describes the robust peripheral 
tolerance to a model antigen in the context of a immunosuppressive TME. We 
found antigen-specific CD8 T cell recognition led to a reduction of effector cytokine 
production.  This tolerance was robust and was not significantly mitigated by either 
the TLR-agonist Poly I:C or by ADT.  Supporting persistent tolerance, we observed 
continued Treg infiltration even late after ADT (at onset of castration-resistance), 
supporting a long-lived tolerogenic mechanism.  Chapter 3 and 4 focus on 
identifying the mechanism that drives the recruitment of PMN-MDSCs into the TME 
of CRPC and the therapeutic implications of mitigating the IL-8 / CXCR2 pathway 
in combination with ICB.  In chapter 3 we analyzed cancer cells isolated from 
castration-sensitive and castration-resistant prostate tumors, and discovered that 
castration resulted in significant secretion of Interleukin-8 (IL-8) and it’s likely 
murine homolog Cxcl15.  These chemokines drove subsequent intra-tumoral 
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infiltration with polymorphonuclear myeloid-derived suppressor cells (PMN-
MDSCs), promoting tumor progression.  PMN-MDSC infiltration was abrogated 
when IL-8 was deleted from PCa epithelial cells using CRISPR/Cas9, or when 
PMN-MDSC migration was blocked with antibodies against the IL-8 receptor 
CXCR2.  In chapter 4 we showed that blocking PMN-MDSC infiltration in 
combination with anti-CTLA-4 delayed the onset of castration-resistance and 
increased the density of polyfunctional CD8 T cells in tumors.  Taken together, our 
findings establish castration-mediated IL-8 secretion and subsequent PMN-MDSC 
infiltration as a key suppressive mechanism in the progression of PCa.  Targeting 
of the IL-8 / CXCR2 axis around the time of ADT, in combination with ICB, 






Chapter I – An Immunogenic Prostate-










Multiple immunological approaches have been studied as therapeutic options for 
CRPC,198 with limited success.  In contrast to other tumor types, immunotherapy 
using immune checkpoint inhibitors (i.e., anti-PD-1 / PD-L1, anti-CTLA-4) has 
shown limited responses in mCRPC  to date.76  Conversely, the ability of the only 
therapeutic FDA-approved PCa vaccine (sipuleucel-T) to extend survival276-278 
suggests that immunotherapy has potential in mCRPC.  Due to the non-vital nature 
of the prostate gland, effective adaptive responses against prostate-restricted 
TAAs such as PAP, PSA, PSCA, TARP, STEAP1, and PSMA are feasible 
therapeutic targets for PCa,76,198,279-281 although their clinical relevance remains 
unknown.  As described above, the identification of novel prostate-restricted TAAs 
that induce de novo anti-tumor immune responses could guide the development 
“Women who developed an immune 
response to the self-protein MUC1 have a 
much lower risk for ovarian cancer.”  
Dr. Olivera J. Finn (2009) – a 
pioneer in cancer immunotherapy. 
Professor at the Department of 




of future immunotherapies.  Here, we used a number of orthogonal approaches to 
identify transglutaminase 4 (TGM4) as a prostate-restricted TAA that is regulated 
in an androgen dependent manner.  The potential immunogenicity of this protein 
was verified using in vitro studies, as well as samples from a neo-adjuvant clinical 
trial.282 
1.2 Results 
1.2.1 Castration-Resistant Luminal Epithelial Cells (CRLECs) Up-
regulate Putative Prostate Antigens    
Prior work showed that the murine prostate gland contains a population of 
Castration-Resistant Luminal Epithelial Cells (CRLECs) that is sufficient to 
regenerate prostatic architecture following consecutive rounds of androgen 
deprivation/repletion and which is the likely population of origin for PCa.283  This 
population shares many features with castration-resistant prostate tumor cells.284-
286  To screen for potential prostate-restricted TAAs expressed by CRLECs, we 
quantified gene expression using a transgenic mouse model in which GFP 
expression is driven by the luminal-restricted Hoxb13 promoter upon doxycycline 
administration.  Using cells sorted from these animals, we quantified the 
transcriptional profile of CRLECs following an androgen deprivation/repletion cycle 
(Fig. 1.1A-D). We next defined a  signature for androgen-responsive genes in our 
dataset as the intersection of genes differentially expressed when comparing 
untreated vs ADT-treated samples and ADT-treated vs ADT-treated followed by 
testosterone repletion (ADT+TR) samples.  To derive this gene signature, we used 
an ADT Log2-fold-change below the 0.005 percentile and a p value below 0.01 
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(Table 1.1; Fig. 1.1E).  We then correlated each sample pair in terms of their 
expression of this gene signature, to quantify the degree of similarity between 
untreated and androgen-repleted samples (Fig. 1.1F). Samples exposed to 
androgens showed a pairwise Pearson correlation of the androgen-responsive 
gene signature greater than 0.8 between samples from untreated animals and 
ADT-treated animals followed by testosterone repletion, confirming the genetic 
program re-established by testosterone treatment (Fig. 1.1F).  Conversely, the 
androgen-responsive gene signature in either untreated or testosterone-repleted 
animals correlated poorly with the signature in androgen-deprived animals, further 
confirming the relative specificity of this signature (Fig. 1.1F).  Consistent with prior 
data,287-292 we found that ADT down-regulated the expression of several androgen-
responsive genes including Psca, Nkx3.1, Fkbp5, and Tmprss2 (Fig. 1.1E).  The 
relative androgen dependence of these transcripts is shown in Figure 1.1D, with 
Spink1, Msmb, and Tgm4 up-regulated 3,500fold, 1,900 fold, and 1,500 fold 
respectively by androgen repletion; while androgen repletion up-regulated the 
expression of Psca by 15 fold, Nkx3.1 by 10 fold, Fkbp5 by 5 fold, and Tmprss2 by 
2 fold.  These results support a role for androgens in the regulation of Spink1, 
Msmb, and Tgm4 genes as part of an androgen-responsive gene signature in 




Figure 1.1 | Putative Prostate Antigens are Expressed by Murine Castration-
Resistant Luminal Epithelial Cells in an Androgen Dependent Manner.  A, 
Schematic representation of Androgen-induced prostate regression/regeneration 
in Hoxb13-rtTA|TetO-H2BGFP transgenic mice to model the cells-of-origin of PCa 
(CRLECs).  Top, representative fluorescent images of GFP+ murine luminal 
epithelial cells to androgen-deprivation therapy (ADT) and testosterone repletion 
(TR) in murine prostates.  Bottom, mice were treated with ADT (androgen 
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depletion), testosterone pellets (androgen repletion), and/or Doxycycline (DOX) as 
indicated in the diagram and described in the methods.  B, top: sorting strategy 
used in the isolation of Castration-Resistant Luminal Epithelial Cells (CRLECs) 
based on their expression of GFP and their CD45-CD11b-F4/80-CD24+CD49fint 
phenotype; bottom: purity check of GFP+ sorted cells.  C, Hoxb13-rtTA|TetO-
H2BGFP transgenic mice were left either untreated, treated with ADT, or treated 
with ADT plus androgen/testosterone repletion (TR; n ≥ 3 per group).  Serum 
testosterone concentrations were measured using the Holm-Sidak method as 
described in the methods.  D, Volcano plot showing gene expression among all 
MTA 1.0 microarray transcripts expressed by GFP+ murine CRLECs from ADT vs 
Untreated groups. E, Differential expression profile of GFP+ CRLECs isolated from 
the prostates of mice left untreated, treated with ADT, or treated with ADT plus 
androgen/testosterone repletion (TR; n ≥ 3 per group).  Heatmap showing 
androgen-responsive genes downregulated by ADT compared to both untreated 
and ADT+TR samples (n ≥ 3 per group).  F, Heatmap showing pairwise Pearson 
correlation of androgen-responsive gene expression between CRLECs isolated 
from each mouse as described above. Androgen-responsive gene signature 
shown in E, with pairwise correlation between mice shown computed across all 
genes and annotated by treatment group.  G, Log2 fold-change in expression of 
androgen-responsive genes in GFP+ CRLECs isolated from the prostates of mice 
treated with ADT in combination with androgen/testosterone repletion (TR) 
compared to ADT alone.   
Table 1.1 | Androgen-Responsive Gene Signature. 
Genes_Names Untreated_Mean ADT_Mean ADT+TR_Mean 
Spink1 974655.826 242.082839 866409.778 
Msmb 185656.976 304.480284 586966.036 
Tgm4 70377.3384 171.134126 258787.337 
Wfdc3 17628.3521 25.6334721 17022.2898 
Abo 21839.4161 18.5782581 12236.6201 
Spin2e 24494.2699 64.7073191 16071.311 
Papss2 47167.7556 155.938174 24754.0592 
Apof 4356.16635 109.809521 6416.89651 
Sbp 271100.203 4318.09719 241202.862 
Sbpl 972667.149 17157.4001 870112.549 
Rgs2 89658.3296 861.462986 38194.7043 
Cd59a 2848.94752 171.7333 7394.37502 
Azgp1 4258.78643 101.636022 4367.89512 
Aldh1a7 1269.07094 48.7085793 1904.55733 
Defb50 84900.5728 5400.16086 189625.374 
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Cited2 84223.3905 2620.51261 83842.1156 
Aldh1a1 792.742768 40.7153434 958.740455 
Bmpr1b 3581.6037 91.7754047 1593.68855 
Psca 761.528032 108.213249 1626.43731 
Car5b 4778.12871 224.429005 3270.96929 
Mme 3666.21751 374.513263 4283.53898 
Aldh6a1 7756.03357 459.040828 4331.99241 
Tox3 4170.44803 172.964242 1625.86584 
Gpr155 2168.92833 84.4151478 787.393368 
Kdelr3 452.66376 45.630999 363.53375 
Tesk2 5409.32676 407.292094 3098.13115 
Iqgap2 2209.91219 289.03826 2145.4395 
Dnajc3 11549.291 1830.1041 12030.3834 
Rcn2 2090.81544 197.998451 1138.20148 
Arfgef3 1607.08665 188.667659 948.79395 
Phgdh 2591.53291 374.639533 1865.79207 
Ttc7b 422.125059 39.7501941 197.90181 
 
We next applied this signature to an independent, publicly available dataset 
in which epithelial lineage-marked YFP+ tumor cells from the prostates of 
transgenic mice expressing YFP under the luminal-restricted Nkx3.1 promoter 
were profiled (GSE39509).293   These data also showed Tgm4 to be among the 
most highly over-expressed genes in prostate tumors with a luminal origin (Fig. 
1.2).  Together, these findings support the notion that TGM4 is an androgen-
responsive transcript expressed by prostate luminal epithelial cells, including 




Figure 1.2 | Tgm4 is Highly Expressed by Prostate Tumors Originated in 
Luminal Epithelial Cells.  Relative expression of androgen-responsive genes, as 
well as Tarp and Steap1, in prostate tumors originated from luminal epithelial cells 
isolated from lineage-marked Nkx3.1CreERT2/+; Ptenflox/flox; R26R-YFP/+ transgenic 
mice (n ≥ 5; GSE39509).293  Boxplots of Log10(FPKM) normalized gene 
expression are shown (n = 6).  For b and d, selected genes for each comparison 
are defined as genes with ADT Log2-fold-change below the 0.005 percentile and 
p < 0.01, in addition to a set of known androgen-responsive genes from the 
literature (Acpp, Klk1b8, Fkbp5, Nkx3.1, Tmprss2, and Folh1).  Wilcoxon test was 
used for statistical analysis between Tgm4 and each indicated gene; p values are 
displayed.      
1.2.2 TGM4 Shows Prostate-Restricted Expression in Murine and 
Human Datasets 
To avoid inducing immunologically off target effects, TAA’s should have high 
expression on tumor tissue and minimal or undetectable expression on normal 
tissue(s). To evaluate which of the androgen-responsive genes are prostate tissue 
restricted, we interrogated two databases of gene expression from murine (RIKEN 
FANTOM5)294 and human (GTEx)295 normal tissues.  We found low expression 
levels of Defb50, Msmb, Sbp, Fkbp5, Spink1 and Tgm4 in all murine extra-prostatic 
tissues evaluated (Fig. 1.3).  Human data, however, showed significant FKBP5 
and SPINK1 expression in lung, liver, skin, colon, kidney, and salivary gland 
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samples; these were greater than those for TGM4 (Fig. 1.4).  Of note, DEFB50, 
MSMB, and SBP were not included in the human database.  The expression levels 
of the established prostate-restricted targets FOLH1/PSMA, KLK3/PSA, and 
PSCA were high in human prostate tissues, however, medium to low levels of 
expression were also observed in extra-prostatic tissues.  Specifically, brain, lung, 
liver, and kidney tissues showed intermediate levels of FOLH1/PSMA expression.  
Detectable expression levels of PSCA, and ACPP/PAP were found in human skin, 
lung and kidney tissues; and both PSCA and ACPP/PAP expression were 
significantly higher than that of TGM4 in these extra-prostatic tissues.  Further, 
expression of KLK3/PSA, PSCA, ACPP/PAP and FOLH1/PSMA was present in 
human colon and salivary glands (Fig. 1.4), whereas TGM4 was not detectable in 
these human tissues.  Expression of additional prostate-restricted TAAs, including 
TARP and STEAP1, were also observed in both murine and human prostates, 
although at lower levels than TGM4 (Fig. 1.3 & 1.4).  While STEAP1 expression 
was present in almost all the human tissues analyzed (lung, liver, skin, colon, 
kidney, and salivary gland), extra-prostatic TARP expression was only observed 
in lung, kidney, and salivary gland (Fig. 1.4). In summary, these data indicate that 
TGM4 is generally not expressed at the message level in non-prostate tissues, 




Figure 1.3 | Expression of Putative Prostate Antigens is Restricted to the 
Prostate in Mouse.  Relative expression of androgen-responsive genes, as well 
as Tarp and Steap1, across normal murine tissues.  Boxplots of Log10(TPM) 
normalized gene expression in prostate (n = 1), brain (n = 9), colon (n = 1), liver (n 
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= 10), lung (n = 9), skin (n = 2), and kidney (n = 7), and salivary gland (n = 1) from 
RIKEN FANTOM5 are shown, and genes are ordered by decreasing expression in 




Figure 1.4 | Expression of Putative Prostate Antigens is Restricted to the 
Prostate in Humans.  Relative expression of androgen-responsive genes, as well 
as TARP and STEAP1, across normal human tissues.  Boxplots of Log10(TPM) 
normalized gene expression in prostate (n = 152), brain (n = 1671), colon (n = 
507), liver (n = 175), lung (n = 427), skin (n = 1203), kidney (n = 45), and salivary 
gland (n = 97) from GTEx are shown.  Wilcoxon test was used for statistical 
analysis between TGM4 and each indicated gene; p values are displayed.   
1.2.3 TGM4 Expression Correlates with Prostate Cancer Recurrence  
We next studied the levels of TGM4 expression in primary PCa and other human 
cancer types included in The Cancer Genome Atlas (TCGA).  Consistent with data 
from murine luminal epithelial prostate tumors (Fig. 1.2), the highest levels of 
TGM4 expression were found in prostate adenocarcinomas (PRAD; Fig. 1.5A).  
We next tested whether TGM4 expression in primary tumors is associated with 
disease progression in an independent dataset of prostate adenocarcinomas 
(GSE21032). This analysis of differential TGM4 expression revealed that patients 
whose primary tumors had higher expression of TGM4 showed a significant 
decrease in time-to-PSA recurrence when compared to patients with low TGM4 
expression in their primary tumors using an optimal cutpoint determined by 
maximizing the long-rank statistic (Fig. 1.5B-C).  These data support the notion 




Figure 1.5 | TGM4 Expression is Maintained by Prostate Tumor Cells.  A, 
Relative expression of TGM4 across human cancer types in The Cancer Genome 
Atlas (TCGA) database, including 558 primary prostate adenocarcinomas 
(PRAD).297  Boxplots of Log10(TPM) normalized gene expression are shown, with 
cancer types ordered by decreasing TGM4 expression.  B, Optimal cutpoint for 
TGM4 expression.  Top, Distribution of TGM4 expression across primary prostate 
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adenocarcinomas (n = 218; GSE21032).298  Bottom, the overall log-rank p-value 
for TGM4 expression is plotted.  A vertical line drawn at the optimal cutpoint of 
843.21.  C, Kaplan-Meier curves comparing biochemical recurrence-free survival 
of patients with prostate adenocarcinomas, with log-rank p-value reported from 
multiple cox regression of biochemical recurrence-free against TGM4 expression 
levels (high TGM4, n = 24; low TGM4 n = 107).  Biochemical recurrence was 
determined as an increase in PSA serum levels ≥0.2 ng/ml on two occasions as 
described in the methods.       
1.2.4 The Prostate-Restricted TAA TGM4 Induces an In Vitro CD8+ T-
Cell Response When Presented By Autologous Monocyte-derived 
DCs 
To further determine whether TGM4 could serve as a potentially targetable TAA, 
we tested whether T cell responses to TGM4 could be induced in vitro.  For these 
experiments, naïve T cells purified from the peripheral blood mononuclear cells 
(PBMCs) of healthy male donors (n = 10) were individually co-cultured with 
autologous monocyte-derived dendritic cells (moDCs) pulsed with either full-length 
protein TAAs (PAP, PSA, and TGM4) or a positive control comprised of an 
overlapping viral peptide-library (CEFT and pp65) in a 30-day culture system (Fig. 
1.6A-B).  To analyze responses, we used multiparametric flow cytometry to 
quantify antigen-driven expansion of CD8 T cells, and identified eight distinct 
populations using self-organizing maps for clustering analysis (FlowSOM; Fig. 
1.6C-D).  Of these, Pop6 appeared to represent central memory (CM) CD8 T cells 
and Pop4 naïve CD8 T cells (Fig 1.6D).  Antigen-driven expansion of effector 
memory (EM) CD8 T cells was reflected by Pop5, which upregulated the self-
renewing transcription factor TCF1 and the interleukin-7 receptor (CD127) (Fig. 
1.6D).  The expansion of both activated CM and EM CD8 T cells was confirmed 
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post-stimulation (Fig. 1.6E-F).  Importantly, activated (CD69+) CD27+CD28+ 
memory CD8 T cells expanded to a significantly greater degree in co-cultures with 
TAA-pulsed moDCs than with the positive control viral antigens (Fig. 1.6E-F).  
Accordingly, higher percentages of CM and EM expressed PD-1 and TIM3 when 
stimulated by TAA loaded moDCs, in this setting these molecules likely represent 
early activation markers rather than markers of exhaustion (Fig. 1.6G).  Additional 
manual gating for the EM CD8 T-cell population expressing the pro-inflammatory 
transcription factor TBET (Pop 1; Fig. 1.6D) was performed (Fig. 1.6H).  Here, we 
found that TGM4-pulsed moDCs drove the expansion of TBET+ activated EM CD8 
T cells to a significantly greater extent than PAP-pulsed and PSA-pulsed moDCs, 
but to a similar degree to the viral control antigens, CEFT and pp65 (Fig. 1.6I).  
These findings show that donor-derived naïve CD8 T cells expand and differentiate 
following TGM4 recognition and suggest that this prostate-restricted TAA could 




Figure 1.6 | TGM4 Induces CD8 T-Cell Activation and Expansion In Vitro.  A, 
Schematic representation of the 30 days prime/boost co-culture of autologous 
monocyte-derive dendritic cells (moDCs) and naïve T cells.  B, Representative 
images of differentiated moDCs.  4X (left) and 40X (right) magnification.  C, 
Differential expression of functional markers on expanded populations of CD8 T 
cells following co-culture with autologous protein-pulsed moDCs.  Heatmap 
showing unsupervised clusters determined with the FlowSOM algorithm as 
described in the methods.  D, Expanded CD8 T-cell populations defined by 
FlowSOM in C were projected onto UMAP space as described in the methods.  
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Colors correspond to FlowSOM populations.  E, Fold change on activated 
CD69+CD27+CD28+ EM CD8 T cells (left) and CM T cells (right) following the last 
12 hrs stimulation in expanded T cells.  F, Activated CD69+CD27+CD28+ cells as 
a percentage of EM CD8 T cells (left) and CM CD8 T cells (right) following in vitro 
expansion as in E.  G, PD1+TIM3+ CD69+CD27+CD28+ cells as a percentage of 
EM CD8 T cells (left) and CD8 T cells (right) following in vitro expansion as in E.  
H, Gating strategy used to manually analyze TBET+ in activated CD69+CD28+ 
effector memory (EM) CD8 T cells defined as CCR7-CD45RA- following co-culture 
with autologous protein-pulsed moDCs.  I,  TBET+ cells as a percentage of 
activated CD69+CD28+ EM CD8 T cells in expanded T cells gated as in c.  
Unpaired t-tests performed, p-values ≤ 0.05 (*), 0.01 (**), and 0.001 (***); not 
statistical significance is represented as ns.   
1.2.5 The Prostate-Restricted TAA TGM4 Induces an In Vitro CD4+ T-
Cell Response When Presented By Autologous Monocyte-derived 
DCs 
We next performed similar analyses to those above for CD4 T cells.  As shown in 
Figure 1.7A-B, FlowSOM clustering showed ten distinct populations of antigen-
driven expanded CD4 T cells.  Most of these clusters were observed in all antigen-
driven expanded CD4 T cells (with the exception of Pop 5; Fig. 1.7A).  Of these, 
Pop9 appears to represent CM CD4 T cells and Pop6 naïve CD4 T cells (Fig 1.7B).  
In terms of CM and EM CD4 T cells, we found that stimulation by TAA-pulsed 
moDCs increased the proportion and percentages of activated (CD69+) 
CD27+CD28+ CM CD4 T cells to a significantly greater extent than did co-culture 
with the positive control viral antigens (Fig. 1.7D). Accordingly, higher percentages 
of CM and EM expressed the activation markers PD-1 and TIM3 when stimulated 
with TAAs (Fig. 1.7E).  Additional manual gating for the EM CD4 T-cell population 
expressing the pro-inflammatory transcription factor TBET (Pop 0; Fig. 1.7B) was 
performed (Fig. 1.7F-G).  Here, we observed TGM4-pulsed moDCs increased 
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expansion of TBET+ activated EM CD4 T cells to a greater degree than PAP-
pulsed or PSA-pulsed moDCs, with levels similar to those from positive control 
viral antigens, CEFT and pp65 (Fig. 1.7H).  These data support the notion that 
TGM4 can potentially drive pro-immunogenic CD4 T cell responses in addition to 
the CD8 responses shown above.  
 
Figure 1.7 | TGM4 Induces CD4 T-Cell Activation and Expansion In Vitro.  A, 
Differential expression of functional markers on expanded populations of CD4 T 
cells following co-culture with autologous protein-pulsed moDCs.  Heatmap 
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showing unsupervised clusters determined with the FlowSOM algorithm as 
described in the methods.  B, Expanded CD4 T cell populations defined by 
FlowSOM in A were projected onto UMAP space as described in the methods.  
Colors correspond to FlowSOM populations.  C, Fold change on activated 
CD69+CD27+CD28+ EM CD4 T cells (left) and CM CD4 T cells (right) following the 
last 12 hrs stimulation in expanded T cells.  D, Activated CD69+CD27+CD28+ cells 
as a percentage of EM CD4 T cells (left) and CM CD4 T cells (right) following in 
vitro expansion as in C.  E, PD1+TIM3+ CD69+CD27+CD28+ cells as a percentage 
of EM CD4 T cells (left) and CM CD4 T cells (right) following in vitro expansion as 
in C.  F, Gating strategy used to manually analyze TBET+ in activated CD69+CD28+ 
effector memory (EM) CD4 T cells defined as CCR7-CD45RA- following co-culture 
with autologous protein-pulsed moDCs.  G, Representative histograms of 
expression levels of functional transcription factors determined by flow cytometry 
in expanded EM and naïve CD4 T cells.  H, TBET+ cells as a percentage of 
activated CD69+CD28+ EM CD4 T cell in expanded T cells gated as in F.  Unpaired 
t-tests performed, p-values ≤ 0.05 (*) and 0.01 (**); not statistical significance is 
represented as ns.    
1.2.6 Prostate Cancer Patients Develop A Humoral Response to 
TGM4 After GVAX Treatment  
Given the induced CD4 T-cell responses to TGM4 observed in vitro (Figure 1.7), 
we hypothesized that PCa patients might leverage CD4 T cell help to mount an 
IgG antibody response against this prostate-restricted TAA.  To address this 
question we analyzed pre- and post-treatment sera from patients with localized 
prostate tumors treated with either ADT (n = 14) or ADT plus a cell-based PCa 
vaccine (GVAX+ADT; n = 13) in the neo-adjuvant setting282 (Figure 1.8A).  To 
profile antibody responses, we used Phage-ImmunoPrecipitation Sequencing 
(PhIP-Seq),27 focusing on IgG antibody responses.  For these assays, serum 
samples pre- and post-treatment were used to immunoprecipitate a T7 phage-
displayed library expressing overlapping 90-aa peptides covering 29,371 human 
open reading frames (Fig. 1.8B).299,300  Fewer than 8% of vaccinated patients 
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developed antibody responses to PSA or PSMA and antibodies against PAP were 
not detected in any patient studied (Fig. 1.8C-D).  By contrast, approximately 30% 
of vaccinated patients developed an antibody response to TGM4.  Further, 
antibody responses to TGM4 and other androgen-responsive TAAs correlated with 
PSA recurrence in this dataset (Fig. 1.8E-F).  These results suggest that vaccine-
induced responses to androgen-responsive TAAs may have clinical relevance in 




Figure 1.8 | GVAX Vaccination Induces Antibody Responses Against TGM4 
In Prostate Cancer Patients.  A, Schematic representation of the treatment 
paradigm of patients with prostate adenocarcinoma treated with ADT alone or 
cyclophosphamide (CP) followed by GVAX and ADT in a neo-adjuvant trial 
(NCT01696877).  B, Schematic diagram of the Phage-ImmunoPrecipitation 
Sequencing (PhIP-Seq) assay.  C, Heatmap of antibody binding to selected 
prostate-restricted tumor associated antigens (TAAs) determined as described in 
the methods.  D, Antibody response to TGM4 across prostate adenocarcinoma 
patients treated as in A; nd stands for not detected.  E, Heatmap of antibody 
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binding to androgen-responsive antigens determined as described in Fig. 2.  F, 
Table summarizing responses for ADT only and GVAX followed by ADT treatment 
groups. Fisher’s exact test shows significant over-representation of immune 
response to androgen-responsive TAAs in the set of patients without biochemical 
recurrence.   
1.3 Discussion 
The clinical activity of a PCa vaccine based on PAP-loaded autologous moDCs 
(Sipuleucel-T) highlights the potential of immunotherapy to enhance de novo anti-
tumor immune responses to prostate-restricted TAAs.  Despite the clinical utility of 
PAP as an immunological target, responses to this prostate-restricted TAA are 
heterogeneous.241,301-304   Other prostate-restricted TAAs such as PSA, PSCA, 
and PSMA have also shown intriguing results in pre-clinical studies and are 
currently under investigation in clinical trials (NCT03089203, NCT04053062, 
NCT03873805, and NCT02744287).234,305-307  However, the identification of novel 
prostate-restricted immunological targets remains an unmet need.  Here we show 
that the putative cell-of-origin for PCa,308 a subpopulation of epithelial cells 
surrounding the ductal lumen that survive after androgen deprivation - known as 
Castration-Resistant Luminal Epithelial Cells (CRLECs), express high levels of 
prostate specific TGM4 in an androgen dependent manner.  Our findings are in 
agreement with a recent study that histologically located TGM4 at the protein level 
to luminal cells in the anterior and dorsal lobes of murine prostates,309 as well as 
with previous in vitro studies suggesting TGM4 may be responsive to androgens 
in a human PCa cell line.287,310  Although Tgm4 is expressed in benign prostate 
tissue, the non-vital nature of the prostate gland makes it a feasible target for 
immunotherapy in patients with recurrent disease after primary therapy with 
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radiation or surgery.  In addition, we found that Tgm4 expression is increased in 
prostate tumors originating from luminal epithelial cells.  Furthermore, the relatively 
low levels of TGM4 expression observed in brain, colon, liver, lung, skin, kidney, 
and salivary gland tissues suggest that targeting TGM4 might be associated with 
fewer off-target immune-related adverse events (irAEs) than other potential TAA’s.   
 Of note, there has been some controversy regarding TGM4 expression in 
prostate tumor lesions as compared to benign prostate tissue, with some studies 
reporting TGM4 expression in tumor lesions to be lower311-313 or higher296 than in 
benign prostate tissue.  At the message level, TGM4 expression has been reported 
to be reduced in prostate adenocarcinoma and metastatic PCa tissue compared 
to the benign tissue by qPCR311 and northern hybridization;312 however, further 
studies demonstrated that only one of four TGM4 splice variants (4-L) is lost in 
PCa samples.314  At the protein level, two independent immunohistochemistry 
analyses of prostate tissue microarray slides revealed that TGM4 expression was 
higher in benign prostatic tissue when a polyclonal antibody was used,313 but 
higher in prostate adenocarcinomas when evaluated with a monoclonal 
antibody.296  Thus, potential discrepancies could possibly be explained by the 
reagents used in each study.  In line with a potential role for TGM4 in disease 
progression,315,316 our results suggest that TGM4 expression is associated with 
decreased time to recurrence.    
 To understand whether TGM4 expression was able to induce an antigen-
driven immune response, we evaluated the immunogenicity of TGM4 and several 
additional prostate-restricted TAAs in functional assays with pulsed moDCs 
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presenting one of the three human proteins (TGM4, PAP, or PSA) to autologous 
naïve T cells from healthy male donors.  Using these tools, we found that pro-
inflammatory activated TBET+ EM CD8 and CD4 T cells were expanded by TGM4-
pulsed moDCs to a greater extent than PAP-pulsed and PSA-pulsed moDCs in 
healthy male donors. These studies were notable in that they support the notion 
that a TGM4 targeted vaccine could potentially induce T cell immunity.    
 We also found that an IgG antibody response to TGM4 was detected in a 
fraction of PCa patients treated with GVAX in a neoadjuvant trial.  Those data 
further support the potential for antigen-driven CD4 T cell responses to TGM4, 
since CD4 T help is required for antibody class switching to IgG.  This finding is in 
line with the modest improvement in time-to-PSA progression observed in this 
trial,317 an improvement which was not associated with an increase in tumor-
infiltrating CD8 T cells. Further supporting the immunogenicity of TGM4, work from 
others showed that autoantibodies were found in 100% of Aire-deficient and 22% 
of non-obese diabetic male mice that spontaneously developed prostatitis, but not 
in females.318  Interestingly, several other members of the transglutaminase family 
have also been identified as immune targets in inflammatory and autoimmune 
disorders.319-321  Aire-deficient mice with antibodies targeting TGM4 lack 
production of TGM4, suggesting that TGM4-expressing cells may be destroyed by 
an autoimmune reaction.318  Further, the development of antibodies targeting 
TGM4 was only observed post-puberty318 which parallels the androgen-responsive 
regulation we observed and implies peripheral antigen recognition in the absence 
of central tolerance. 
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In summary, these studies support further evaluation of TGM4 as a 
prostate-restricted TAA.  Given the immunosuppressive nature of the tumor 
microenvironment in PCa,198,322-325 it is likely that vaccine induced responses 
against TGM4 may not be sufficient alone for an effective anti-tumor response. 
Instead, targeted vaccines may need to be administrated in combination with other 
therapies targeting the recruitment and accumulation of regulatory T cells and / or 
myeloid-derived suppressive cells.  Future studies evaluating TGM4 as a putative 
target antigen in mCPRC are required to explore these issues.        
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Chapter II – Robust Antigen-Specific 
CD8 T Cell Tolerance to a Model 










As discussed above, antigens expressed only in the tumor, neoantigens, are by 
definition not susceptible to central tolerance.  However, multiple peripheral 
tolerance mechanisms attenuate or otherwise prevent responses to antigens 
presented in a non-inflammatory context.  Immunotherapy must overcome these 
peripheral tolerance mechanisms in order to mount an effective adaptive anti-
tumor immune response.274,326-329  Several studies have shown T cell tolerance in 
mice with prostate-specific expression of a model or viral antigen.327,330-333  For 
example, using a model in which influenza hemagglutinin is over-expressed in the 
prostate gland and in autochthonous prostate tumors of transgenic 
“Effector cells in the innate or adaptive 
systems should become tolerant to 
continuously expressed motifs, or even 
gradually increasing ones.” 
Dr. Paul Ehrlich (1909) – a pioneer of the 
concept of cancer immunosurveillance 
and one of the main founders of 
chemotherapy. 




adenocarcinoma of mouse prostate (TRAMP) mice, we showed CD4 T cell 
tolerance that could be transiently mitigated by androgen-deprivation therapy 
(ADT).327  Peripheral tolerance to this continuously expressed antigen was further 
supported by studies in double transgenic mice in which cytolytic activity of 
hemagglutinin-specific CD8 T cells was restored after adoptively transferring 
hemagglutinin-specific CD8 T cells from TRAMP tumor-bearing hosts into tumor-
free hosts.330  Additional models support T cell tolerance to prostate-restricted 
expression of ovalbumin in prostate gland of probasin ovalbumin expressing 
transgenic (POET-1) mice331 and influenza virus in autochronous prostate tumors 
of TRAMP mice.332  In each of these models, antigens were expressed using the 
androgen-driven rat probasin promoter where antigen levels can be abrogated 
through androgen deprivation. Thus, it is not known whether similar tolerance 
mechanisms exist to an antigen whose expression is independent of androgen 
signaling.  
To understand peripheral tolerance to a bona-fide cancer antigen and to 
investigate whether immunotherapy interventions can break CD8 peripheral 
tolerance, we developed a murine PCa cell line (Myc-CaP/Neu) that expresses the 
rat Her-2/neu protein which is immunogenic in a breast cancer model.334,335  In 
addition, rat Her-2/neu specific CD8 T cells from TCR transgenic mice are 
available, and these facilitate antigen-specific interrogation of T cell tolerance.336  
Using these tools, we found that the rat Her-2/neu protein was successfully 
processed and the immunodominant peptide (RNEU420-429) was presented to 
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transgenic CD8 T cells.  We further investigated whether peripheral tolerance was 
induced, and whether tolerance could be mitigated by TLR-agonists or ADT.   
2.2 Results 
2.2.1 Generation of Neu Expressing Myc-CaP Cells 
To study antigen-specific CD8 T cell responses to androgen-deprivation therapy 
(ADT) sensitive PCa, we introduced a model tumor antigen for which an antigen-
specific T cell expressing a transgenic TCR has been generated.336  The model 
was based on the Myc-CaP cell line,337 which was derived from a transgenic PCa 
model driven by prostate-specific overexpression of the MYC oncogene338 – a 
gene commonly up-regulated in invasive PCa patients.339  Myc-CaP cells originate 
from the immunocompetent FVB/N strain.    To model a bona-fide cancer antigen, 
Myc-CaP cells were transduced with a lentivirus encoding the rat Her-2/neu 
(pWPXL-Neu; Fig. 2.1A-B).  This construct included the immunodominant epitope 
previously shown to bind to the class I MHC molecule H-2Dq.340  Transduced tumor 
cells were sorted to > 99% purity (Fig. 2.1C) and rat Her-2/neu (RNEU) expression 




Figure 2.1 | Generation of the Myc-CaP/Neu Cell Line.  A, Schematic for the 
transduction of the Her-2/neu neoantigen into the androgen responsive Myc-CaP 
cell line.  B, The extracellular rat Her-2/neu (neu) cDNA fragment containing the 
immunodominant MHC-I epitope recognized by the FVB/N-derived T cell clone 
TCRVβ4 (RNEU420-429 peptide: PDSLRDLSVF)340 was ligated into the vector 
pWPXL.  C, Sorting strategy to isolate Myc-CaP cells based on their expression of 
the rat neu antigen.  Myc-CaP cells pre- and post- transduction with lentivirus 
containing RNEU420-429 peptide (top,) and pre- and post- sorting for neu expressing 
cells (Myc-CaP/Neu; bottom).  D, Fluorescent detection of Her-2/neu in formalin-
fixed WT Myc-CaP and Myc-CaP/Neu tumor cells grown on poly-D-Lysine coated 
coverslips.  Expression of the antigen on tumor cells was evaluated with CF640-
labeled αHer-2/neu antibody (red); nuclei were counterstained with DAPI (blue).  
Scale bar = 100 μm. 
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2.2.2 RNEU-specific Cytotoxic CD8 T Cell Responses to Myc-
CaP/Neu Tumor Cells 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the 
recruitment of dendritic cells and augments tumor antigen presentation.334,341  
Thus, GM-CSF has been used as a component of therapeutic cancer vaccines to 
stimulate anti-tumor immunity in pre-clinical models342 as well as in multiple clinical 
trials.343,344  To determine whether CD8 T cells recognize RNEU420-429 in Myc-
CaP/Neu cells, we performed vaccination studies using a vaccine (GVAX) 
comprised of irradiated Myc-CaP/Neu cells co-administered with GM-CSF 
secreting bystanders.  As a readout for Her-2/neu expression, CFSE-labeled 
RNEU-specific CD8 T cells from Thy1.2+ donor mice were adoptively transferred 
24 hours post-vaccination into Thy1.1+ recipient FVB/NJ mice (Fig. 2.2A-B).  Five 
days post-transfer, RNEU-specific CD8 T cells recovered from the inguinal lymph 
nodes (ILNs) and spleens of vaccinated recipient mice had undergone significant 
division (Fig. 2.2C).  In contrast, RNEU-specific CD8 T cells recovered from ILNs 
and spleens of naïve recipients had not undergone significant division (Fig. 2.2C); 
these data support antigen expression and subsequent recognition.  Intracellular 
staining for canonical effector cytokines (TNFα, IFNγ, GzB, and IL-2) confirmed T 




Figure 2.2 | GVAX Vaccination Induces a Systemic Cytotoxic CD8 T Cell 
Response to Rat-Neu Neoantigen.  A, Treatment scheme for the neu-expressing 
(GM-CSF–secreting) vaccination (GVAX) group.  One day after the vaccination, 
1x106 high-avidity CFSE-labeled Thy1.2+ RNEU420–429-specific CD8 T cells were 
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adoptively transferred (AT) into mice.  On day 5, inguinal LNs (ILN) and spleens 
were harvested and analyzed by flow cytometry.  B, Gating strategy to profile 
RNEU-specific CD8 T cells by flow cytometry. FVB/N-derived T cell clone TCRVβ4 
were gated based on CD45+CD8+Thy1.2+.  C, Percentages of proliferating 
TCRVβ4+ CD8 T cells in indicated tissues (representative flow plots and 
quantification; n ≥ 4 per group, repeated x 2).  D, Percentages of cytokine 
production by RNEU-specific TCRVβ4+ CD8 T cells (representative flow plots and 
quantification; n ≥ 4 per group, repeated x 2).  E, Percentages of polyfunctional 
RNEU-specific TCRVβ4+ IFNγ+GzB+TNFα+ CD8 T cells in indicated tissues (n ≥ 4 
per group, repeated x 2).  Proliferating TCRVβ4+ CD8 T cells, and their cytokine 
production, were calculated as fraction of TCRVβ4+ CD8 T cells. 
We next tested whether adoptively transferred Her-2/neu specific CD8 T 
cells could recognize well-established Her-2/neu-expressing tumors (Fig. 2.3A-C).  
As shown in Figure 2.3, implanted Myc-CaP/Neu tumors induced proliferation of 
adoptively transferred RNEU-specific CD8 T cells in tumor-draining lymph nodes 
(TDLNs) and spleens, while Myc-CaP/WT tumors did not (Fig. 2.3D).  To evaluate 
the functional capacity of RNEU-specific CD8 T cells recovered from TDLNs and 
spleens, we performed intracellular staining for TNFα, IFNγ, GzB, and IL-2.  In line 
with our previous observations (Fig. 2.2D), a fraction of RNEU-specific CD8 T cells 
isolated from Myc-CaP/Neu tumor-bearing recipients expressed these cytotoxic 




Figure 2.3 | Established Myc-CaP Tumors Maintain Her-2/neu Expression and 
Induce a Systemic Cytotoxic CD8 T Cell Response to Rat-Neu Neoantigen.  
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A, Treatment scheme for tumor implantation with either 1x106 Myc-CaP/WT or 
Myc-CaP/Neu cells.  Fourteen days after tumor implantation, 1x106 high-avidity 
CFSE-labeled Thy1.2+ RNEU420–429-specific CD8 T cells were adoptively 
transferred (AT) into the mice.  On day 5, tumor-draining lymph nodes (TDLNs) 
were harvested and analyzed by flow cytometry.  B, Tumor growth curves of mice 
from Myc-CaP/WT and Myc-CaP/Neu tumor bearing mice.  Average tumor volume 
(±s.e.m.) for each experimental group.  C, Her-2/neu expression on indicated 
murine allografts (representative immunohistochemistry; repeated x 2).  Scale bar 
= 50 μm.  D, Percentages of proliferating TCRVβ4+ CD8 T cells in indicated tissues 
(representative flow plots and quantification; n ≥ 3 per group, repeated x 2).  E, 
Percentages of cytokine production by RNEU-specific TCRVβ4+ CD8 T cells in 
indicated tissues (representative flow plots and quantification; n ≥ 3 per group, 
repeated x 2).  Proliferating TCRVβ4+ CD8 T cells, and their cytokine production, 
were calculated as fraction of TCRVβ4+ CD8 T cells. 
2.2.3 Established Tumors Suppress Antigen-Specific CD8 T 
Responses Induced by Vaccination 
We next tested whether vaccination with Myc-CaP/Neu cells + GM-CSF producing 
bystander (GVAX) would affect tumor antigen-specific CD8 T cell responses in the 
setting of a suppressive TME (Fig. 2.4A-C).  Here we found that RNEU-specific 
CD8 T cells recovered from vaccinated Myc-CaP/Neu tumor-bearing recipients 
divided less and exhibited a lower percentage of TNFα, IFNγ, and IL2 cytokine 
producing RNEU-derived CD8 T cells than those harvested from vaccinated, non-
tumor bearing (naïve) recipients (Fig. 2.4D-E).  These data suggest that 
recognition of the Her-2/neu peptide (RNEU420-429: PDSLRDLSVF) is tolerogenic 
in the context of a suppressive TME, and that vaccination may not be sufficient to 




Figure 2.4 | Myc-CaP/Neu Tumors Attenuate The RNEU-specific CD8 T Cell 
Response Induced by Vaccination with Her-2/neu Expressing Cells.  A, 
Treatment scheme for tumor implantation with 1x106 Myc-CaP/Neu cells.  One day 
after the neu-expressing (GM-CSF–secreting) vaccine (GVAX) was administrated, 
1x106 high-avidity CFSE-labeled Thy1.2+ RNEU420–429-specific CD8 T cells were 
adoptively transferred (AT) into the mice.  On day 5, tumor-draining lymph nodes 
(TDLNs; tumor) and inguinal LNs (ILNs; non-tumor) were harvested and analyzed 
by flow cytometry.  B, Tumor infiltrating lymphocytes (TIL; CD3), regulatory T cells 
(FoxP3), myeloid-derived suppressor cells (Ly6G), and Mϕ (F4/80) of indicated 
murine allografts (representative immunohistochemistry; repeated x 2).  Scale bar 
= 50 μm.  C, Counts of immune cells in tumor microenvironment (TME).  D, 
Percentages of proliferating TCRVβ4+ CD8 T cells in TDLNs and ILNs 
(representative flow plots and quantification; n ≥ 4 per group, repeated x 2).  E, 
Percentages of cytokine production by RNEU-specific TCRVβ4+ CD8 T cells in 
TDLNs and ILNs (representative flow plots and quantification; n ≥ 4 per group, 
repeated x 2). Proliferating TCRVβ4+ CD8 T cells, and their cytokine production, 
were calculated as fraction of TCRVβ4+ CD8 T cells. ILNs and TDLNs were 
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isolated from naïve and tumor bearing mice respectively. Whole-cell vaccination 
(GVAX) was prepared as described in materials and methods.   
2.2.4 TLR Agonists Do Not Mitigate Antigen-Specific CD8 T Cell 
Tolerance to a Tumor Antigen 
The TLR3 agonist Poly I:C is a synthetic polyinosinic-polycytidylic double-stranded 
RNA widely used as a vaccine adjuvant due to its ability to induce DC maturation 
and TH1 polarization.345,346  Thus, we tested whether Poly I:C would affect the 
induction of tolerance in dividing RNEU-specific CD8 T cells isolated from Myc-
CaP/Neu tumor-bearing recipient mice (Fig. 2.5A). We found that IP treatment with 
Poly I:C 24 hours prior to the adoptive transfer of RNEU-specific CD8 T cells did 
not mitigate the induction of peripheral tolerance in TDLNs of Myc-CaP/Neu tumor-
bearing recipient mice (Fig. 2.5B-D).  As a positive control, we tested whether IP 
Poly I:C treatment was able to induce a cytotoxic effector response in RNEU-
specific T cells harvested from the ILN of naïve recipients; indeed this was the 
case (Fig. 2.6).   So, while Her-2 specific T cells may achieve cytolytic potential 
with Poly I:C, recognition of peripherally expressed tumor antigen in the context of 




Figure 2.5 | Tumor-Induced RNEU-specific CD8 T Cell Tolerance is 
Maintained After Stimulation with a TLR3 Agonist.  A, Treatment scheme for 
tumor implantation with 1x106 Myc-CaP/Neu cells.  One day after Poly I:C IP 
administration, 1x106 high-avidity CFSE-labeled Thy1.2+ RNEU420–429-specific 
CD8 T cells were adoptively transferred (AT) into the mice.  On day 5, tumor-
draining lymph nodes (TDLNs) were harvested and analyzed by flow cytometry.  
B, Percentages of proliferating TCRVβ4+ CD8 T cells in TDLNs (representative 
flow plots and quantification; n ≥ 4 per group, repeated x 2).  C, Percentages of 
cytokine production by RNEU-specific TCRVβ4+ CD8 T cells (representative flow 
plots and quantification; n ≥ 4 per group, repeated x 2).  D, Percentages of 
polyfunctional TCRVβ4+ CD8+ IFNγ+GzB+TNFα+ in TDLNs (n ≥ 4 per group, 
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repeated x 2).  Proliferating TCRVβ4+ CD8 T cells, and their cytokine production, 
were calculated as fraction of TCRVβ4+ CD8 T cells. 
 
Figure 2.6 | TLR3 Agonist Induces a Systemic Cytotoxic CD8 T Cell Response 
to Rat-Neu Neoantigen.  A) Treatment scheme for stimulation with TLR3 agonist.  
One day after Poly I:C IP administration, 1x106 high-avidity CFSE-labeled Thy1.2+ 
RNEU420–429-specific CD8 T cells were adoptively transferred (AT) into the mice.  
On day 5 and 7, inguinal LNs (ILN) were harvested and analyzed by flow 
cytometry.  B, Percentages of proliferating TCRVβ4+ CD8 T cells in ILNs (unique 
flow plots; n = 1 per group). C, Percentages of proliferating TCRVβ4+ CD8 T cells 
in ILNs (unique flow plots; n = 1 per group). 
2.2.4 Androgen-Deprivation Therapy (ADT) Does Not Mitigate 
Antigen-Specific CD8 T Cell Tolerance to a Tumor Antigen 
Our prior work showed that ADT transiently mitigates CD4 T cell tolerance to a 
model antigen expressed under the androgen-regulated probasin promoter.  To 
test whether a similar effect occurred, in the context of a tumor antigen whose 
expression is not driven by an androgen-regulated promoter, we implanted Myc-
CaP/Neu tumors in WT recipients and then treated them with ADT prior to adoptive 
transfer of CFSE-labeled RNEU-specific CD8 T cells (Fig. 2.7A).  Consistent with 
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prior data,55 over time, ADT increased the infiltration of immune cells with the 
potential to suppress CD8 T cell responses – Tregs, PMN-MDSCs, and Mϕ (Fig. 
2.7B-C).  ADT (7 or 24 days) prior to adoptive transfer did not significantly increase 
the percentage of dividing RNEU-specific CD8 T cells relative to intact (vehicle; 
non-castrated) recipients (Fig. 2.7D), and did not increase cytokine secretion by 
RNEU-specific CD8 CTLs (Fig. 2.7E).   These data support the robustness of CD8 
T cell tolerance to this prostate-tumor restricted antigen and suggest that prior 
results using influenza hemagglutinin driven by the androgen-responsive probasin 





Figure 2.7 | Androgen-Deprivation Therapy (ADT) Does Not Significantly 
Attenuate Tumor-Induced RNEU-specific CD8 T Cell Tolerance. A, Treatment 
scheme for tumor implantation with 1x106 Myc-CaP/Neu cells.  Seven or twenty-
four days after androgen-deprivation (ADT) was administrated, 1x106 high-avidity 
CFSE-labeled Thy1.2+ RNEU420–429-specific CD8 T cells were adoptively 
transferred (AT) into the mice.  On day 5, tumor-draining lymph nodes (TDLNs) 
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were harvested and analyzed by flow cytometry.  B, Tumor infiltrating lymphocytes 
(TIL; CD3), regulatory T cells (FoxP3), myeloid-derived suppressor cells (Ly6G), 
and Mϕ (F4/80) of indicated murine allografts (representative 
immunohistochemistry; repeated x 2).  Scale bar = 50 μm.  C, Counts of immune 
cells in tumor microenvironment (TME).  D, Percentages of proliferating TCRVβ4+ 
CD8 T cells in TDLNs (representative flow plots and quantification; n ≥ 4 per group, 
repeated x 2).  E, Percentages of cytokine production by RNEU-specific TCRVβ4+ 
CD8 T cells (representative flow plots; repeated x 2).  F, Percentages of 
polyfunctional TCRVβ4+ CD8+ IFNγ+GzB+TNFα+ in TDLNs (n ≥ 4 per group, 
repeated x 2).  Proliferating TCRVβ4+ CD8 T cells, and their cytokine production, 
were calculated as fraction of TCRVβ4+ CD8 T cells.  IL-2 production was 
evaluated as a fraction of polyfunctional IFNγ+GzB+TNFα+ TCRVβ4+ CD8 T cells. 
2.3 Discussion 
We previously showed that androgen-derivation therapy (ADT) has an additive 
effect when combined with immunotherapeutic interventions.55  However, the lack 
of models to study antigen-specific CD8 T cell responses to neoantigens 
expressed in an androgen-independent manner has limited understanding of the 
cellular and molecular mechanisms involved in antigen-specific immune 
responses to PCa antigens that are not androgen-regulated.  In this study, we 
developed a model to study antigen-specific CD8 T cell peripheral tolerance in an 
implantable, androgen-responsive murine cell line in which expression of a bona-
fide cancer antigen is uncoupled from androgen receptor signaling.  We found that 
tumor cells expressing Her-2/neu maintain their immunogenicity in vivo, and recruit 
RNEU-specific CD8 T cells.  Furthermore, we found this recognition led to a 
reduction of effector cytokine production in the context of a suppressive TME.  This 
tolerance was robust and was not significantly mitigated by either the TLR-agonist 
Poly I:C or by ADT.  These data are consistent with clinical data showing that use 
of immunotherapy has generally met with limited clinical success in PCa.347   
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These data are potentially discordant with our prior work using a variant of 
the TRAMP model that expresses influenza hemagglutinin under the control of the 
androgen-responsive, prostate-specific minimal rat probasin promoter.348  There, 
we found that ADT results in de novo presentation of a prostate-restricted antigen 
in TDLN when castration (ADT) is performed 1 day prior to adoptive transfer of 
antigen-specific CD4 T cells.  In those studies we also showed that CD4 T cell 
proliferation was diminished when ADT was performed 10 days prior to adoptive 
transfer.327  Thus, those results are likely consistent with the notion that persistent 
expression of tissue antigen is important in the establishment of peripheral 
tolerance.  Consistent with this, studies from another group showed that ADT 
dramatically decreased probasin-driven expression of ovalbumin in POET-1 
mice.331  Here, in the presence of both antigen and antigen-specific CD8 T cells, 
we found more profound tolerance – that was not significantly mitigated by ADT.   
The differences between the prior models and the current one are possibly related 
to how the T-cell recognized antigen is expressed; in prior studies antigen 
expression was driven by the androgen-responsive probasin promoter and was 
thus transiently decreased after ADT. By contrast, here the bona-fide tumor 
antigen Her-2 was constitutively expressed in an androgen-insensitive manner – 
with persistent presentation likely driving the more robust tolerance seen in the 
new model.  
Supporting persistent tolerance, we observed continued Treg infiltration even 
late after ADT (24dP ADT; at onset of castration-resistance), supporting a long-
lived tolerogenic mechanism. These data are consistent with our prior studies in 
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which we used the androgen-responsive murine PCa cell line Myc-CaP, and found 
that the initial pro-inflammatory infiltrate (apparent in the early post-ADT period) 
was subsequently followed by an infiltration of Tregs into the TME that diminished 
late after ADT.55  Indeed, anti-CTLA-4 treatment prior to ADT resulted in Treg 
depletion and delayed tumor growth in that model,55 suggesting that tumor 
infiltrating Tregs may be an important mechanism of primary resistance to 
immunotherapy. These data align with the observation that CD8 T infiltration was 
accompanied by a proportional influx of Tregs in PCa patients upon neoadjuvant 
ADT treatment.317  Interestingly, we found that PMN-MDSCs infiltrated tumors as 
castration-resistance emerges, suggesting their suppressive role may be 
important in the development of acquired resistance to immunotherapy.  In line 
with this hypothesis, we and others have demonstrated that blocking PMN-MDSC 
trafficking into the tumor augments responses to immune checkpoint blockade.349  
In addition, the rationale for targeting these cells in combination with other immune 
therapeutic interventions has also been supported by studies using TRAMP 
mice,350,351 and recently reviewed in the literature.352  Further studies 
characterizing tumor infiltrating Tregs and PMN-MDSCs in the novel model 
presented here may aid in the development of new therapeutic approaches to 
overcome immunotherapy resistance in PCa, including metastatic PCa.  Although, 
metastasis has not been observed in MYC driven Myc-CaP tumors,338 a potential 
limitation of this model, the TME of prostate tumors in bone, the most clinical 
relevant metastatic niche, can be studied by direct intratibial injection of Myc-
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CaP/Neu tumor cells353 followed by adoptive transfer of CFSE-labeled RNEU-
specific CD8 T cells.  
In summary, we report a novel cell line / adoptive CD8 T cell transfer model 
to study antigen-specific T cell tolerance to PCa.  Although the interventions 
explored here were insufficient to significantly break tolerance, this system may 
serve as a useful tool to further interrogate methods by which to augment antigen-
specific CD8 T cell anti-tumor responses.  
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As discussed above,354 myeloid-derived cells may be of critical importance in 
cancer progression and may also contribute to the failure of PCa patients to 
respond to treatment.  Recent clinical studies showed that increased macrophage 
infiltration in the primary tumor at baseline correlates with failure of ADT.141  In 
addition, a recent study reported that circulating MDSCs correlate with a failure to 
respond to cancer vaccines and immune checkpoint blockade.275  Taken together, 
these data highlight the potential of targeting myeloid-derived cells or the 
mechanism(s) that regulate their recruitment to improve the response to 
immunotherapy in men with PCa.  Understanding the alterations that lead to the 
“Where we’re going is this much more 
individualized approach – just like 
infectious diseases. If you have a very 
bad infection – very bad – your doctor will 
take a sample of the bug, grow it, and pick 
an antibiotic or two or sometimes three –
mix them together and hopefully cure you 
–and that’s what we’re trying to do in 
oncology now.”  
Dr. George Demetri (2015) – a pioneer 
in the development of targeted therapy. 
Dana-Farber Cancer Institute. 
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dysregulation of intrinsic signaling pathways in prostate tumor cells and the 
mechanisms by which they regulate the infiltration of myeloid-derived cells may 
have a significant impact on PCa treatment.  Here, we identified the IL-8 / CXCR2 
pathway as a major mechanism for PMN-MDSC recruitment to the TME of CRPC 
tumors following ADT.  
3.2 Results 
3.2.1 Androgen-Deprivation Therapy (ADT) Increases IL-8 
Transcription in Prostate Cancer Cells 
To identify immune-related tumor-cell intrinsic factors involved in PCa progression, 
we performed expression analyses on murine PCa cells pre- and post- castration. 
We used the MCRedAL PCa cell line; an RFP expressing version of the Myc-Cap 
cell line characterized by MYC overexpression.337 Like human PCa, MCRedAL 
tumors are initially castration-sensitive (CS), but castration-resistance (CR) 
develops approximately 30 days after castration (Fig. 3.1A).  Pre- and post- ADT 
tumor cells were sorted to > 96% purity (Fig. 3.1B) and analyzed (Fig. 3.1C-D).  A 
number of cytokine and chemokine transcripts were significantly up-regulated 
post-ADT (Fig. 3.1D right), including Cxcl15, a CXC chemokine with a conserved 
ELR motif (Table 3.1), which is the likely murine homolog of human IL-8 
(CXCL8).355-358  qRT-PCR and ELISA assays confirmed the upregulation of Cxcl15 
post-ADT at the protein level (Fig. 3.1F).  In addition to the chemokines above, 
GSEA revealed the upregulation of several pro-inflammatory pathways post-ADT 
(Fig. 3.1E).  In vitro experiments using the human androgen-responsive LNCaP 
cell line corroborated a role for these pro-inflammatory signals, showing that in the 
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absence of androgen, TNFα upregulated IL-8 expression in a dose-dependent 
manner (Fig. 3.1G left); while AR signaling in the absence of inflammation did not 
affect IL-8 expression (Fig. 3.1G right).  These data led to the hypothesis that AR 
signaling directly suppresses IL-8 expression in PCa cells.  We performed in silico 
ChIP-Seq analyses using human LNCaP cells (GSE83860) and found AR binding 
at the IL-8 promoter in the presence of the potent androgen dihydrotestosterone 
(DHT; Fig. 3.1H top).  This androgen dependent binding was verified by ChIP-qRT-
PCR (Fig. 3.1I left).   
Table 3.1 | Amino Acid Sequence Homology Between Human IL-8 (CXCL8) 
and the Murine Homologues.  
RefSeq 
Accession #


















































Figure 3.1 | Androgen-Deprivation Therapy (ADT) Increases IL-8 Expression 
in Prostate Cancer Cells.  A, Androgen responsive tumor epithelial cells progress 
from castration-sensitive (CS) to androgen responsive (ADT), and eventually 
developed castration-resistance (CR). CR was tumor size defined as ≥ 30% of 
nadir tumor volume. Left, fluorescent tag-in strategy to generate mCherry+ Myc-
Cap cells (MCRedAL cells). Right, tumor growth curve of MCRedAL tumors. CTX: 
Castration (n ≥ 3 per group, repeated x 2).  B, Sorting strategy to isolate tumor 
epithelial cells from A based on their expression of mCherry and their CD45-
CD11b-F4/80- phenotype.  C, Differential expression profile of tumor epithelial cells 
isolated from castration-sensitive (CS) and ADT-treated MCRedAL tumor bearing 
mice. Heatmap showing transcripts 3 standard deviations away from the mean (n 
= 3 per group).  D, Differential chemokine expression of tumor epithelial cells 
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isolated from CS and ADT tumor bearing mice (replicate numbers as in C). Left, 
volcano plot showing gene expression among all MTA 1.0 microarray transcripts. 
Right, heatmap of normalized chemokine transcripts.  E, Hallmarks gene sets 
pathway analysis post-ADT shows NF-κB up-regulation post-ADT.  F, Gene and 
protein expression of Cxcl15 in indicated MCRedAL tumor cells in vitro by qRT-
PCR and ELISA, respectively (n = 3 per group).  G, qRT-PCR quantification of IL-
8 in LNCaP cells cultured at indicated concentrations of TNFα and DHT, cells 
cultured in androgen-free media as described in materials and methods (n = 3 per 
condition, repeated x 2).  Expression levels normalized to mean ΔCT level in 
samples cultured in androgen free media without TNFα or DHT.  H, ChIP-Seq 
analysis of AR and p65 (the the NF-κB subunit) at the IL-8 (CXCL8) promoter in 
LNCaP cells cultured in the presence of either vehicle (DMSO), DHT (100 nM), or 
TNFα (1000 U/ml) (n = 2 per group; GSE83860).  I, left: ChIP quantitative RT-PCR 
(qRT-PCR) analysis of AR and pSer2 Pol II at the IL-8 (CXCL8) promoter (n = 3 
per group). Right: percentage input bound in ChIP–qRT-PCR assays assessing 
binding of pSer2 Pol II and control IgG at PSA (KLK3) promoter loci. Experiments 
were performed in LNCaP cells treated for 24 h with or without DHT (100 nM; n = 
3 per group). For H, loci with significant differential binding (black bar) were 
identified as described in materials and methods.  Error bars represent standard 
error.  Unpaired t-tests were performed, p-values ≤ 0.05 (*), 0.01 (**), 0.001 (***) 
and 0.0001 (****); p-values ≥ 0.05 (ns).   
To further explore the role of AR in IL-8 regulation, we interrogated RNA 
polymerase binding and transcription marks found at sites of active promoters.359 
In the presence of DHT, binding of phosphorylated serine 2 RNA polymerase II 
(pSer2 pol II) to the IL-8 locus was substantially reduced, consistent with reduced 
transcriptional activity (Fig. 3.1I left).  Conversely, pSer2 pol II binding to the 
promoter of the well-established AR-regulated gene PSA (KLK3), was significantly 
increased in the presence of DHT as expected (Fig. 3.1I right).  Consistent with a 
role for inflammation, TNFα significantly increased p65 binding at the IL-8 (CXCL8) 
promoter in LNCaP cells (Fig. 3.1H bottom).  No significant binding of AR was 
detected at the promoters of the chemokines CXCL1, CXCL2, CXCL5 or CXCL12 
(Fig. 3.2).  These data suggest that AR directly suppresses IL-8 expression 
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through repressive AR binding to the IL-8 promoter.  Taken together, we found that 
IL-8 transcription is up-regulated by pro-inflammatory signaling, and down-
regulated by AR signaling. 
 
Figure 3.2 | Chemokine Regulation Upon AR signaling Stimulation and an 
Inflammatory Stimuli in Prostate Tumor Epithelial Cells.  ChIP-Seq enrichment 
of AR at the CXCR1, CXCR2, CXCR5, and CXCL12 promoters in LNCaP cells 
cultured in the presence of either vehicle (DMSO), AR signaling (DHT: 100 nM), or 
an inflammatory stimuli (TNFα: 1000 U/ml) (n = 2 per group; GSE83860).   
3.2.2 IL-8 is Differentially Expressed in Castration-Resistant Versus 
Castration Sensitive Prostate Cancer Cells 
We next investigated the effects of ADT on the expression of Cxcl15 in vivo, using 
RNA in situ hybridization (RISH) to study Myc-Cap tumors.  We found that CR 
tumors expressed increased Cxcl15 as compared to CS tumors, particularly in 
epithelial (PanCK+) tumor cells (Fig. 3.3A).  These findings were confirmed in vitro, 
both at the mRNA and protein level (Fig. 3.3B).  To investigate these findings in 
the context of human PCa, we used three paired cell lines in which isogenic CR 
lines were derived from CS progenitors.  For each pair, the CR line expressed 
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significantly increased IL-8 as compared to the CS counterpart, both at the mRNA 
and protein level (Fig. 3.3C-D).  This observation held across a panel of AR 
expressing PCa cell lines; with higher levels of IL-8 expression in cell lines from 
castration-resistant disease (Fig. 3.3E).  To test whether AR modulates Cxcl15 
expression in benign prostate epithelium, we used RISH to study WT mice treated 
with ADT, and WT mice treated with ADT followed by testosterone (T) repletion 
(Fig. 1.1A-C).  These data (Fig. 3.3F-G) showed increased epithelial Cxcl15 
expression in ADT samples with expression significantly decreased by 
testosterone repletion (Fig. 3.3G).  This observation was further corroborated by 
interrogating a dataset (GSE8466) profiling human prostate epithelial cells isolated 
by laser-capture microdissection (LCM) from men undergoing ADT and ADT with 
testosterone supplementation. Testosterone repletion significantly reduced IL-8 
mRNA expression (Fig. 3.3H), supporting the hypothesis that AR signaling down-
regulates IL-8 expression. In agreement with these data from benign prostate 
tissues, we LCM-enriched tumor prostate epithelium from high-risk PCa patients 
treated with ADT on a neo-adjuvant trial (NCT01696877) and found increased IL-
8 expression as compared to tumors from age and stage-matched untreated 
controls (Fig. 3.3I).  Taken together, analyses using human tissues strongly 





Figure 3.3 | IL-8 is Up-Regulated in Post-Castration and Castration-Resistant 
Prostate Cancer Cells.  A, Representative images of Cxcl15 fluorescent detection 
(murine homologue of IL-8) in Myc-Cap tumors. Tumors were harvested when 
volumes reached ~500mm3 (CS group), 7 days after androgen-deprivation (ADT), 
or at the time of castration-resistance (CR) and hybridized with CF568-labeled 
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probe sets (white) to Cxcl15, CF640-labeled anti-PanCK antibody (red), and 
CF488-labeled anti-CD45 antibody (green). Nuclei counterstained with DAPI 
(blue).  Repeated x 3.  B, Gene and protein expression of Cxcl15 in MCRedAL 
cells of indicated tumor samples by qRT-PCR and ELISA, respectively (n = 3 per 
group, repeated x 2).  C, qRT-PCR quantification of IL-8 in human AR positive 
castration-sensitive cells (CS: LNCaP, LAPC4, and VCaP) and their castration-
resistant counterparts (CR: LNCaP-abl, LAPC4-CR, and VCaP-CR), replicate 
numbers as in B. D, IL-8 protein expression in the isogenic cell pairs from C 
quantified by ELISA, replicate numbers as in C.  E, qRT-PCR quantification of IL-
8 in AR positive castration-sensitive (LNCaP, LAPC4, and VCaP) and AR 
independent castration-resistant (E006AA, CWR22Rv1, DU145, and PC3) human 
PCa cell lines (n = 2 per group, repeated x 2).  F, Representative images of Cxcl15 
fluorescent detection in benign murine prostate tissue samples from castration-
sensitive (CS), androgen-deprivation treated (ADT), and ADT-treated mice that 
received testosterone repletion (ADT + T). Tissue sections hybridized with CF568-
labeled probe sets (white) to Cxcl15, and CF640-labeled anti-PanCK antibody 
(red). Nuclei were counterstained with DAPI (blue).  Repeated x 3.  G, qRT-PCR 
analysis of Cxcl15 expression in prostate luminal epithelial cells from indicated 
treatment groups (n = 3 per group). Prostate luminal epithelial cells were isolated 
based on their GFP+CD49fintCD24+CD45-F4/80-CD11b- expression by flow sorting 
into Trizol LS.  H, Expression of IL-8 in human prostate epithelial cells micro-
dissected from patients in a clinical trial (NCT00161486) receiving placebo, 
androgen-deprivation treatment (ADT), or ADT plus testosterone repletion (ADT + 
T).  Z-score values of microarray transcripts from benign prostate biopsies were 
normalized to placebo samples (n = 4 per group; GSE8466).  I, Expression of IL-8 
in human PCa epithelial cells micro-dissected from untreated or ADT-treated 
(NCT01696877; n = 8 per group) patients as determined by qRT-PCR.  RISH 
images are at 60X magnification; scale bar = 100 μm.  Gene expression levels 
were normalized to the mean ΔCT level in samples from CS, untreated or placebo 
groups.  For B-H, unpaired t-tests were performed; for I a Mann-Whitney U test 
was used due to the non-normal data distribution observed.  p-values ≤ 0.05 (*) 
and 0.01 (**); p-values ≥ 0.05 (ns) shown. The range in box and whiskers plots 
shows min and max values such that all data are included.   
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3.2.3 ADT-mediated IL-8 Up-Regulation Promotes PMN-MDSC 
Infiltration 
We next quantified castration-mediated immune infiltration in Myc-Cap allografts 
(Fig. 3.4A).  Consistent with prior data,55 ADT promoted a transient T cell influx, 
without significant changes in tumor associated macrophage (TAM) populations 
(Fig. 3.4B).  By contrast, PMN-MDSC infiltration was significantly increased in CR 
tumors (Fig. 3.4B), as verified by IHC (Fig. 3.4C).  We found similar results in 
human PCa xenografts (Fig. 3.4D-E).  PMN-MDSC infiltration also increased in 
WT mice treated with ADT, but not in WT mice treated with ADT then repleted with 
testosterone (Fig. 3.4F), supporting a causal relationship between ADT and PMN-




Figure 3.4 | Castration-mediated IL-8 Up-Regulation Promotes PMN-MDSC 
Infiltration.  A, Gating strategy used to profile the immune compartment of the 
TME by flow cytometry. Tumor associated Mϕ (TAMs) gated based on 
CD45+Ly6G-F4/80+CD11b+, Inflammatory (Inf.) TAMs as 
CD45+CD11b+F4/80+Ly6C+MHCII-, immature (Imm.) TAMs as 
CD45+CD11b+F4/80+Ly6C+MHCII+, MHCIIhi TAMs as CD45+CD11b+F4/80+Ly6C-
MHCII+, MHCIIlow TAMs as CD45+CD11b+F4/80+Ly6C-MHCII-, tumor Infiltrating 
Lymphocytes (TILs) CD45+CD4+ or CD45+CD8+, tumor infiltrating 
polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) as 
CD45+CD11b+Ly6C+Ly6G+.  B,  TAM, TIL, and PMN-MDSC density normalized to 
mg of tumor weight (cells/mg; n ≥ 3 per group, repeated x 2).  C, Representative 
H&E and immunohistochemistry (F4/80 and Ly6G) of indicated murine allografts 
(repeated x 3).  D, PMN-MDSCs as a percentage of CD45+ cells in the TME of 
indicated human prostate tumors as determined by flow cytometry (n = 3 per group, 
repeated x 2).  E, Representative H&E and immunohistochemistry (Ly6G and 
F4/80) sections of the indicated human prostate xenografts (repeated x 3).  F, 
Representative H&E and immunohistochemistry of Ly6G in non-cancerous murine 
prostate from castration-sensitive (CS), androgen-deprivation treated (ADT) non-
tumor bearing mice, and ADT treated mice that received testosterone repletion 
(ADT + T). Repeated x 2.   
3.3 Discussion 
We identified that ADT mediates increased IL-8 secretion by PCa epithelial cells 
by reliving AR mediated transitional repression.  IL-8 up-regulation further drives 
prostate tumor infiltration with PMN-MDSCs.  Recent studies have suggested 
potential mechanisms that explain the migration of PMN-MDSCs in response to a 
few of the ligands of Cxcr4 (Cxcl12) and Cxcr2 (IL-8 murine functional 
homologues: Cxcl1, Cxcl2, Cxcl5).360,361  Here, we found Cxcl15 expression is 
upregulated after inhibition of AR-signaling in murine tumor epithelial cells in a 
manner similar to which IL-8 is up-regulated in human PCa epithelial cells (Fig. 
3.3).  Interestingly, we did not observe AR binding to the promoter of other 
chemokines reported to modulate neutrophil infiltration (Fig. 3.2).  Complimentary 
to the mechanism described here, a recent study found that Cxcl12 expression 
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could be induced in prostate tumor cells by treatment with the tyrosine kinase 
inhibitor cabozatinib in Pten/tp53 deficient animals.361   
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Chapter IV – Targeting Tumor Intrinsic 
Mechanisms Alone or in Combination 










We and others have shown that ADT initially increases CD8 T cell infiltration into 
prostate tumors,141,238,327 and this response is augmented pre-clinically with anti-
CTLA-4.55  Emerging data suggest that immune-resistance in PCa involves 
dysfunctional myeloid cells known as MDSCs in the TME.362  MDSCs secrete IL-
23, which acts directly on PCa epithelial cells to drive castration-resistance.289 
Here we found that mitigating the suppressive effects of PMN-MDSCs influx driven 
by ADT increase anti-tumor immune responses when given in combination with 
ICB. 
 “Immunotherapy represents a new 
frontier in prostate cancer.  We’re also 
looking at how it can be used 
synergistically with traditional therapies, 
both in prostate cancer as well as in other 
tumor types.” 
Dr. Charles G. Drake (2016) – a pioneer 
in cancer immunotherapy. 
Professor and hematology oncologist at 
Columbia University, and the co-director 




4.2.1 Blockade of the IL-8 / CXCR2 Pathway Attenuates the Migration 
of PMN-MDSCs But Not Their Function 
Molecular profiling of the infiltrating myeloid cells revealed a signature consistent 
with functional PMN-MDSCs, including up-regulation of IL-1b, Arg2 and IL-23a289 
(Fig. 4.1A).  In particular, increased expression of IL-23a and Cxcr2 was verified 
by qRT-PCR (Fig. 4.1B) and flow cytometry (Fig. 4.1C).  To test whether blocking 
the IL-8 / CXCR2 axis was sufficient to attenuate post-ADT PMN-MDSC infiltration, 
we treated prostate-tumor bearing mice with anti-CXCR2 and found that blocking 
CXCR2 significantly diminished tumor infiltration with PMN-MDSCs in both human 
(PC3) and murine (Myc-Cap) immunodeficient and immunocompetent models 
(Fig. 4.1D-F).  To confirm this observation at the genetic level, we used 
CRISPR/Cas9 to generate human (PC3) and mouse (Myc-Cap) lines that were 
knocked out for human IL-8 or the murine IL-8 homolog Cxcl15, respectively.  We 





Figure 4.1 | PMN-MDSCs Infiltration Relays on IL-8 (Cxcl15) / CXCR2 
Signaling Following ADT.     A, Normalized expression of selected genes 
determined by NanoString nCounter gene analysis in sorted myeloid fractions 
defined as in Fig. 3.4A (n = 3 per group).  B, qRT-PCR quantification of Cxcr2 and 
Il-23 in indicated populations of Myc-Cap tumors (n = 3 per group).  C, 
Representative histograms of protein expression determined by flow cytometry in 
PMN-MDSCs from indicated organs (repeated x 2).  D and E, Density of PMN-
MDSCs normalized to mg of tumor weight (cells/mg) in Myc-Cap and PC3 tumors  
(n ≥ 4 per group, repeated x 2).  Cells quantified by flow cytometry as in Fig. 3.4A, 
tumors implanted and harvested as in materials and methods.  H&E and IHC 
images at 40X magnification; scale bar = 50 μm.  Gene expression levels 
normalized to the mean ΔCT level in samples from the Immature TAMs (Imm.) 
group.  Unpaired t-tests performed, p-values ≤ 0.05 (*), 0.01 (**), 0.001 (***) and 
0.0001 (****); p-values ≥ 0.05 (ns).  F, Representative H&E and 
immunohistochemistry (Ly6G and F4/80) on CR-Myc-Cap allografts treated as 
105 
 
indicated (repeated x 3).  G, Representative H&E and immunohistochemistry 
(Ly6G and F4/80) in PC3 tumor xenografts treated as indicated (repeated x 3).  
H&E and IHC images are 40X magnification; scale bar = 50 μm.  Unpaired t-tests 
were performed, p-values ≤ 0.0001 (****).   
We next asked whether the supernatant from castration-resistant MCRedAL 
(CR-MCRedAL) cells was sufficient to drive PMN-MDSC migration in vitro. In line 
with in vivo results (Fig. 4.1D-G and Fig. 4.2A-C), we found that PMN-MDSC 
migrated towards the supernatant of CR tumors and migration was significantly 
attenuated by CXCR2 blockade (Fig. 4.2D).  Human PCa (PC3) showed an 
identical pattern.  To confirm a role for IL-8 in PMN-MDSC migration, we generated 
IL-8 KO CR-LNCaP (LNCaP-abl) using CRISPR/Cas9. Supernatants from IL-8 KO 
cells were significantly attenuated in their ability to promote PMN-MDSC migration 
(Fig. 4.2E).  These PMN-MDSCs were functional and suppressed CD8 T cell 
proliferation in a dose-dependent manner (Fig. 4.2F-I).  Although CXCR2 blockade 
decreased PMN-MDSC migration, it did not significantly alter suppressor function 
(Fig. 4.2J). Similarly, Cxcl15 loss did not diminish the suppressive function of PMN-
MDSCs (Fig. 4.2K).  Taken together these findings reinforce a functional role for 




Figure 4.2 | PMN-MDSCs Migrate in Response to Cxcl15 and Suppress 
Antigen Specific T Cell Function.   A, Analysis of Ly6G+ PMNs in peritoneal 
washings receiving Cxcl15 (200ng/mouse, i.p.) in mice pre-treated with either 
isotype or αCXCR2 (n ≥ 4 per group, repeated x 2).  B, Analysis of the fold change 
between the number of Ly6G+ PMNs in peritoneal washings from A in relation to 
PMNs’ numbers in peripheral blood of indicated treated mice.  C, Representative 
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plots of Ly6G+ PMNs in peritoneal washings from A of indicated treated mice 
(repeated x 2).  D, PMN-MDSC in vitro migration towards tumor supernatants in 
the presence of either isotype or anti-CXCR2 (200 µg/ml). Antibodies were added 
at the beginning of the experiment (n ≥ 2 per group, repeated x 2).  E, PMN-MDSC 
in vitro migration towards CR-LNCaP (LNCaP-abl) WT or IL-8 KO tumor 
supernatants (n = 3 per group, repeated x 2).  F, Schematic representation of PMN-
MDSC suppression assay. OT-I splenocytes (CD45.2) were mixed with naïve 
splenocytes (CD45.1) in a 1:10 ratio, labeled with CTV, and co-culture with PMN-
MDSCs at the indicated ratios. T cell proliferation was stimulated (Stim) by OVA 
peptide (5pM) for 60 hours.  G, Percent suppression when either unselected or 
low-density PMN-MDSCs were used for the experiment (n = 3 per group, repeated 
x 3).   H, Percent of CD8 T cells (left) and antigen specific OT-I cells (CD45.2; right) 
proliferating at different proportions of PMN-MDSCs when stimulated with or 
without 5pM of OVA, replicate numbers as in G. I, Representative histograms of 
antigen specific OT-I cells proliferation based on the dilution of CTV dye when 
stimulated as in H (repeated x 2).  J, Percent suppression in the presence of either 
isotype or anti-CXCR2 (200 µg/ml). Antibodies were added at the beginning of the 
experiment (n = 3 per group, repeated x 2).  K, Percent suppression of PMN-
MDSCs derived from spleens of WT or Cxcl15 KO Myc-Cap tumor bearing mice 
(n = 3 per group, repeated x 2). For A-C, PMNs were gated on CD45+Ly6G+ cells.  
Cell migration in vivo was evaluated 4 hours after PBS or cytokine treatment and 
normalized to 10,000 beads.  PBS was injected as the control for these 
experiments.  For D-E, PMN-MDSCs were isolated from spleens of mice bearing 
CR-Myc-Cap tumors and placed in the top chamber of a transwell. Culture 
supernatants were plated in the bottom chamber, and number of PMN-MDSCs 
migrating from the top to the bottom chamber after 2.5 hours was evaluated. For 
G, J-K, percent suppression (% Suppression) was calculated by the following 
formula: % Suppression = [1-(% divided cells of the condition / the average of % 
divided cells of T responder only conditions)] x 100.  Unpaired t-tests were 




4.2.2 CXCR2 Blockade Improves Response to Immune Checkpoint 
Blockade Following Androgen-Deprivation  
Finally, we investigated the pre-clinical activity of blocking the IL-8 / CXCR2 axis 
at the time of androgen-deprivation in the Myc-Cap model.  Notably, in the absence 
of immunotherapy the combination of ADT and CXCR2 blockade was not effective 
(Fig. 4.3A&C).  In contrast, combining CXCR2 blockade with ICB (anti-CTLA-4; 
Fig. 4.3E) resulted in significantly increased survival (Fig. 4.3F).  This triple 
combination (ADT + anti-CXCR2 + anti-CTLA-4) was effective even when tumors 
were relatively advanced (400 mm3) at the time of treatment (Fig. 4.3G).  
Macrophage modulation with anti-CSF1R was not effective therapeutically in this 






Figure 4.3 | CXCR2 Blockade Improves Response to Immune Checkpoint 
Blockade Following Androgen-Deprivation Therapy.  A, Tumor growth and 
survival curves of mice from isotype vs. αCXCR2 treatment groups (green vs. blue, 
respectively; n = 10 per group, repeated x 2).  B, Tumor growth and survival curves 
of mice from isotype vs. αCSF1R treatment groups (green vs. purple, respectively; 
n ≥ 7 per group, repeated x 2).  C, PMN-MDSCs as a percentage of CD45+ cells 
in the TME of indicated treatment groups, repeated x 2.  D, TAMs as a percentage 
of CD45+ cells in the TME of indicated treatment groups, replicate numbers as in 
B.  E, Treatment scheme, scale = weeks.  Animals sacrificed for immune 
phenotyping 1 week post-ADT.  F, Tumor growth and survival curves of mice from 
isotype vs. anti-CTLA-4 vs. anti-CTLA-4 + anti-CXCR2 groups treated as 
described in E (black line vs. orange line vs. purple line, respectively; n ≥ 8 per 
group, repeated x 2).  Treatment was initiated when tumor volumes reached 
200mm3.  G, Tumor growth and survival curves of mice from isotype vs. αCTLA-4 
vs. αCTLA-4 + αCXCR2 treatment groups (green vs. orange vs. purple, 
respectively; n ≥ 7 per group, repeated x 2). Treatment started when tumor 
volumes reached 400mm3.  Average tumor volume (±s.e.m.) for each experimental 
group.  Wilcoxon test used for survival analysis.  Flow cytometry as in materials 
and methods.  Unpaired t-tests performed, p-values ≤ 0.05 (*), 0.01 (**), 0.001 (***) 
and 0.0001 (****); p-values ≥ 0.05 (ns).  
Mechanistically, the increased anti-tumor effects mediated by the addition 
of anti-CXCR2 to ADT + anti-CTLA-4 did not appear to be due to increased T cell 
infiltration (Fig. 4.4A&C-D), nor due to decreased Treg infiltration (Fig. 4.4B), but 
rather correlated with an increase in polyfunctional effector CD8 T cells in tumor-




Figure 4.4 | The Therapeutic Effect of the Triple Combination is Associated 
with PMN-MDSC Reduction.  A, Tumor infiltrating lymphocyte (TILs) density in 
indicated treatment groups (n ≥ 5 per group, repeated x 2).  B, Treg percentages 
(as fraction of CD4) in indicated tissues (n ≥ 5 per group, repeated x 2).  C, Memory 
CD8 T cells as a percentage of CD45+CD8+ TILs and TDLN of indicated treatment 
groups, replicate numbers as in A.  D, Representative plot of memory CD8+ TILs 
and TDLN of indicated treatment groups (repeated x 2).  E, Polyfunctional CD8 T 
cells, left panel = density, center/right panels = percentage of total CD8, animals 
numbers as in A.  F, Representative histograms and dot plots of polyfunctional 
CD8+ IFNγ+GzB+TNFα+ from tumor draining lymph nodes (TDLN).For For A-F, 
treatment started when tumor volumes reached 200mm3.  Average tumor volume 
(±s.e.m.) for each experimental group.  Wilcoxon test was used for survival 
analysis.  Flow cytometry as in materials and methods.  Unpaired t-tests were 
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performed, p-values ≤ 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****); p-values ≥ 
0.05 (ns). 
4.3 Discussion 
We found that blocking CXCR2 at the time of ADT attenuates PMN-MDSC 
infiltration, rendering prostate tumors more sensitive to ICB.  It is noteworthy that 
in other murine models the recruitment of PMN-MDSC and neutrophils may be 
driven by other chemokines, including Cxcl1360 and Cxcl12.361  Our findings are 
corroborated by clinical data showing that PMN-MDSCs accumulate in the blood 
of patients with advanced PCa,135,136,363 and that an intra-tumoral PMN signature 
is associated with poor outcome.364  Our data are also supported by pre-clinical 
studies showing that blocking MDSC function increases the efficacy of ICB in 
animal models of CRPC.362  Consistent with recent data, we found that the PMN-
MDSCs infiltrating prostate tumors express IL-23.289  We further showed that 
inhibiting the recruitment of these cells peri-castration augmented the CD8 T cell 
effector function initiated by ICB.  Based on these findings, our group has launched 
an investigator-initiated phase Ib/II trial (NCT03689699) to test whether adding ICB 
and anti-IL-8 to a short course of ADT can prevent PMN-MDSC infiltration and 
delay progression in men with castration-sensitive PCa.  In summary, targeting the 
IL-8 / CXCR2 pathway following ADT in combination with ICB may represent a 
novel treatment paradigm to improve responses to immunotherapy and delay the 




The promise of cancer immunotherapy in PCa and other so called ‘cold’ tumors, is 
likely to lay in combination therapy.  Even though prostate tumor-associated 
antigens lead to pro-inflammatory CD4 and CD8 T-cell responses, the 
immunosuppressive microenvironment of PCa tumors renders these antigen-
specific T-cell responses tolerant.  Although androgen-derivation therapy (ADT) 
drives the infiltration of T cells into the TME, it also up-regulates the expression of 
interleukin-8 (IL-8) and it’s likely murine homolog Cxcl15, which in turns drives the 
recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-
MDSCs).  Indeed, combining immune checkpoint blockade with a treatment 
intervention that mitigates the recruitment of PMN-MDSCs prior to ADT delays the 
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Materials and Methods 
Patient Samples 
Serum samples from human prostate cancer patients were obtained from 
consented patients treated with ADT alone (degarelix; 240 mg SQ) or 
cyclophosphamide (200 mg/m2 IV) followed by GVAX and ADT in a neo-adjuvant 
trial (NCT01696877) at the Johns Hopkins Sidney Kimmel Comprehensive Cancer 
Center (Baltimore, MD) under an IRB-approved clinical protocol (IRB # 
NA_00073453).317,365  Men with high-risk localized prostate adenocarcinoma, 
defined as clinical stage T1c-T3b, N0, M0 and a Gleason sum ≥ 4+3 (grade group 
≥3) in at least two cores were considered eligible if they were planning to undergo 
prostatectomy. All patients were required to have an Eastern Cooperative 
Oncology Group performance status of 0 or 1; and normal kidney, liver, and 
marrow function. Patients with nodal (N1) or distant (M1) metastases were 
excluded. Additional key exclusion criteria included prior immunotherapy or 
vaccine therapy for prostate cancer, prior radiation, hormonal, or chemotherapy, 
autoimmune disease requiring corticosteroids, and known allergy to 
cyclophosphamide or G-CSF/GM-CSF.  All patients provided written, informed 
consent authorizing the collection of clinical data, serum and other biospecimens.    
Primary human peripheral blood mononuclear cells (PBMCs) from anonymous 35-
year-old or older healthy male donors were acquired from the New York Blood 
Center.  
Formalin fixed, paraffin embedded (FFPE) human prostate cancer samples were 
obtained from consented patients treated with ADT (degarelix; 240 mg SQ) in a 
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neo-adjuvant trial (NCT01696877)365 and matched control radical prostatectomies 
were obtained from patients treated at the Johns Hopkins Sidney Kimmel 
Comprehensive Cancer Center (Baltimore, MD) under IRB-approved clinical 
protocol J1265.  All patients provided written, informed consent.  
Cell Lines 
Myc-CaP, derived from spontaneous prostate cancer in c-Myc transgenic 
mice,337,338 was a generous gift from Dr. C. Sawyers.  To generate MCRedAL, Myc-
Cap cells were transfected with pRetroQ-mCherry-C1 (Clontech) using 
lipofectamine 2000 (Invitrogen) and isolated by FACS sorting based on mCherry 
expression.  Myc-CaP cells were transduced with viral particles containing the rat 
Her-2/neu transcript and isolated by FACS sorting based on Her-2/neu expression 
to establish Myc-CaP/Neu cells. Myc-Cap, MCRedAL, and Myc-CaP/Neu cells 
were cultured in DMEM as previously described.337  LNCaP, VCaP, E006AA, 
CWR22Rv1, DU145, and PC3 cell lines were obtained and cultured as 
recommended by the ATCC.  LAPC4 (a gift from Dr. S. Yegnasubramanian) were 
maintained in RPMI-1640 (Corning) supplemented with 10% fetal bovine serum 
(FBS; Gemini Bio-Products).  Androgen independent LNCaP-abl cells were a gift 
from Dr. Z. Culig and cultured as described previously.366 LAPC4-CR and VCaP-
CR (a gift from S. Yegnasubramanian) were derived by passaging LAPC4 and 
VCaP cells through castrated animals and further subculturing in RPMI-1640 
supplemented with 10% charcoal stripped serum (CSS; Gemini Bio-Products) 
supplemented with 1X B-27 Neuronal Supplement (Gibco).  For experiments when 
cells were grown in androgen-free conditions, 10% FBS was substituted for 10% 
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CSS in complete media.  For migration/chemotaxis assays, prostate cancer cell 
lines were cultured in complete media containing either 0.5% or 2.5% FBS for 
human and murine cells, respectively.  All cell lines were cultured in 1% 
penicillin/streptomycin media at 37°C, 5% CO2. 
Mouse Strains  
Seven-week-old FVB/NJ Thy1.1 male mice were purchased from The Jackson 
Laboratory (JAX stock #001800).  FVB/N Thy1.2+ mice were created by 
backcrossing the Thy1.2 allele onto the FVB/N background for 10 generations.  
These mice were then crossed to FVB/N clone 100 transgenic mice carrying T 
cells specific for MHC I (H-2Dq) rat neu immunodominant peptide (RNEU420-429).340   
Breeding pairs of clone 100 transgenic mice and FVB/N Thy1.2 labeled mice were 
kindly transferred from the Laboratory of Dr. Elizabeth M. Jaffee at Johns Hopkins 
to Columbia University.  Experimental animals were bred in-house and phenotyped 
with TCRVβ4 and Thy1.2 staining as previously described.367  Mice were 
acclimated for at least 1 week before any experimental procedures were 
performed. Animals were kept in specific pathogen-free facilities in either Johns 
Hopkins University School of Medicine or Columbia University Medical Center.  All 
animal experiments were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Johns Hopkins 
University School of Medicine and Columbia University Medical Center.  
Seven-week-old FVB/NJ, J:NU, C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I), and 
B6.SJL-PtprcaPepcb/BoyJ (CD45.1) male mice were purchased from The 
Jackson Laboratory.  A breeding pair of Hoxb13-rtTA|TetO-H2BGFP (HOXB13-
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GFP) mice368 was received from UMBC and experimental animals were bred in-
house.  Animals were kept in a specific pathogen-free facility at either Johns 
Hopkins University School of Medicine or Columbia University Medical Center.  All 
animal experiments were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) at the respective 
institutions.  
Her-2/Neu Transfection 
Rat neu cDNA was cloned from pSV2-neu-N (gift from Bob Weinberg; Addgene 
plasmid # 10917)369 and ligated into the pWPXL vector to replace EGFP sequence 
(gift from Didier Trono; Addgene plasmid # 12257); pMD2.G and psPAX2 plasmids 
were used as envelop and packing systems.  All plasmids were transfected into 
293T using lipofectamine 2000 (Invitrogen) and 293T cell supernatants were 
collected 48 hours post-transfection and used to transduce Myc-CaP cells. Viral 
load was titrated to mimic different multiplicity of infections (MOI 5 - 50) using 
appropriate volumes of medium with lentivirus containing polybrene (Sigma-
Aldrich).  The same parental Myc-CaP cells were transduced with a murine GM-
CSF lentivirus using the same method for inserting the rat Her-2/neu containing 
the RNEU420-429 peptide (PDSLRDLSVF) to create Myc-CaP/Neu cells.  
Successfully transduced cells were isolated based on their Her-2/neu expression 
by FACS for Myc-CaP/Neu and based on their GM-CSF expression levels by 
ELISA for GM-CSF secreting bystanders.  Efficiency was evaluated 24 hours after 
transduction in both cases. 
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Adoptive transfer (AT) experiments 
High-avidity RNEU-derived CD8 T cell were isolated untouched from the spleens 
of 8-week old male clone 100 transgenic mice using CD8a immunomagnetic 
negative selection beads (Miltenyi Biotec).  CD8 T cells were then labeled with 
CFSE (Invitrogen) and resuspended in PBS.  One million CFSE-labeled Thy1.2+ 
RNEU420–429-specific CD8 T cells were adoptively transferred intravenously into 8-
week old male FVB/NJ mice (JAX stock #001800) – that, unlike most strains, 
express the congenic marker Thy1.1.367  On days 5 and 7, LNs (draining or 
inguinal) and spleens were harvested.  CFSE dilution of the adoptively transferred 
Thy1.2+ RNEU-derived CD8 CTLs was measured by flow cytometry. To maximize 
identification of adoptively transferred CFSE-labeled RNEU420–429-specific CD8 T 
cells, we first gated on the congenic marker Thy1.2 and next gated on the 
clonotypic Vβ chain, Vβ4. 
Toll-like receptor 3 (TLR3) stimulation experiments.  
Naïve mice received a low molecular weight (LMW) synthetic polyinosinic-
polycytidylic acid (Poly I:C) intraperitoneally (IP) at a dose of 100 μg/mouse 
(InvivoGen).  Twenty-four hours later, mice received an intravenous injection of the 
high-avidity CFSE-labeled Thy1.2+ RNEU420–429-specific CD8 T cells. 
Tumor Allografts and Xenografts 
Eight-week-old male FVB/NJ and J:NU mice were subcutaneously inoculated with 
either Myc-CaP or MCRedAL (1×106 cells/mouse), and LNCaP or PC3 (3×106 
cells/mouse) in the right flank, respectively.  Tumor diameters were measured with 
electronic calipers every 3 days as indicated and the tumor volume was calculated 
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using the formula: [longest diameter × (shortest diameter)2]/2.  Myc-Cap tumor 
bearing mice received androgen-deprivation therapy (ADT) 4 weeks after tumor 
implantation when tumor volume reached ~500mm3, as indicated in figure legends.  
ADT was administered via subcutaneous (sc) injection of degarelix acetate (a 
GnRH receptor antagonist; Ferring Pharmaceuticals Inc.) at a dosage of 0.625 
mg/100 μl H2O/25 g body weight every 30 days, unless otherwise indicated.  Onset 
of castration-resistance was defined as the time to tumor size increased by 30% 
(~650 mm3) after ADT.  Chemical castration by ADT was compared to bilateral 
orchiectomy as described in Extended Data Fig. 1a.  
Tumor Allografts 
Eight-week-old male FVB/NJ mice were subcutaneously inoculated with either 
Myc-CaP or Myc-CaP/Neu (1×106 cells/mouse) in the right flank.  Tumor diameters 
were measured with an electronic caliper every 3 days as indicated and the tumor 
volume was calculated using the formula: [longest diameter × (shortest 
diameter)2]/2.   
Whole Genome Expression Profiling and Analysis of MCRedAL Tumors 
MCRedAL tumor were harvested when their tumor volume reached ~500mm3 (CS 
group), and 7 days after chemical castration (ADT).  MCRedAL cells were isolated 
based on their mCherry+ CD45- F4/80- CD11b- expression by flow sorting on a 
DakoCytomation MoFlo.  RNA was extracted using Trizol LS (Invitrogen) and 
treated with DNAse-I using RNA clean & Concentrator (Zymo Research).  The 
analysis was performed using Affymetrix Mouse Clariom D (MTA 1.0) array 
according to the manufacturer’s instructions.  Resulting CEL files were analyzed 
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in Affymetrix Expression Console (v. 1.4) using the SST-RMA method, and all 
samples passed the quality control.  Log2 probe intensities were extracted from 
CEL (signal intensity) files and normalized using RMA quantile normalization, then 
further analyzed using Partek Genomics Suite v6.6. Illustrations (volcano plots, 
heatmaps, and histograms) were generated using TIBCO Spotfire DecisionSite 
with Functional Genomics.  Gene set enrichment analysis (GSEA) of differently 
expressed genes was performed using the hallmark gene sets Molecular Signature 
Database (MSigDB).  
Nanostring 
RNA extraction was performed using the Trizol LS reagent (Thermo Fisher) as per 
manufacturer's instructions.  For NanoString analysis, the nCounter mouse 
PanCancer Immune Profiling panel was employed using the nCounter Analysis 
System (NanoString, Seattle, WA).  Analysis was conducted using nSolver 
software (NanoString).  Heatmap analyses were performed using The R Project 
for Statistical Computing (https://www.r-project.org/). 
Pairwise Alignment 
The homology of the murine chemokines Cxcl1, Cxcl2, Cxcl5, Cxcl15, Cxcl12, and 
Cxcl17 to human IL-8 was evaluated using BLASTP 2.9.0+ 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins).370  Proteins were 
consider homologous if they shared > 30% amino acid identity.371 Expected values 
of <0.05 were consider statistically significant. The expected value includes an 
inherent Bonferroni correction. 
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Chromatin immunoprecipitation assay (ChIP)-Seq 
ChIP-Seq data was obtained from 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83860 which contains 
ChIP-Seq data acquired with androgen receptor (AR) and nuclear factor NF-
kappa-B p65 subunit (p65) specific antibodies on cell lysates from LNCaP cells 
cultured under the following treatments: DMSO, DHT, and TNFα. For each 
treatment the dataset contains two ChIP-Seq replicates pulled down using the AR 
and p65 antibodies.372  ChIP-Seq data were aligned to the hg38 reference version 
using the subread package, and then the BAM files were sorted and indexed using 
SAMtools.  Loci with significant differential binding (FDR = 0.05) of pulled-down 
proteins to DNA were identified using the csaw package for ChIP-Seq analysis, 
closely following Lun and Smyth’s script.  ChIP-Seq visualization was performed 
using the Integrative Genomics Viewer (IGV) from the Broad Institute 
(http://software.broadinstitute.org/software/igv/). 
ChIP-qRT-PCR 
Chromatin immunoprecipitation was performed as described.373  In brief, LNCaP 
cells were washed with serum-free media and then grown in media containing 10% 
charcoal stripped FBS for 48 hours.  Cells were treated with 100nM DHT or vehicle 
for 8 hours.  DNA was cross-linked with 1% formaldehyde in PBS for 10 minutes 
and crosslinking was quenched by addition of 0.125 M glycine.  Fixed cells were 
then lysed in lysis buffer (1% SDS, 5mM EDTA, 50mM Tris HCl, pH8.1) and 
sonicated to a fragment size of 200-600 bp using a Covaris water bath sonicator 
(Woburn, MA).  Sheared chromatin was then incubated with primary antibodies 
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(AR [06-680, Millipore], H3K4me3 [ab8580, Abcam], phospho-Ser5 RNA 
polymerase 2 [ab5131, Abcam], RNA polymerase 2 [4H8, Cell Signaling 
Technologies] or control IgG [Cell Signaling Technologies]) overnight at 4ºC. 
Complexes were immobilized on Dynabeads (Thermo Fisher) by incubating for 4 
hours at 4ºC.  Beads were sequentially washed with TSEI (0.1% SDS, 1% Triton 
X-100, 2mM EDTA, 20mM Tris HCl, pH 8.1, 150mM NaCl), TSEII (0.1% SDS, 1% 
Triton X-100, 2mM EDTA, 20mM Tris HCl, pH 8.1, 500mM NaCl) and TSEIII (0.25 
M LiCl, 1% NP-40, 1% deoxycholate, 1mM EDTA, 10mM Tris HCl, pH 8.1). DNA 
was eluted with IP Elution buffer (1% SDS, 0.1M NaHCO3, proteinase K) and 
incubated at 56ºC for 15 minutes.  Enriched DNA libraries were analyzed using 
primers specific to IL-8 locus: Forward: 5’ AGCTGCAGAAATCAGGAAGG 3’ and 
Reverse: 5’ TATAAAAAGCCACCGGAGCA 3’ using quantitative (q) RT-PCR.  
Data is shown as relative enrichment normalized to input DNA.  
Quantitative (q) RT-PCR  
Total RNA was extracted using Trizol (Ambion).  cDNA was prepared from total 
RNA preps using the RNA to cDNA EcoDry Premix (Clontech).  Real-time assays 
were conducted using TaqMan real-time probes (Applied Biosystems).  ΔΔ CT 
method was used for relative gene expression.  Expression of the target gene was 
normalized to the reference gene (18S) and the mean expression level of the 




Laser Capture Microscopy (LCM)  
Formalin fixed-paraffin embedded radical prostatectomy specimens, from patients 
enrolled in a neoadjuvant clinical trial (NCT01696877)365 who received 240 mg 
(SQ) of degarelix and matched control cases (patients that did not receive any 
hormone therapy), were sectioned at a thickness of 8 μm and transferred onto PEN 
membrane glass slides (Leica).  Sections were deparaffinized, hydrated and 
stained with hematoxylin prior to microdissection. Individual cancer cells and 
cancer cell clusters were microdissected by a trained pathologist using a LMD 
7000 laser capture microscope (Leica).  RNA was recovered from the 
microdisseceted material using the RNeasy FFPE kit (Qiagen).  Quantitative RT-
PCR was performed as described above. For the analysis, a Mann-Whitney U test 
was performed.  
IL-8 and Cxcl15 CRISPR/Cas9 Knock Outs 
The 20 bp long gRNA, designed using Deskgen online software, for targeting IL-8 
and Cxcl15 in exon 3 (5’- TTCAGTGTAAAGCTTTCTGA -3’ and 5’-
ACAGAGCAGTCCCAAAAAAT -3’, respectively) were incorporated into two 
complementary 100-mer oligonucleotides and cloned into a gRNA containing 
plasmid containing the (NeoR/KanR) cassette (Addgene # 41824).  The human 
codon optimized pCAGGS-Cas9-mCherry was used for gene-editing experiments 
(a gift from Stem Cell Core Facility at Columbia University).  gRNA and Cas9 
containing plasmids were introduced to prostate epithelial cells using the basic 
nucleofector kit (Amaxa, Lonza) following the manufacturer’s instructions for 
primary mammalian epithelial cells (program W001).  Successfully transfected 
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cells were selected by culturing in the presence of 400µg/ml of neomycin sulfate 
analog (G418; Sigma), and isolated based on their mCherry expression 24 hours 
after transfection.  Knock out clones were screened for IL-8 and Cxcl15 expression 
by ELISA and gene-editing confirmed by PCR amplification and Sanger 
sequencing (GENEWIZ) using primers ~200bp away from the cut site (IL-8 
Forward: 5’- TTTGGACTTAGACTTTATGCCTGAC -3; IL-8 Reverse: 5’- 
TCCTGGGCAAACTATGTATGG -3; Cxcl15 Forward: 5’- 
GCTAGGCACACTGATATGTGTTAAA -3; Cxcl15 Reverse: 5’- 
ACATTTGGGGATGCTACTGG -3). 
Migration/Chemotaxis Assay 
Cells and supernatants used in this assay were resuspended in culture media 
containing 0.5% or 2.5% FBS.  Transwell plates of 3-mm pore size were coated 
with Fibronectin (Corning Costar) and loaded with 500 ml of medium or with 
different cell supernatants in triplicates (lower chamber).  Cells were resuspended 
at 2x107 cells/ml, and 200 ml of this suspension was placed in each of the inserts 
(upper chamber).  After 2.5 hours of incubation at 37°C and 5% CO2, inserts were 
removed and 10,000 beads (Thermo Fisher) were added to each well.  In some 
cases, either isotype or anti-CXCR2 (200 µg/ml) were added at the beginning of 
the experiment.  The cells in the lower chamber were collected along with the 
starting cell population, stained with L/D, CD11b, Ly6C, and Ly6G and evaluated 
by flow cytometry in a BD FACSCelesta (BD Biosciences).  The ratio of beads to 
cells was determined, allowing calculation of the number of cells that had migrated 
to the bottom well.  In vivo, LD-PMN-MDSCs were collected as described below 
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from splenocytes of CR-Myc-Cap tumor bearing mice and labeled with DiD 
(DiIC18(5) or 1,1'-Dioctadecyl-3,3,3',3'- 
Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate Salt; Invitrogen), a 
lipophilic membrane dye, as described previously.374  DiD+ LD-PMN-MDSCs were 
adoptively transferred into FVB/NJ recipient 8-week male mice and their ability to 
migrate in response to 200ng of recombinant Cxcl15 was evaluated 4 hours after 
injection.  Beads were also used to calculate absolute numbers of Ly6G+ PMNs 
and DiD+ LD-PMN-MDSCs in vivo. 
PMN-MDSC Enrichment 
Animals were sacrificed and spleens were collected.  After dissociating cell 
clumps, the cell suspension was centrifuged (740 g, 10 minutes, RT) and 
resuspended in 1 ml HBSS–EDTA containing 0.5% BSA.  Cells were then 
resuspended in 50% Percoll solution and treated on a three-layer Percoll gradient 
(55%, 72%, and 81%) at (1500 g, 30 minutes, 10°C without break).  LD-PMN-
MDSCs were collected from the 50-55% and 55-72% interfaces.  Red blood cells 
(RBCs) were eliminated with RBC lysis solution (Miltenyi).  
In vitro Suppression Assays  
PMN-MDSCs were isolated from the spleen of CR-Myc-Cap-tumor bearing mice 
using the neutrophil isolation kit (Miltenyi) according to the manufacturer’s 
instructions; greater than 95% enrichment was confirmed by flow cytometry.  
Unless otherwise indicated, a density gradient separation was performed prior to 
column purification.  OT-I (CD45.2) transgenic splenocytes were mixed at a 1:10 
ratio with sex-matched CD45.1 splenocytes.  Splenocytes containing CD8 T 
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responder cells were stained with CellTrace Violet (5µM CTV; Thermo Fisher) and 
plated on a 96-well round-bottom plate at a density of 2x105 cells per well.  PMN-
MDSCs cells were added at 2-fold dilutions starting from 2x105 cells, in the 
presence of their cognate peptides (5pM OVA) and incubated for 60 hours.  
Proliferation of CD8 T responder cells (gated as L/D-CD8+CTV+) was quantified by 
flow cytometry based on the dilution of Cell Trace Violet (CTV).  Percent 
suppression (% Suppression) was calculated by the following formula: % 
Suppression = [1-(% divided cells of the condition/ the average of % divided cells 
of T responder only conditions)] x 100.  
Luminal Epithelial Regression/Regeneration 
Eight-week-old male HOXB13-GFP mice carrying the Hoxb13-rtTA transgene and 
a Tetracycline operator–Histone 2B-Green Fluorescent Protein (TetO-H2BGFP), 
which results on GFP expression being restricted to luminal epithelial Hoxb13+ 
cells  (described previously368), were castrated via bilateral orchiectomy.  A cycle 
of prostate regression/regeneration was induced as described previously.283  
Briefly, mice were allowed to regress for six weeks to reach the fully involuted 
state.  Mice were randomized to ADT or ADT + testosterone (T) treatment groups.  
Testosterone was administered for four weeks for prostate regeneration by 
subcutaneous pellets; this regimen yields physiological levels of serum 
testosterone. All mice received 2mg/ml of Doxycycline (Sigma) in the drinking 
water to induce GFP expression368 under the control of the luminal epithelial 
promoter, HoxB13, one week prior euthanizing them for their analysis. 
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Vaccination (GVAX) experiments 
Naïve and tumor bearing mice received a whole-cell GM-CSF vaccine composed 
of a mixture of irradiated Myc-CaP cells expressing GM-CSF adjuvant (3x106) and 
Myc-CaP/Neu cell expressing Rat Her-2/neu protein (GVAX).  The two types of 
cells were harvested, washed in PBS, and irradiated at 30,000 rads using a γ 
irradiator (GammaCell 1000 irradiator), and administered subcutaneously (SC) in 
equal aliquots in the remaining three limbs (50 µL volume). 
Androgen-deprivation treatment (ADT) experiments 
Myc-CaP/Neu tumor bearing mice received androgen-deprivation therapy (ADT) 2 
weeks after tumor implantation.  ADT was administered via subcutaneous (SC) 
injection of degarelix acetate (a GnRH receptor antagonist; Ferring 
Pharmaceuticals Inc.) at a dosage of 0.625 mg/100 μl H2O/25 g body weight.  
Antibody Blockade 
Anti-CXCR2 (murine IgG1-D265A, clone: 11C8; a non-FcγR-binding mutant with 
deficient FcγR-mediated depletion), anti-CSF1R (rat IgG2a, clone: AFS98; with 
competent FcγR-mediated depletion), and anti-CTLA-4 (murine IgG2a, clone: 
12C11; with competent FcγR-mediated depletion)55 were used.  Antibody 
treatment was administered via intraperitoneal (ip) injection at a dose of 
50 mg/kg body weight for 3 doses every 4 days for CXCR2, 50 mg/kg body 
weight every 3 days for the duration of the experiment for CSF1R, 
and/or10 mg/kg body weight for 3 doses every 3 days for CTLA-4. Mouse IgG1 
(clone: 4F7), rat IgG2a (clone: 2A3), and mouse IgG2a (clone: 4C6) were used 
as isotype controls.  Anti-CXCR2 and anti-CSF1R treatments started 7 days 
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before ADT; while anti-CTLA-4 treatment was started either 3 or 12 days before 
ADT (400mm3 vs. 200mm3, respectively). 
Antibody Profiling  
Phage-ImmunoPrecipitation Sequencing (PhIP-Seq) antibody profiling was 
performed on 32 PCa patient serum samples using a 90-aa peptide human 
proteome T7 phage display library as described previously.299,300,375,376  Briefly, 2 
µg of IgG, based on ELISA measurement of total IgG, was mixed with 
2.5 × 1010 particle forming units of the 90-aa human peptidome library and 
incubated at 4C overnight. IgG-bound phages where then immunoprecipitated 
using 20µl of protein A magnetic Dynal beads and 20µl of protein G coated Dynal 
beads (Invitrogen).  After three bead washes, the library DNA inserts were 
amplified for 20 cycles of PCR using Herculase II Polymerase (Agilent).  A second 
20 cycle PCR reaction was performed in order to add sample-specific DNA 
barcodes and P5/P7 Illumina sequencing adapters.  Sequencing was performed 
on an Illumina HiSeq 2500 in rapid mode (50 cycles, single end reads). 
Transcription Profile of Prostate Luminal Epithelial Cells Following 
Androgen-Induced Regression/Regeneration of the Prostate 
We evaluated the transcription profile of Castration-Resistant Luminal Epithelial 
Cells (CRLECs) from the above ‘luminal epithelial regression/regeneration’ 
experiments.  Briefly, eight-week-old male Hoxb13-GFP mice carrying 
the Hoxb13-rtTA transgene and a Tetracycline operator–Histone 2B-Green 
Fluorescent Protein (TetO-H2BGFP), which results in GFP expression restricted 
to luminal epithelial Hoxb13+ cells,368 were castrated via bilateral orchiectomy.  A 
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cycle of prostate regression/regeneration was induced by allowing murine 
prostates to regress for six weeks to reach the fully involuted state.  Mice were 
randomized to untreated, ADT or ADT + testosterone repletion (TR) treatment 
groups.  Testosterone was administered for four weeks for prostate regeneration 
by subcutaneous silastic implants yielding physiological levels of serum 
testosterone.  All mice received 2mg/ml of doxycycline (Sigma) in the drinking 
water to induce GFP expression368 under the control of the luminal epithelial 
promoter, Hoxb13, one week prior to euthanization.  CRLE cells were isolated 
based on their GFP+ expression and CD45-CD11b-F4/80-CD24+CD49fint status by 
flow sorting on a DakoCytomation MoFlo.  Differential gene expression was 
computed using the R limma package.377  Transcriptional distribution of Log2-fold-
changes for each gene in ADT vs untreated samples were normalized to z-scores.  
Z-score values were obtained by scaling the data for each gene in each sample 
to: (expression - mean expression across all genes) / (standard deviation of 
expression across all genes).  The expression of androgen-responsive genes 
between ADT+TR/ADT samples was further evaluated by Log2 fold-change.  
Androgen-responsive gene signature was defined by the differential analysis of 
murine CRLECs from GFP+ luminal prostate epithelial cells comparing ADT vs 
untreated and ADT vs ADT+TR groups and included all differentially expressed 
genes with an ADT Log2-fold-change below the 0.005 percentile and a Bonferroni-
corrected p < 0.01, as well as a set of known androgen-responsive genes  (Klk1b8, 
Fkbp5, Nkx3.1, and Tmprss2).  Statistical analysis was performed in R378 and 
plotting was done using the ggplot2 R package (version 3.1.0).379   
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Quantification of Serum Testosterone  
Whole blood was collected from the tail vein and allowed to clot for 1 h at 4 °C.  
Serum was obtained by centrifuging (1000 × g for 30 min) and collecting the 
supernatant.  Sera were stored at −80 °C prior to analysis.  Testosterone 
concentration was determined by enzyme-linked immunosorbent assay according 
to the manufacturer’s instructions (Enzo, Farmingdale, NY). 
Transcriptional Analysis Across Normal and Cancer Tissues 
The expression profile of a subset of androgen-responsive genes was evaluated 
in publicly available dataset from mice (RIKEN FANTOM5)294 and human 
(GTEx)295 normal tissues (prostate, brain, colon, liver, lung, skin, kidney, and 
salivary gland), as well as in lineage-marked benign or tumor prostate epithelial 
cells from transgenic mice (GSE39509).293  For the later, we used RNA-seq data 
from luminal origin tumors of Nkx3.1CreERT2/+; Ptenflox/flox; R26R-YFP/+ mice that 
were uninduced (benign), or at 3 months after induction.  For tamoxifen induction, 
mice were administered 9 mg/40 g tamoxifen (Sigma) suspended in corn oil, or 
vehicle alone for negative controls, by oral gavage once daily for 4 consecutive 
days.  In all presented boxplots, the medians for relative gene expression are 
shown. The ‘hinges’ represent the first and third quartile. The whiskers are the 
smallest and largest values after exclusion of outliers (greater than the 75th 
percentile plus 1.5 times the interquartile range (IQR), or less than 25th percentile 
minus 1.5 times the IQR).  The expression levels of the complete signature of 
androgen-responsive genes, including KLK3/PSA, FKBP5, NKX3.1, and 
TMPRSS2, as well as the prostate-restricted TAAs: STEAP1 and TARP were also 
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evaluated.  The statistical analysis was performed in R378 and plotting was done 
using the ggplot2 R package (version 3.1.0).379  
In addition, transglutaminase 4 (TGM4) expression was plotted across human 
cancer types in The Cancer Genome Atlas (TCGA) database (n = 11,284 
samples), including 558 primary prostate adenocarcinomas (PRAD), and across 
an independent dataset that includes primary prostate adenocarcinomas with 
clinical information on time to biochemical recurrence (n = 218; GSE21032).298  
Biochemical recurrence was defined as PSA ≥0.2 ng/ml.  Following radical 
prostatectomy, patients were followed with history, physical exam, and serum PSA 
testing every 3 months for the first year, 6 months for the second year, and annually 
thereafter.  The subset of primary prostate cancer samples from this dataset were 
tested for association of TGM4 expression with survival by cox regression. Optimal 
cutpoint for TGM4 selection was determined by maximizing the log-rank statistic 
using the R survminer package.380  
Relative expression was quantified accordingly to the normalization methods used 
in the different publicly available databases analyzed here.  RNASeq data from 
RIKEN FANTOM5 and GTEx were normalized to Log10(TPM), while RNASeq data 
from the GSE39509 dataset was normalized to FPKM rather than TPM.  Raw un-
normalized RNASeq data from TCGA were normalized to Log10(TPM+1).  
Microarray data from GSE21032 was normalized with circular binary segmentation 
and analyzed with RAE as previously described.298  
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Monocyte Isolation and DC Maturation 
Peripheral blood mononuclear cells (PBMCs) from 10 anonymous healthy male 
donors ≥ 35 years-old obtained from the New York Blood Center were isolated 
using LymphoprepTM and SepMateTM PBMC isolation tubes (STEMCELL 
Technologies). Untouched classical monocytes (CD14+CD16-) were then isolated 
from the PBMC fraction using magnetic beads following the manufacturer’s 
instructions (Pan Monocyte Isolation Kit; Miltenyi Biotec). Following density 
gradient isolation, monocytes were resuspended in media containing IL-4 (1000 
IU/ml) and GM-CSF (1000 IU/ml) at a concentration of 2x106 cells per ml and 
cultured for 3 days. Cells were maturated for 2 days by adding lipopolysaccharides 
(LPS) to a final concentration of 500 IU/ml (Sigma).  Monocyte-derived dendritic 
cells (moDCs) were stimulated with 1 µg/ml of whole protein (TGM4, PAP, or PSA; 
Fisher Scientific & BioLegend) or viral peptide-libraries (CEFT or pp65; JPT 
Peptide Technologies) overnight before co-culturing with autologous T cells.     
Antigen-driven T-cell Purification and Expansion 
Functional assays of protein-stimulated T-cell expansion were performed for 10 
healthy male donors. On day 0, naïve T cells (CCR7+CD45RA+) were isolated from 
PBMCs by negative selection following the manufacturer’s instructions (Naïve Pan 
T-Cell Isolation Kit; Miltenyi Biotec).  Naïve T cells were co-cultured with antigen-
pulsed moDCs at a 1:10 ratio in cultured media (1:1 mix of AIM-V media and 
RPMI1640 [Thermo Fisher] with 10% human serum [Gemini Bio], 1% penicillin 
streptomycin [Life Technologies] and 1% GlutaMAX [Life Technologies]) 
supplemented with IL-7 (25ng/ml; Peprotech).  IL-2 (25ng/ml; Peprotech) was 
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added to the cultures 72hrs following priming of naïve T cells.  Media was 
supplemented every 1-3 days with fresh culture media containing the same 
concentrations of IL-2 and IL-7.  Every 10 days, cells were co-incubated with a 
fresh set of antigen-pulsed moDCs.  Cells were harvest and washed twice with 
PBS on day 30.  As positive controls, cells were stimulated with a mixture of 
pathogen-associated peptides, CEFT pool and pp65 (JPT Peptide Technologies).  
Cells were stained for FACS analysis 10 days after the last stimulation, and also 
stimulated with antigen-pulsed moDCs for 12 hours to evaluate the effect of 
activation markers on expanded T cells following stimulation.      
Flow Cytometry in Human Samples  
Prior staining, cells were Fc-blocked with purified rat anti-mouse CD16/CD32 
(Clone: 2.4 G2, Becton Dickinson BD) for 15 minutes at RT.  Dead cells were 
discriminated using the LIVE/DEAD (L/D) fixable viability dye eFluor 506 dead cell 
stain kit (Thermo Fisher) and samples were stained for extracellular and 
intracellular markers.  The following antibodies were used: CD3 (UCHT1), CD4 
(A161A1), CD8 (SK1), CCR7 (3D12), CD45RA (MEM-56), CD69 (FN50), CD28 
(CD28.2), CD27 (M-T271), CD161 (DX12), PD-1 (EH12.1), TIM3 (F38-2E2), 
CTLA-4 (L3D10), TBET (eBio4B10), GATA3 (TWAJ), RORg(t) (REA278), FOXP3 
(PCH101), TCF1 (C63D9), and EOMES (WD1928).  Extracellular staining was 
performed at room temperature for 30min.  For intracellular staining, cells were 
fixed and permeabilized using BD Perm/Wash (BD Biosciences) at room 
temperature for 45 minutes.  Cells were stimulated with protein-pulsed moDCs for 
12 hours to evaluate their activation status.  Gates for transcription factors were 
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determined by fluorescence minus one (FMO) controls.  Staining was visualized 
by fluorescence activated cell sorting (FACS) analysis using a Cytek Aurora 
(Cytek Biosciences) and analyzed using FlowJo (Flowjo LLC) in combination 
with R packages UMAP (version 0.2.0.0)381 and FlowSOM (version 1.14.1).382  
Multiparametric Flow Cytometry Analysis 
Following compensation, FCS files underwent standard pre-processing to remove 
debris, doublets and to enrich for live cells.  Live, single cells were analyzed by 
manual gating and unsupervised computational methods in parallel.  
For manual gating, T cells were identified based on CD3 expression followed by 
CD4 and CD8 extracellular markers using FlowJo V10.6.  Naïve, effector, central 
memory, effector memory subpopulations within CD4 and CD8 T cells were 
identified based on CD45RA and CCR7 expression.  Antigen-driven T cells were 
quantified following three rounds of prime/boost autologous stimulation based on 
CD69, TBET, CD27, CD28, PD1 and TIM3, expression by manual gating.   
Unsupervised computational analysis was performed separately for unstimulated 
and stimulated samples. In each case, 10,000 cells of post-gated live, single CD4+ 
or CD8+ T cells from each of the 10 healthy donors were randomly selected using 
the DownSampleV3 plugin in FlowJo.  Subsequently, unsupervised clustering was 
performed on the expression values of the activation and functional markers 
separately using the FlowSOM algorithm,382 which uses a self-organizing map 
followed by hierarchical consensus meta-clustering to detect cell populations.  
Default parameters and a predetermined number of 10 clusters were used.  The 
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median levels of the activation and functional markers across all cells per cluster 
were visualized in separate heatmaps.  The subpopulations between clusters were 
based on the expression levels of activation and functional markers after applying 
the non-linear dimensionality reduction technique UMAP of the randomly selected 
cells using the R package UMAP for visualization of the multiparametric data.381  
The cells were colored according to their FlowSOM cluster membership.  
Flow cytometry in Murine Samples 
Single-cell suspensions from prostate tumor and tissues were prepared using the 
mouse tumor dissociation kit according to the manufacturer’s recommendations 
(Miltenyi).  Single-cell suspensions of tumor-draining lymph nodes (TDLNs) and 
spleens were homogenized mechanically with the back of a syringe.  Cells were 
Fc-blocked with purified rat anti-mouse CD16/CD32 (Clone: 2.4 G2, Becton 
Dickinson BD) for 15 minutes at RT.  Dead cells were discriminated using the 
LIVE/DEAD (L/D) fixable viability dye eFluor 506 or near-IR dead cell stain kit 
(Thermo Fisher) and samples were stained for extracellular and intracellular 
markers.  The following antibodies were used: Her-2/neu (7.16.4), anti-mouse 
IgG2a (RMG2a-62), Thy1.2 (53-2.1), TCRVβ4 (KT4), CD45 (30F-11), CD45.2 
(104), CD24 (M1/69), CD49f (GOH3), Ly6C (HK1.4), Ly6G (1A8), Gr1 (RB6-8C5), 
CD11b (M1/70), F4/80 (BM8), MHCII (2G9), PD-L1 (10F.9G2), CD4 (RM4-5), CD8 
(53-6.7), CD44 (IM7), CD62L (MEL-14), CD25 (PC61), Ki67 (16A8), IFNγ 
(XMG1.2), TNFα (MP6-XT22), IL-2 (JES6-5H4), GZβ (GB11), CXCR2 (242216), 
and IL-23 (FC23CPG).  For intracellular staining, cells were fixed and 
permeabilized using BD Perm/Wash (BD Biosciences) at room temperature for 45 
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minutes.  For intracellular cytokine staining, cells were stimulated with PMA (50 
ng/ml) and ionomycin (500 ng/ml) for 4 hours in the presence of protein transport 
inhibitor cocktail (eBiosciences).  Gates of cytokines were determined by 
fluorescence minus one (FMO) controls.  Staining was visualized by fluorescence 
activated cell sorting (FACS) analysis using a BD FACSCelesta (BD 
Biosciences) and analyzed using FlowJo (Flowjo LLC).  Prostate luminal 
epithelial cells are defined as CD45-CD11b-F4/80-CD24+CD49fintGFP+, and 
prostate epithelial tumor cells are defined as CD45-CD11b-F4/80-mCherry+. Tumor 
associated macrophages (TAMs) are referred to as CD45+CD11b+F4/80+,  
inflammatory TAMs as CD45+CD11b+F4/80+Ly6C+MHCII-, immature TAMs as 
CD45+CD11b+F4/80+Ly6C+MHCII+, MHCIIhi TAMs as CD45+CD11b+F4/80+Ly6C-
MHCII+, MHCIIlow TAMs as CD45+CD11b+F4/80+Ly6C-MHCII-. PMN-MDSCs are 
defined as CD45+CD11b+Ly6C+Ly6G+.  CD4 T cells as CD45+CD4+, regulatory T 
cells as CD45+CD4+CD25+, CD8 T cells as CD45+CD8+, polyfunctional CD8 T 
Cells as CD45+CD8+IFNγ+TNFα+Gzβ+, and memory CD8 T cells as CD45+ 
CD8+CD44+CD62L-. 123Count eBeads counting beads (Thermo Fisher) were 
used to normalize the numbers of PMN-MDSCs in migration/chemotaxis 
experiments. 
Protein Quantification 
Tumors collected at different treatment time points were minced, lysed in CelLytic 
MT (Sigma) containing halt protease and phosphatase inhibitor (Thermo Fisher) in 
a 1:100 ratio, and incubated on ice for 30 minutes with intermittent vortexing.  
Tumor lysates were assayed for raw protein concentration with Coomassie assay 
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(Bio-Rad).  IL-8 and Cxcl15 were analyzed by ELISA kits following the 
manufacturer’s instructions (BD Bioscience and R&D Systems, respectively).  
Immunohistochemical staining (IHC) 
Tumor and tissue samples were fixed with either 10% formalin (Fisher Scientific, 
Pittsburgh, PA) or zinc fixative (BD) for 24 hours before paraffin embedding and 
sectioning.  Sections were stained with hematoxylin and eosin (H&E), and 
antibodies against mouse Ly6G (1A8; BD Pharmingen), FoxP3 (D6O8R; Cell 
Signaling), CD3 (SP7; Spring Bioscience), F4/80 (BM8; eBioscience), and Her-
2/neu (7.16.4; Emdmillipore).  Staining was performed by the Molecular Pathology 
core of the Herbert Irving Comprehensive Cancer Center at Columbia University.  
All images were acquired on a Leica SCN 400 system with high throughput 384 
slide autoloader (SL801) and a 40X objective; files were processed with Aperio 
ImageScope v12.3.1.6002. Marker-positive cell counts were obtained from 5 
random 40X fields per histological section and results were averaged over the 
number of counted fields.  
RNA In Situ Hybridization (RISH) and Immunohistochemistry 
Manual fluorescent RISH was performed on formalin-fixed and zinc-fixed paraffin 
embedded sections using company protocols.  Briefly, 5µm sections were cut, 
baked at 60 ℃ for 1 hour, dewaxed, and air-dried before pre-treatments.  RISH 
Cxcl15 probe, 3-plex positive control probes (Polr2a, Ppib, Ubc) and 3-plex 
negative control probes (DapB of Bacillus subtilis strain) from Advanced Cell 
Diagnostics (ACD) were used in this study.  Detection of specific probe binding 
sites was performed with RISH Multiplex Fluorescent Reagent Kit v2 Reagent kit 
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from ACD following the manufacturer’s instructions.  Tyramide CF568 (Biotium) 
was used to visualize RISH signal. 
For a more precise identification of cells expressing Cxcl15, RISH was coupled to 
immunohistochemistry of PanCK (Poly; Dako) and CD45 (30-F11; BD 
Biosciences).  Immediately after RISH detection, samples were permeabilized with 
0.2% TBS-Tween 20 for 10 minutes at RT, and then blocked with 2.5% of normal 
goat serum (Vector) for 30 minutes at RT.  Primary antibody for PanCK was diluted 
1/400 in renaissance background reducing diluent (Biocare Medical) and 
incubated overnight at 4 °C.  After washing off the primary antibody, the slides 
were incubated 15 minutes at RT horseradish peroxidase (HRP) secondary 
antibody (Vector).  Tyramide CF640R (Biotium) was used to visualize PanCK 
staining.  In some cases, CD45 staining was also performed. For this, HRP signal 
was abolished by a 30 minute incubation at RT with PeroxAbolish (Biocare 
Medical) and then blocked with 2.5% of normal goat serum (Vector) for 30 minutes 
at RT.  Primary antibody for CD45 was diluted 1/50 in renaissance background 
reducing diluent (Biocare Medical) and incubated 90 minutes at RT.  After washing 
off the primary antibody, the slides were incubated 15 minutes at RT HRP-
secondary antibody (Vector).  Tyramide CF488A (Biotium) was used to visualize 
CD45 staining.  All images were acquired on a Nikon A1RMP confocal microscope 





Manual fluorescent staining was performed using company protocols.  Briefly, 
tumor cells were grown on poly-D-Lysine coated coverslips for 24hrs and fixed with 
10% neutral buffered formalin for 30min at RT.  Samples were permeabilized with 
0.2% TBS-Tween 20 for 10min at RT, then blocked with mouse IgG blocking 
reagent for 60min at RT, followed by 2.5% of normal goat serum (Vector) for 5min 
at RT.  Primary antibody for Her-2/neu was diluted 1:100 in renaissance 
background reducing diluent (Biocare Medical) and incubated overnight at 4 °C.  
After washing off the primary antibody, the slides were incubated 10 min at RT with 
peroxidase micropolymer for detecting mouse primary antibodies on mouse tissue 
(Vector M.O.M.).  Tyramide CF640R (Biotium) was used to visualize Her-2/neu 
staining.  After washing off the primary antibody, the slides were incubated 15 min 
at RT with HRP secondary antibody (Vector).  All images were acquired on a Nikon 
A1RMP confocal microscope using a 60X objective.  Image analysis was 
performed using ImageJ. 
Antibody Analysis 
PhIP-seq data analysis was performed as described in the phip-stat package 
(https://github.com/lasersonlab/phip-stat). Reads were aligned to the phage library 
insert sequences using bowtie2383 to generate a matrix of reads per million (RPM) 
values for each peptide in each sample (paired pre- and post-treatment serum).  
Using the phip-stat call-hits command with the ‘--fdr 0.05’ option, we defined a set 
of statistically significant ‘hits’ where the RPM value was significantly higher than 
a set of control wells loaded with beads only.  We also calculated the Log2 fold-
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change (FC) in post-treatment reactivity compared to pre-treatment repertoire, with 
Laplace smoothing applied to avoid NA fold-change values from zero-inflated 
matrix.  We further analyzed only peptides with a post-treatment ‘hit’, such that 
RPM value is higher than the statistical baseline.  For PhIP-Seq Log2 FC analysis, 
RPM values were aggregated across peptides corresponding to each gene before 
computing FC for this analysis.   
We generated a heatmap of sample-by-sample on-treatment vs pre-treatment 
Log2 FC for the set of genes defined as androgen-responsive within patients with 
prostate adenocarcinomas treated with ADT only or with GVAX followed by ADT 
treatment. This heatmap includes all androgen-responsive proteins profiled with at 
least one ‘hit’ by PhIP-Seq.  Relationship between immune response to androgen-
responsive tumor associated antigens (TAAs) and biochemical recurrence-free 
survival among patients with prostate adenocarcinoma in either treatment group 
was assessed by Kaplan Meier curve with cox regression p-value as well as by 
Fisher’s Exact test comparing frequency of immune response to any androgen-
response gene in patients with recurrence vs patients without recurrence. All 
comparisons were performed in the R statistical computation environment.378  
Patients with positive Log2 FC for any androgen-responsive TAAs were 
considered to mount an immune response to any androgen-responsive TAAs.  
Androgen-responsive genes were defined in the differential analysis of murine 
CRLECs from GFP+ luminal prostate epithelial cells, combined with a set of known 




IL-8 expression was evaluated in a publicly available data set (GSE8466)384 using 
z-score values of quantile-normalized microarray transcripts from benign prostate 
biopsies. Z-score values were obtained by scaling the data for each gene in each 
patient to: (expression - mean expression across all genes) / (standard deviation 
of expression across all genes).  
Statistical Analysis 
Statistical analysis was performed using R (version 3.6.1)378 or Prism 7 
(GraphPad).  All statistical tests performed were two-sided with Bonferroni 
multiple-testing correction where applicable. Tests were considered statistically 
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Invited talks at local, national, and international meetings 
2020 “ADT-mediated Intra-Tumoral Myeloid Infiltration 
Promotes Resistance to Immune Checkpoint Blockade 
in Prostate Cancer” talk at the Advances in Cancer 
Immunotherapy eSymposia Meeting.  
Virtual Keystone 
2019 “ADT-mediated IL-8 Promotes Myeloid Infiltration and 





2019 “The Effect of Inflammatory Cytokines on Prostate 
Cancer Progression” talk at Prostate Cancer Meeting. 
Columbia 
University 
2018 “Decoding the TME of Castrate-Resistant Prostate 
Cancer: A Novel Immunotherapeutic Approach 
Targeting PMN-MDSCs” talk at the Center Meeting, 




2018 “Targeting PMN-MDSCs and TAMs in a Preclinical 
Castrate-Resistant Prostate Cancer Model: A Novel 




2017 “Murine Models to Study Castrate-Resistant Luminal 




2016 “Antigen Screening for the Treatment of Castrate-





Research in Progress Meeting. Bloomberg~Kimmel 
Institute for Cancer Immunotherapy. 
2014 “Antigen Screening for the Treatment of Castration-




Inventions, Patents, Copyrights 
2020 Targeting of TGM4 to treat prostate cancer. 
Inventors: Charles G. Drake and Zoila Areli Lopez Bujanda. 
IR CU21049 
2019 Treatment of Prostate Cancer by Androgen Ablation and IL-8 Blockade. 
Inventors: Charles G. Drake and Zoila Areli Lopez Bujanda. 
IR CU19210 
2013 A Quantitative Multiplex Methylation Specific PCR Method-cMethDNA, 
Reagents, and Its Use. 
Inventors: Saraswati Sukumar, Mary Jo Fackler, Wei Wen Teo, and Zoila 
Areli Lopez Bujanda. 
Publication No: WO/2013/177265 
Service and leadership  
2018 Mentor to Summer Student Nicholas 
Venturini  
Columbia University  
2014 Teaching Assistant for the Pathology 
for Graduate Students course 
Johns Hopkins School of Medicine 
 
 
